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Background: Cancer treatment-related cardiac dysfunction (CTRCD) and heart failure were first described in 
the published literature over 50 years ago. Once it was determined that CTRCD was frequently irreversible 
with a high mortality burden, cardiologists and oncologists worked together to utilize cardiac imaging to tailor 
anti-cancer treatments to reduce cardiac dysfunction risk. However, the guidelines established at that time 
predated several modern techniques for imaging the heart, and many cardiovascular treatments with 
demonstrated efficacy in reducing heart failure mortality were not available when traditional strategies for 
managing cardiac risk in cancer patients were established. Currently the morbidity and mortality of cancer-
treatment-related cardiac dysfunction remains high, and there is now a strong evidence base supporting the 
concept of increased long-term risk of cardiac complications in the cancer survivor community. 
Cardio-oncologists today now have a number of cardiac imaging techniques to choose from for the detection 
of CTRCD, including nuclear multi-plane acquisition scans (MUGAs), echocardiography and cardiac MRI 
(CMR). Several techniques themselves have recently introduced additional imaging features that allow for 
more thorough and accurate interrogation of cardiac function. There is currently a limited amount of high 
quality published scientific evidence evaluating the utility of these imaging techniques in the cancer 
population, which is reflected by the lack of a consensus among practitioners about which of these imaging 
modalities may be optimal. Given the significant differences in clinical information provided and risks of each 
technique, it is possible that one technique could more appropriate than the alternatives. While novel cardiac 
imaging techniques such as assessment of diastolic function and myocardial mechanics by CMR offer new 
insights into mechanisms of cardiac dysfunction, their utility in the cancer population is yet untested.    
Aims: The work in this thesis is divided into four distinct sections. The first section is concerned with 
recognizing CTRCD secondary to either chemotherapy or radiotherapy. The first section aims to answer 
the following: 1) What is the frequency and optimal imaging timing of cardiac dysfunction secondary to 
chemotherapy? 2) What are the most frequent cardiac imaging abnormalities in patients treated with chest-





Who should be tested – in particular, what is the impact of traditional heart failure risk factors on 
echocardiographic measurements of cardiac function? 
The second section is concerned with identifying the strengths and limitations of the two most frequently 
utilized cardiac imaging techniques in Australia (MUGA and echocardiography) with the intention of 
determining whether one technique is likely to be superior to the other. The second section aims to answer the 
following: 5) how do MUGA and echocardiography compare in frequency of utilization, agreement in 
measurements and prediction of cardiac dysfunction in the cancer population? 6) Given the importance of 
accurate and reproducible LVEF measurements in the cardio-oncology population, can automation in 
echocardiography be utilized to improve patient outcomes? 
Section 3 investigates the use of novel imaging techniques to provide additional information regarding 
pathophysiology in addition to traditional cardiac imaging techniques. Cardiac MRI (CMR) is not practical for 
routine cardiac imaging due to issues of cost and access but may be a reasonable adjunct to either 
echocardiography or MUGA to further guide treatment by identifying mechanism and phenotypes of cardiac 
dysfunction. The third section aims to answer the following:   7) Does the observed decline in LVEF as 
measured by CMR in breast cancer patients reflect preload reduction or reduced myocardial contractility? 8) 
What does CMR tell us about the phenotypic diversity of cardiac dysfunction secondary to breast cancer 
therapy?  
The final section recognizes that cardiac imaging decisions do not occur based solely on clinical 
characteristics, and issues of financial burden and quality of life must be clarified before society can invest 
in widespread uptake. The fourth section asks the question: 9) What is the most cost-effective approach for 
preventing CTRCD? 
Methods: These questions were addressed using a number of study designs. First, a narrative review of peer-
reviewed published research describes the current state of cardiac dysfunction secondary to chemotherapy. 
Second, a systematic review was performed to quantify cardiac structural and functional changes secondary 





risk of heart failure secondary to chest-directed-radiotherapy as treatment for cancer. Fourth, the role of 
traditional heart failure risk factors was tested in a cohort study of adult survivors of childhood cancer, in 
which the effect sizes of clinical and echocardiographic changes were sought. Fifth, a prospective cohort 
study of 35 consecutive cancer patients judged by their treating oncologist to be at risk of CTRCD were 
recruited from a single regional Australian hospital. They underwent simultaneous oncologist-guided serial 
cardiac imaging with nuclear multi-plane acquisition (MUGA) scans and echocardiography performed by 
researchers at 3-month intervals over 12 months. Sixth, a systematic review of published literature 
regarding automation in echocardiography, limited to seven common echocardiographic measurement 
techniques, was performed and reported. In addition, strength of scientific evidence for each automated 
technique was assessed, and recommendations for implementation in echo labs is provided. Seventh, the 
effects of preload reduction (reduction in end-diastolic volume) or reduced myocardial contractility (increase 
in end-systolic volume) were evaluated in a short-term cohort of HER2+ve early breast (EBC) cancer 
patients satisfying criteria for CTRCD in serial cardiac MRI examinations and global longitudinal strain 
measurements by echocardiography. Eighth, a longitudinal cohort design was used to identify different 
phenotypes of cardiac response to potentially cardiotoxic chemotherapy in HER2+ve EBC patients. Ninth, a 
Markov model was used to assess the cost-effectiveness of different cardioprotective strategies. 
Results: First, CTRCD is a relatively frequent complication of contemporary anti-cancer treatments and 
sequential cardiac imaging is advised for high-risk patients. Second, mediastinal radiotherapy is associated 
with long-term heart failure due to left ventricular systolic dysfunction, with limited information suggesting 
significant contribution from right ventricular systolic dysfunction. Despite previous reports in the literature, 
long-term diastolic left ventricular dysfunction was infrequent. Third, meta-analysis of available quality 
publications revealed that mediastinal radiotherapy approximately doubled the risk of heart failure (HR 1.83 
[95%CI 1.09 to 3.08], p=0.022), but with significant heterogeneity between studies (I2 88.5%). Meta-
regression demonstrated that 80% of heterogeneity could be explained by differing age at time of radiotherapy 
and length of follow-up. Fourth, traditional heart failure risk factors were demonstrated to increase risk of 





Reduced 3D-LVEF was significantly associated with hypertension (OR 1.81 [95% 1.25 to 2.62]), reduced 
global longitudinal strain was associated with insulin resistance (OR 1.72 [95%CI 1.30 to 2.28]) and obesity 
(OR 1.58 [95%CI 1.19 to 2.11]) and diastolic dysfunction was associated with hypertension (OR 1.41 [95% 
1.03 – 1.94]), insulin resistance (OR 1.44 [95%CI 1.08 to 1.92]) and obesity (OR 1.92 [95%CI 1.42 to 2.58]). 
These findings suggest that childhood cancer survivors with traditional heart failure risk factors may benefit 
from long-term monitoring of cardiac function. Fifth, it was determined; i) there was poor correlation between 
LVEF measurements by MUGA and echocardiographic techniques; ii) echocardiography found that 28% of 
patients had a significant decline in LVEF, whereas only 3% of patients were found to have LVEF decline by 
MUGA, and iii) relative change in GLS at 2 months was predictive of significant later LVEF decline, with 
receiver-operating curve demonstrating AUC 0.74 (95%CI 0.55 – 0.94). These results suggest that MUGA and 
echocardiography have large limits of agreement for LVEF measurements and that echocardiography may 
detect cardiac dysfunction earlier than MUGA. Sixth, current echocardiographic LVEF measurements suffer 
from low reproducibility, which reduces confidence in echocardiography-guided CTRCD diagnoses. One 
potential strategy for improving echocardiographic LVEF reproducibility is by increased utilization of 
automated measurement techniques. Seventh, a cohort of 83 patients with early HER2 +vet breast cancer was 
recruited, of which 15 patients (13.4%)developed CTRCD as defined by LVEF drop measured by CMR. Of 
these 12 cases (80%) were due to isolated increase in LVESV, 2 cases (13.3%) were due to concurrent 
increase in LVESV and decrement in LVEDV and 1 case (7.7%) was due to non-significant volume changes 
in both LVEDV and LVESV. No patients developed CTRCD due to isolated LVEDV reduction. These results 
suggest that preload reduction does not significantly contribute towards observed reduction in LVEF in breast 
cancer patients diagnosed with CTRCD. Eighth, of a cohort of 66 EBC patients, 13 (19.7%) developed 
systolic dysfunction, 13 (19.7%) developed diastolic dysfunction with 4 patients overlapping, and 44 (66.7%) 
had a phenotype characterized by absence of overt systolic and diastolic dysfunction with subclinical cardiac 
dysfunction diagnosed by examining myocardial mechanics. Patients with diastolic dysfunction were older, 
more likely to have hypertension, diabetes and be treated with higher chest-directed radiotherapy doses than 
patients with systolic dysfunction. Ninth, strain-guided cardioprotective therapy dominated the alternative 





$1808 over 5 years) and LVEF-guided cardioprotective therapy (gain of 0.26 QALYs and savings of $2874 
over 5 years) in a cost-effectiveness analysis, demonstrating that strain-guided cardioprotection is the most 
cost-effective approach for preventing CTRCD. 
Conclusions: Contemporary cancer treatments may increase the risk of cardiac dysfunction. Traditional 
methods of screening for CTRCD are limited by suboptimal reproducibility and sensitivity. Novel cardiac 
imaging techniques, specifically echocardiographic myocardial deformation imaging, can offer additional 
information regarding subclinical cardiac dysfunction and may provide earlier diagnosis, information 
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Successful advances in oncology have led to cancer patients living longer than ever before, but these cancer 
survivors are at risk of non-cancer related morbidity and mortality. Cancer survivors are at increased risk of 
many chronic health conditions, including secondary cancers, renal dysfunction, severe musculoskeletal 
problems, endocrinopathies, cardiovascular disease and anxiety or depression. Cardiomyopathy accounts for a 
significant proportion of cancer survivor morbidity.  
 
Aims of this thesis. 
This thesis was compiled as response to several contemporary aspects of cardio-oncology care; 1) cancer 
survivors are accounting for increasingly large percentage of Australian public; 2) contemporary treatments for 
common cancers confer increased risk of cardiac dysfunction and heart failure; 3) early treatment with 
cardioprotective medications has demonstrated benefit in preventing and  reversing cancer-therapeutic-related 
cardiac dysfunction; 4) cardioprotective medications are less efficacious if administered at later stages of 
CTRCD and 5) currently there is substantial disagreement regarding which cardiac imaging technique to guide 
starting cardioprotective medication is superior.  
 
Therefore, the main aims of this thesis are to determine the utility of different cardiac imaging strategies 
for CTRCD and identify the optimal approach for targeting cardioprotective therapies. We also sought to 
elucidate the competing manifestations of cardiac dysfunction in response to cancer treatments, identify different 
phenotypes of cardiac dysfunction and identify the most cost-effective approach to cardioprotection. In order to 
achieve that, the studies presented in this thesis aim to address the list of issues below. This list is in similar 
order to the thesis chapters. 





 How does the risk and presentation of CTRCD differ between different anti-cancer therapies? 
 Is automation a reasonable strategy for earlier diagnosis of CTRCD?  
 Does chest-directed radiotherapy also contribute towards CTRCD risk? 
 What is the pathophysiological mechanisms underlying CTRCD? 
 What are the different phenotypic manifestations of CTRCD? 
 What is the most cost-effective strategy for targeting cardioprotection? 
 
Structure of this thesis 
Chapter 1: Background – review of current literature and summarising clinical evidence and knowledge 
gaps 
Chapter 2: Systematic Review of effects of chest-directed radiotherapy towards CTRCD  
Chapter 3:  Meta-analysis of risk of heart failure with chest-directed radiotherapy as treatment for cancer  
Chapter 4:  Impact of traditional risk factors towards heart failure in the cancer survivor cohort. 
 
Chapter 5: Prospective cohort of cancer patients evaluated with echocardiography and nuclear imaging. 
Chapter 6: Strategies for improved cardiac imaging for diagnosis of CTRCD, including automation. 
Chapter 7:  Using cardiac MRI to determine the aetiology of CTRCD in a breast cancer cohort. 
Chapter 8: Determining different phenotypes of cardiac dysfunction in a prospective cohort of early breast 
cancer patients. 
Chapter 9: Use of Markov model to evaluate cost-effectiveness of competing strategies for cardio-
protection. 






1.11 Sources of data used in this thesis 
Data used for analysis for chapter 4 was derived from the SJLIFE study (Establishment of a Lifetime of Cohort 
of Adults Surviving Childhood Cancer) with the ClinicalTrials.gov identifier number NCT00760656. The 
SJLIFE trial had 4575 patients recruited at the time that data was analysed for this thesis. 
Data used in chapter 5 was derived from a prospective cohort of 31 patients from the Royal Hobart Hospital 
presenting with cancer that would likely require treatment with potentially cardiotoxic anticancer therapies 
(Tasmanian Health and Medical Human Research Ethics Committee approval reference number H13115). 
Data used for analysis in chapter 8 used 112 patients with early breast cancer recruited from 2 centres in Canada. 
83 patients were recruited from the Princess Margaret Cancer Centre and Toronto General Hospital, after being 
recruited into the EMBRACE-MRI (evaluation of Myocardial Changes during BReast Adenocarcinoma 
Therapy to Detect Cardiotoxicity Earlier with Cardiac MRI) prospective cohort study with the ClinicalTrials.gov 
identifier number NCT02306538. 29 patients were recruited from the Stephenson Cardiovascular CMR Centre 
at the Libin Cardiovascular Institute of Alberta. 
Data used in chapter 9 used 66 patients recruited from the Princess Margaret Cancer Centre and Toronto General 
Hospital, after being recruited into the EMBRACE-MRI (evaluation of Myocardial Changes during BReast 
Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier with Cardiac MRI) prospective cohort study with the 
ClinicalTrials.gov identifier number NCT02306538. 
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Epidemiology of CTRCD 
 
Successful advances in oncology over the past decades have led to cancer patients living longer than 
previously. The five-year survival rate for all cancers in the US has increased from 50% in 1975-1977 to 68% 
in 1999-2005(3). This success has also led to a large pool of cancer survivors who are at increased risk of non-
cancer related morbidity and mortality.  Chronic long-term health issues arising from cancer survivorship are 
becoming increasingly recognized as an important issue. In Australia it is estimated that 3.2% of the population 
are cancer survivors, which is equivalent to 654,977 patients(4). Cancer survivors are at increased risk of many 
chronic health conditions, including secondary cancers, renal dysfunction, severe musculoskeletal problems, 
endocrinopathies, cardiovascular disease and anxiety or depression. To date, the best long-term information on 
cancer survivorship comes from paediatric patients, who would be expected to have lower incidence of 
cardiovascular disease (CVD) than adult patients followed for the same period. One retrospective cohort study 
of paediatric cancer survivors over a mean of 17.5 years found a 73% prevalence of any chronic health condition, 
and 42% prevalence of any severe or disabling health condition(5). Compared with their siblings, cancer 
survivors had a three-fold increased risk for any chronic health condition, and an eight-fold increased risk of a 
severe or life-threatening health condition. They also had an increased risk of CVD, with a fifteen-fold increase 
seen in relative risk for congestive heart failure (RR 15.1, 95%CI 4.8-47.9). This increase in relative risk for a 
chronic condition was the second highest identified, suggesting that cardiomyopathy accounts for a significant 
proportion of cancer survivor morbidity.  
These findings have been supported by observational studies of adult cancer survivors in whom 
cardiovascular disease is a leading cause of mortality, even when death due to cancer recurrence is taken into 
account(6). In addition to increased frequency, patients with heart failure due to cytotoxic therapy also have a 
three-fold higher mortality rate than those with idiopathic dilated cardiomyopathy(7). The link between cancer 
survivorship and CVD is likely multifactorial - being partly due to the overlap in risk factors for cancer and 
CVD (e.g. smoking, age), but is also attributable to well-documented cardiotoxic effects of contemporary 
chemotherapy(8,9).  
It can therefore be appreciated that cancer-therapy-related cardiac dysfunction (CTRCD) is an under-
appreciated and relatively frequent cause of heart disease in the Australian community. Sequential cardiac 




imaging places substantial burdens on the patient and increases healthcare costs; however, the frequency of 





Cardiovascular complications. Examples of potential aetiological agents 
Vascular 
Hypertension Chemotherapy (cis-platinum, anti-angiogenic agents) 
Premature coronary artery disease Radiation therapy 
Arterial thrombosis Chemotherapy, malignancy 
Venous thrombosis Tamoxifen, bevacizumab 
Structural 
Conduction abnormalities Anthracyclines, thalidomide 
Valvular dysfunction Radiation therapy 
Pericardial effusion Radiation therapy, anthracyclines 
Constrictive pericarditis Radiation therapy, surgery. 
Myocardial 
Myocarditis Cyclophosphamide, anthracyclines 
Cardiomyopathy Anthracyclines, trastuzumab, mitoxantrone. 
 
Subtypes of CTRCD 
Overview: Two broadly different patterns of cytotoxicity have been recognized, and it has been prognostically 
useful to categorize cardiotoxic cancer drugs into groups based on these patterns. Type I cardiotoxicity refers 
to the effects of drugs that cause acute myocyte injury (as measured either by biomarkers or endomyocardial 
biopsy) causing irreversible damage and depressed cardiac function on a dose-dependent basis(10). Re-
initiation of the offending drug is usually contraindicated, and even in the absence of re-exposure, a gradual 
and progressive deterioration of function has been reported, perhaps explained by concurrent sources of 
myocyte damage (see below). Anthracyclines are the prototype for this category of drug reaction. In contrast, 
type II cardiotoxicity refers to a pattern of often reversible cardiomyopathy with no evidence of acute myocyte 
injury, is not dose-dependent and re-initiation of the offending drug is usually not contraindicated. 
Trastuzumab is an example of an agent that could potentially cause type II cardiotoxicity. Another example of 
Table 1‐1: Potential cardiovascular complications of cancer treatment. 




a group of agents implicated in type II cardiotoxicity are the growth factor inhibitors, for example sunitinib, 
where left ventricular dysfunction appears to be mediated by hypertension(11). 
This distinction between type I and type II cardiotoxicity remains clinically relevant, as they have 
different LVEF thresholds beyond which cancer treatment should be ceased(12). It is worth noting that the 
boundaries of these groupings remain unclear, and the cardiotoxic reversibility of several of these agents remains 
debated(13). Additionally, further studies have found that mean LVEF of traztuzumab-treated patients may 
remain depressed by absolute value of -3.8% at 3 years, suggesting that an element of irreversible dysfunction 
persists. This raises the possibility that this Type I and Type II classification of 2 arbitrary categories may be 
simplistic(14). It is anticipated that future research may lead to the ability to phenotype CTRCD due to 
intracellular pathways and histopathological findings, but until then the Type I and II categorisation based on 
cardiac imaging findings remains the most practical and easily communicated approach, and we will utilize it 
for the purposes of this chapter. Table 2 summarizes the forms and frequencies of cardiotoxicity profiles 
observed with different chemotherapeutic agents. For purposes of clarity, we will discuss anthracyclines and 
trastuzumab as representatives of class I and class II cardiotoxicity respectively. 
 
Type I cardiotoxicity (anthracyclines): The widespread use of anthracyclines began in the 1970’s, and this 
family of drugs remain commonly used for breast cancer, leukemias, lymphomas and sarcomas. Initial high-
dose use was limited by myelosuppression, but this was largely reversible after drug discontinuation. 
Cardiomyopathy has since been found to be a more insidious and potentially fatal complication. Recent 
prescribing patterns show a fall in anthracycline use(15). This fall has a number of probable explanations, 
including concern regarding late cardiomyopathy and improvements in availability of alternative effective 
cytotoxic agents, particularly for breast cancer(16,17).  
 Anthracyclines exert their antineoplastic effect by intercalating with DNA and then inhibiting the 
topoisomerase II enzyme, thereby preventing synthesis of RNA and DNA(18). They exert their cardiotoxic 
effect through oxidative damage, generated by the anthracycline forming a complex with iron, which in turn 
catalyzes free radical production. The free radicals then act within the cell to cause membrane disruption and 




cellular dysfunction. Myocytes are especially vulnerable to oxidative damage, as they lack the catalase or 
glutathione reductase enzymes, which could act as reserves for managing oxidative stress. Agents that protect 
against free radical damage, such as dexrazoxane, have been trialed with some success in preventing 
chemotherapeutic cardiotoxicity. However, due to concerns that dexrazoxane may reduce the anti-cancer 
efficacy of anthracyclines, this approach has not been widely adopted(19). An alternative, or possibly 
complementary, mechanism of cardiac damage is by disabling topoisomerase-IIβ, an isoform relatively specific 
to myocytes(20). 
 The risk of anthracycline cardiotoxicity is proportional to the cumulative anthracycline dose. One 
pivotal study showed that for total doxorubicin-equivalent dose of <400 mg/m2 the risk of cardiotoxicity was 
0.14%, for 400-700 mg/m2 the risk was 7% and of doses >700 mg/m2 the risk was 18%(21). It is likely that the 
real-life incidences of cardiotoxicity are higher, as this trial did not have a long follow-up period nor access to 
modern echocardiography, and changes in patient populations in the past 30 years mean that older patients with 
more cardiovascular comorbidities are now being treated with chemotherapy. There is strong evidence of acute 
cardiac injury at the time of anthracycline administration(22). Myocardial biopsies taken in the peri-
chemotherapy period show characteristic cardiotoxic changes, including sarcoplasmic reticulum ballooning, 
depletion of myofibrillar apparatus and vacuole formation(23). Additionally, biomarker assays reveal troponin 
elevations in the same time frame(22). However the timeline of development of cardiotoxicity shows steady 
incremental gain, with prevalence increasing from 11% at 1 year, to 14% at 2 years and 20% at 5 years(24). One 
case report describes a patient who developed severe anthracycline cardiotoxicity (on the basis of exclusion of 
alternative diagnoses) 17 years after treatment with a low-to-moderate cumulative dose(25). The discrepancy 
between acute myocyte injury and risk of long-term cardiomyopathy suggests the possibility that anthracyclines 
may “prime” the heart for dysfunction, a process described in the “multiple-hit” hypothesis of heart failure 
development(26). 
 In comparison with other cardiomyopathies, anthracycline-cardiotoxicity appears to have a substantially 
worse prognosis, with mortality rates up to 60% at 2 years(7). The hazard ratio for mortality for anthracycline-
cardiotoxicity has been reported as being over three-fold that of idiopathic dilated cardiomyopathy. The number 
of Australians alive in 2007 who had been diagnosed in the past 26 years with a cancer that was likely to be 




treated with anthracyclines (e.g. breast cancer, hematological malignancies, sarcomas) was over 197,000, i.e. 
0.9% of total Australian population(4). Hence, the combination of a large at-risk pool, delayed yet steadily 
increasing risk of cardiotoxicity years after treatment and resultant high mortality means that CTRCD may be 
an under-recognized problem that could account for a meaningful proportion of the national morbidity and 
mortality of heart failure. 
 
Type II cardiotoxicity (trastuzumab): Trastuzumab is a monoclonal antibody against the human epidermal 
growth factor receptor tyrosine kinase (HER2-erbB2), which is a member of a cell-receptor family that aids in 
regulating cell growth and intracellular repair(27). Overexpression of HER2 receptor occurs in approximately 
25% of breast cancers and confers increased proliferative and metastatic potential. Trastuzumab has been used 
in HER2+ve breast cancers, with significant reductions in recurrence rates and overall mortality, with a pivotal 
study in the metastatic setting demonstrating a 33% reduction in mortality at 1 year and a 5-month increase in 
median survival(9). 
Trastuzumab’s mechanism of cardiotoxicity remains unclear, but the established importance of HER2-
ErbB2 complex in normal cardiac function and development suggests possible explanations(28). Erb-B2 is a 
co-receptor for other ErbB tyrosine kinase receptors, which activate specific pathways on dimerization. Cardiac 
endothelial cells release a glycoprotein called neuregulin-1, which binds to ErbB4 receptor, which 
heterodimerizes with the trastuzumab target, ErbB2, to activate downstream intracellular signaling pathways, 
namely the ERK-MAPK (extracellular signal-regulated kinase - mitogen-activated protein kinase) and PI3K 
(phosphatidylinositol 3-kinase) pathways. These pathways promote cardiomyocyte proliferation, contractile 
function and myocyte survival(29). In mice, germline deletion of ErbB2, ErbB4 or neuregulin-1 genes causes 
failure of embryonic ventricle formation. It is possible that trastuzumab-mediated disruption of these pathways 
generates a pro-apoptotic state that could lead to cardiac dysfunction after additional insult. This is supported 
by the absence of microscopic myocyte changes after trastuzumab administration(28). Other possible 
cardiotoxic mechanisms include antibody-dependent cell-mediated cytotoxicity, interactions with other 
chemotherapeutic agents, disordered cellular homeostasis (e.g. calcium regulation) that causes increased 
sensitivity to increased afterload, or by causing structural change and gain of signaling function of ErbB2. 




 Trastuzumab has been associated with cardiotoxicity, but its true intrinsic cardiotoxicity remains 
debated(13). The original trials showed significant reductions in left ventricular ejection fraction (LVEF) in up 
to 27% of patients, with symptomatic heart failure seen in 5%, but this trial involved trastuzumab being 
administered concurrently with anthracyclines(9), and it has been historically difficult to disentangle 
trastuzumab cardiotoxicity from anthracycline cardiotoxicity as many patients receive both. However, the trials 
that have imposed the longest intervals between anthracycline and trastuzumab therapy have reported the lowest 
rates of cardiotoxicity.  One trial that compared an anthracycline-and-trastuzumab arm with a trastuzumab-alone 
arm found that the incidence of congestive heart failure was five fold higher in the anthracycline arm than in the 
trastuzumab alone arm (2.0% vs. 0.4%)(30). Interestingly amongst 10,000 patients who received trastuzumab 
as adjuvant therapy, only a single cardiac death was recorded(31). In the same trial, asymptomatic LVEF 
decrease occurred in 8%-10%, and approximately half demonstrated LVEF recovery and had trastuzumab 
reinitiated.  
Overall, trastuzumab monotherapy appears to have a lower than expected incidence of cardiotoxicity, 
with no characteristic histopathological findings on endomyocardial biopsy(28). Regardless of the intrinsic 
cardiomyopathic potential of trastuzumab, there is clearly a synergistic effect with anthracyclines. The 
mechanism underlying this may be that trastuzumab turns off previously described cellular pathways required 
for repair of subclinical anthracyclines damage, thereby unmasking a pre-existing cardiomyopathy. Evidence 
that anthracycline administration upregulates HER2- receptor concentration supports this possibility(32). 
 
Screening for cardiotoxicity:  Current professional society guidelines support the use of cardiac imaging to 
screen for cardiotoxicity. The European Society of Cardiology guidelines for the diagnosis and treatment of 
acute and chronic heart failure (2012) advise both pre-and post-chemotherapy screening of LVEF(33). 
Responses to the development of LV dysfunction include treatment for systolic heart failure and cessation of 
chemotherapy. A position statement from the Heart Failure Association of the ESC (2011), further elaborates: 
“Regular cardiovascular evaluation should be part of routine care in patients receiving treatment regimens 
known to be associated with significant cardiotoxicity, and follow-up beyond the completion of chemotherapy 
should be considered, especially in those receiving high-doses of anthracyclines”. In neither of these documents 




is there a suggested modality for screening, a suggested timeframe or cut-offs for treatment. In USA, the 
ACC/AHA 2005 guideline update for diagnosis and management of congestive cardiac failure in the adult 
specifically recommends echocardiography as an imaging modality, but is similarly vague in terms of screening 
timeframes and cut-off points(34). 
Sequential LVEF measurement is a common theme in professional society recommendations. However, a 
reduction in LVEF is likely a final step in a long-standing cardiomyopathic process, and the use of LVEF may 
therefore result in missing a window for earlier treatment. It has been reported that up to 58% of patients with 
CTRCD fail to recover LV systolic function despite appropriate treatment(22). The existence of a latent stage 
appears supported by the biomarker evidence of myocyte injury and late cardiac decompensation. The model 
proposed by 2005 ACC/AHA guidelines suggests that cardiomyopathy follows a predictable sequence of 
stages(34). The majority of chemotherapy-treated patients would be considered equivalent to stage A, i.e. at 
high risk of future development of cardiomyopathy. In the absence of screening, patients likely would not come 
to medical attention until they became symptomatic (stage C). Evidence of LV dysfunction characterizes stage 
B. Screening for stage B HF would detect patients at an earlier stage and enable earlier treatment. To extrapolate 
from the Framingham study, 26% of patients in stage B heart failure progressed to symptomatic heart failure 
over 5 years(35), so a strong case can be made for treating asymptomatic cardiotoxicity if it can be diagnosed 
early. 
 




Table 1-2: Categories of chemotherapeutic agents associated with cardiomyopathy and description of observed pathology 




Acute Chronic     











Uncommon and not usually life-
threatening (approx. 3%)1 
Includes atrial fibrillation, acute 
heart failure, myocarditis and 
acute coronary syndromes. 
Cardiomyop
athy 
Dose-dependent, approximately 5% at 
adriamycin dose 400-450 gm/m2 
Sarcoplasmic 
reticulum dilatation, 
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1% Chu et 
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Nil Cardiomyopathy 1.6% clinical heart failure or LVEF drop >20%1  
0.2% clinical heart failure 
Not available Low Perez et al 
(38) 




























Arterial thrombosis Unknown 3% acute serious arterial thrombotic events Not available Low Cotres et 
al(40) 




Proposed Screening Modalities. 
ECG: Due to their low cost, ready availability and provision of additional diagnostic information (e.g. 
heart rate, rhythm), ECGs have been studied for signs of cardiotoxicity. They are effective in detecting 
acute cardiotoxicity, which is often associated with rhythm disturbance, heart block, ischaemic changes 
or pericarditis (Table 1-3). However acute anthracycline cardiotoxicity is infrequent (approx. 1%), 
usually reversible, not life-threatening and probably not predictive of later cardiac events(36). 
Reductions in QRS voltage have been reported in the peri-anthracycline period, but this is not predictive 
of future events(41). There is currently no evidence suggesting that ECG monitoring has a role in 
identifying patients at risk of future chemotherapy-related cardiomyopathy. 
Biomarkers: Histopathological evidence of acute myocyte injury at time of chemotherapy has led 
researchers to examine troponin as a biomarker for identifying patients at high risk of developing 
cardiomyopathy. Approximately a third of chemotherapy patients will have a detectable troponin rise in 
the peri-chemotherapy period(42). Several studies have found an association between perioperative 
troponin rise and LVEF decline, future cardiac events and response to HF treatment(22). A frequently 
cited study recruited 703 cancer patients and collected troponin levels at two timepoints, one shortly after 
chemotherapy and one 1 month later(43). Over a follow-up of 20 months, patients in whom both troponin 
levels were <0.08 ng/mL had a 1% cumulative rate of cardiac events, compared with 84% rate in patients 
with two troponin levels ≥0.08 ng/mL. In contrast, another study examined 81 HER2-+ve breast cancer 
patients, and found that troponin level > 30 ng/L was only modestly predictive of future cardiomyopathy, 
with PPV of 44% and NPV of 77%(44). Although the information to date suggests that troponin testing 
holds promise, larger trials incorporating control groups and blinding in regard to assignment to 
treatment groups are needed. 
MUGA: Multi-acquisition gated scintigraphy (MUGA) scans are frequently used for the assessment of 
LVEF in patients receiving chemotherapy. They have the advantages of being accessible, accurate and 
reproducible with low inter-observer variability(45). Their disadvantages include being more costly, 
radiation exposure (approx. 8-12 mSv), the lack of additional diagnostic information obtainable from 
other modalities (e.g. diastolic function, valvular function) and being insensitive for cardiac dysfunction 




before LVEF decline. Recent studies have also raised concern regarding the precision of MUGA-derived 
LVEF measurements, with limits of agreement with the gold standard of cardiac MRI being reported as 
wide as -19.4% to +16.0%(46). 
Echocardiography: Echocardiography is the most frequently used imaging modality for screening for 
chemotherapy-cardiotoxicity and is specifically referred to in several guidelines as the imaging modality 
for this context(34). It is inexpensive, accessible, does not involve radiation exposure and provides other 
useful diagnostic information. Its main disadvantage is that it is operator-dependent. Two-dimensional 
imaging has significant test-retest variation, such that the minimum LVEF decrement for which 
observers can state with 95% confidence is a true LVEF decline is at least 10%(47).  
 Three-dimensional echocardiography is more accurate than two-dimensional echocardiography 
for measuring LV volumes, with significantly less test-retest variation. One study of 50 HER2-+ve breast 
cancer patients compared correlation between two-dimensional echocardiography and CMR with three-
dimensional echocardiography with CMR, and found that the correlation coefficient improved from 
r=0.69 with 2D-TTE/CMR to r=0.95 with 3D-TTE/CMR, confirming the incremental higher accuracy 
and reproducibility of 3D-TTE(48). Further studies are required to determine the strength of correlation 
between LVEF measured by 3D-TTE and clinical outcomes. Again, both standard 2D and 3D imaging 
are dependent on accurate contouring of LV. 
Speckle-tracking strain imaging: Strain is a unitless measure of the deformation of the myocardium. 
The reduction of longitudinal strain appears to be an initial step in the development of many early 
cardiomyopathic processes, with the LVEF preserved by compensatory increases in other strain 
parameters. Hence detection of reductions in global longitudinal strain can potentially detect 
derangements in systolic myocardial mechanics before LVEF decline and could lead to earlier detection 
of patients at risk of developing chemotherapy-related cardiotoxicity. Several studies support this 
hypothesis. A significant reduction of global longitudinal strain (>10% from baseline) after 3 months 
has been reported to predict future cardiotoxicity diagnosis with sensitivity of 78-79% and specificity of 
79-82%(44). This appears to be a promising technique with the potential for earlier accurate diagnosis 




of cardiotoxicity. A randomised trial comparing the strategy of using strain imaging to guide treatment 
compared with standard sequential LVEF measurements is currently underway(49). 
Cardiac Magnetic Resonance (CMR): CMR is currently the gold standard for measuring myocardial 
volumes and masses, due to its excellent endocardial definition, ability to image in any plane and 
excellent spatial resolution. It also has the ability to image myocardial scarring by using gadolinium 
contrast, and new experimental techniques hold the promise of quantifying diffuse myocardial fibrosis. 
The use of CMR in screening for chemotherapy-related cardiomyopathy is limited by cost, access and 
contraindication for patients with metallic implants. Additionally gadolinium administration is 
contraindicated for patients with significant renal dysfunction. Although used primarily in detecting 
LVEF reduction (with the same considerations about the limitations of LVEF), strain measurement is 
possible with CMR and methods have been described to identify cardiac oedema. The value of late-
gadolinium enhancement (LGE) in chemotherapy-related cardiotoxicity also remains unclear, with some 
studies suggesting a typical pattern of lateral subepicardial enhancement, and other studies suggesting 
that LGE is rarely seen in this condition (50). Presently, the role of CMR in routine screening for 
chemotherapy-related cardiomyopathy is not supported outside of a clinical trial.  
 
Prevention of cardiotoxicity. 
Cardioprotective medications (i.e. ACE inhibitors, β-blockers) appear to prevent or delay the 
progression of this problem, and early stages of this condition appear to respond well to these agents(22).  
Alterations to the chemotherapy regimen can substantially reduce the risk of cardiotoxicity, although 
there is the possibility of a trade-off of reduced anti-neoplastic efficacy. Reducing the total cumulative 
dose of cardiotoxic anti-cancer treatments certainly reduces the risk of cardiotoxicity(51). Using longer 
infusions (at least 6 hours) reduces cardiotoxic risk, but places extra demands on the patient and hospital 
resources. Epirubicin, a semi-synthetic anthracycline analogue, is recorded to have a lower incidence of 
cardiotoxicity than doxorubicin, with up to an extra 33% chemotherapy cycles allowed before epirubicin 
cardiotoxicity rates equal those of doxirubicin(51). Liposomal preparations of anthracyclines are also 




less cardiotoxic, putatively due to an increased molecular size making the agent less diffusible over well-
formed vasculature (e.g. myocardium) but retains the ability to diffuse across poorly differentiated 
vasculature (e.g. cancer tissue). Lastly, dexrazoxane is an anti-oxidant agent that lowers the risk of 
cardiotoxicity when given concurrently with anthracyclines(51). Although its efficacy in reducing 
cardiotoxic risk is robust(19), one trial that showed a reduced anti-neoplastic effect when given with 
anthracyclines(51) has led to current recommendations that it only be used in the treatment of metastatic 
cancers. 
 
Cardio-protection against CTRCD 
 There is substantial heterogeneity in approaches to screening for CTRCD throughout the world, 
which has led to diagnostic confusion and possible waste of resources. This thesis aims to identify a 
high-yield cardiac imaging strategy that will allow earlier and more effective treatment of CTRCD. For 
screening with cardiac imaging to be effective, however, there is a requirement for effective treatment 
that alters the natural history of the disease. 
Several agents have been shown to improve outcomes with CTRCD. The OVERCOME trial 
randomized 90 patients with malignant hemopathies, majority of whom were treated with anthracyclines, 
to prophylactic enalapril and carvedilol versus observation(52). A reduced composite outcome of death, 
heart failure or final LVEF<45% was found in the treatment group (6.7% vs. 24.4%, p=0.02). Statins 
may also offer protection against LV dysfunction(53). A recent meta-analysis suggested that ACE 
inhibitors, β-blockers, statins and dexrazoxane have similar efficacy in preventing CTRCD(19), and may 
be considered for preventing progression of CTRCD. Provided that LV function recovers, it would be 
prudent for these patients to have long-term regular cardiac monitoring and follow-up to monitor for 
cases of late onset.  














This chapter provides an overview of the burden of CTRCD and utility of standard cardiac imaging 
techniques used for diagnosis. The following points summarise the main findings of scientific literature 
to date; 1) there is a substantial population of cancer survivors alive in Australia who are at risk of 
CTRCD; 2) CTRCD is a source of significant morbidity and mortality amongst the cancer survivor 
population; 3) earlier treatment of  CTRCD with cardio-protective medications prevents adverse 
cardiac events, and this effect is attenuated with later administration of cardio-protective medications; 
4) contemporary definitions of CTRCD are dependent on accurate LVEF measurements, which 
represent a late stage of the disease and 5) novel cardiac imaging techniques, such as global 
longitudinal strain, may permit earlier and more effective treatment of CTRCD, leading to better 



























Figure 1-1: Suggested screening and treatment algorithm for patients treated with chemotherapy regimens 
associated with chemotherapy-related cardiomyopathy. 2D- two-dimensional; GLS- global longitudinal strain; 
LVEF – left ventricular ejection fraction 





The next chapter aims to assess the effect of chest-directed radiotherapy on cardiac function and 
attempt to determine whether patients who receive significant cardiac irradiation represent an at-risk 
group for long-term heart failure who may merit an early interventional strategy with cardioprotective 
medications. 










Risk of Cardiac Dysfunction from Chest-
Directed Radiotherapy 
 
Part of the research contained in this chapter has been published as(1,2): 
 Nolan MT, Russell DJ and Marwick TH. Long-term risk of heart failure and myocardial 









Chemotherapy and radiotherapy represent the two primary non-surgical approaches to treating cancer. 
The role of chemotherapy in causing CTRCD has previously been discussed, but the association 
between radiotherapy and CTRCD is less well understood.  Many small breast cancers without lymph 
node involvement (i.e. stage 1) may be treated by surgery and radiotherapy without chemotherapy. 
Assessment of cardiac complications in context of radiotherapy alone can determine whether screening 












Background: Chest irradiation is a commonly used treatment for malignancy, with demonstrated 
symptomatic and survival benefit. The frequency and presentation of cardiovascular complications of 
radiotherapy remains unclear.  
Methods: We performed a systematic review to evaluate the prevalence and manifestations of myocardial 
dysfunction (asymptomatic and symptomatic) in long-term cancer survivors treated with radiotherapy.  
Results: Thoracic radiotherapy is associated with increased risk of heart failure in long-term follow-up, 
with hazard ratios ranging from 2.7 to 7.4 for Hodgkin lymphoma, and 1.5-2.4 for breast cancer. Although 
ejection fraction is often normal, systolic dysfunction has been more widely reported with modern 
techniques including 2-dimensional speckle strain and cardiac magnetic resonance. This might have 
implications for the selection of patients for cardioprotection. Despite common emphasis, diastolic 
functional abnormalities were infrequent in the long term. A limited amount of data suggest that right 
ventricular dysfunction is important in this population.  
Conclusions: The reports were heterogeneous, used different treatments, end points, and definitions of 
myocardial dysfunction, and most studies on the cardiac consequences of radiotherapy involved small 
numbers of patients and were published decades ago, making it difficult to formulate definitive conclusions 
for the current era. 
 





Radiation therapy (RT) is currently used in management of up to 50% of cancer patients, with over 
100,000 courses of RT administered in Canada in 2010 (54). Significant RT-induced reductions in 
cancer recurrence and mortality have been demonstrated (55), but this success is partially offset by 
long-term complications. RT has been associated with damage to all components of the cardiovascular 
system, including myocardial, valvular, conduction and pericardial diseases (56). The relationship 
between RT and certain cardiovascular diseases has been well-characterized. For example, a large case-
control study has demonstrated a relative 7.4% increase in major coronary events per Gy over 5 decades 
(57), and a large nested case-control study demonstrated an incidence of 12.4% for at-least moderate 
valvular heart disease in patients who received >35 Gy over 30 years (58). However, the relationship 
between radiotherapy and myocardial disease is less clear, with diastolic dysfunction and restrictive 
cardiomyopathy (56,59) commonly cited as common manifestations, often on the basis of single studies. 
Heart failure (HF) represents a serious healthcare burden, with 54,333 HF hospitalizations in Canada in 
2005/2006 alone (60). Due to a clearly identifiable population of patients and onset of risk, RT-induced 
myocardial disease might represent an opportunity for effective preventative screening, but consensus 
statements by professional guidelines have been inconsistent. According to recent HF guidelines (61), 
previous chemotherapy represents a HF risk factor and confers a Stage A Heart Failure status, but no 
specific guidance is given for patients treated with RT. The European Society of Medical Oncology 
2010 guidelines (62) state that “RT-induced risk is lifelong and requires long term follow-up”, but also 
note that “follow-up protocols are based on departmental or personal experience”. Expert consensus 
from the American College of Cardiology and European Association of Cardiovascular Imaging suggest 
echocardiography at ten years post-RT, with subsequent echocardiograms every 5 years (63), but further 
guidance regarding high-risk populations, disease manifestations and prevalence are needed to guide 
screening.  The purpose of this systematic review is to summarize the existing scientific literature 
regarding the type and prevalence of long-term myocardial dysfunction and heart failure after RT for 
malignancy, so to assist in guiding future screening and management. 
 





We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines for reporting the systematic review(64). The search strategy was designed prospectively. 
PubMED and EMBASE were searched from inception to July 2015. Citations and details were stored 
in a database (EndNote X7.4, Thomson Reuters, New York, NY).  
Search criteria. Due to the potentially large number of variables, including different malignancies, 
different cardiac imaging techniques or outcomes and different treatment descriptions (e.g. 
radiotherapy, chemoradiotherapy), a liberal search strategy was employed to increase sensitivity. Two 
reviewers conducted a literature search of Medline/PubMed and EMBASE for published reports that 
investigated cohorts of cancer patients treated with mediastinal radiotherapy for subclinical for clinical 
myocardial dysfunction, including heart failure for all years from inception to 2015. Papers were limited 
to those published in English. References of publications and relevant papers were also searched for 
further reports. 
Inclusion criteria: Publications in peer-reviewed, English-language journals evaluating long-term 
myocardial function after radiotherapy were included in this systematic review if they met the following 
criteria:  1) average patient age (either median or mean) of ≥18 years at time of RT administration, 2) 
administration of RT therapy for cancer, 3) quantification of myocardial function, either by using 
noninvasive cardiac imaging to report ventricular function, or reporting outcome of symptomatic heart 
failure as a specific outcome of study design, 4) presence of a time interval of at least 5 years between 
RT and measurement of myocardial function. Exclusion criteria included 1) studies not meeting all of 
the inclusion criteria, 2) non-human studies and 3) abstracts or conference proceedings. No restrictions 
were applied to the types of patients, study’s country of origin or type of institution where outcomes 
were evaluated. 
Outcomes: For selected studies reporting subclinical myocardial dysfunction, primary outcomes were 
cardiac imaging parameters that quantified the degree of myocardial dysfunction, including but not 
limited to, left ventricular ejection fraction and volumes, measures of diastolic dysfunction and 




myocardial deformation measurements. For selected studies reporting the outcome of clinical 
myocardial outcome, primary outcome was cumulative incidence of heart failure and measure of effect 
size associated with mediastinal radiotherapy (reported as odds ratio, relative risk or hazard ratio). 
Data extraction:   Data were extracted by one review author (M.N.) and checked by a second review 
author (D.R.) Discrepancies between review authors were resolved by consensus or, if necessary, by a 
third author (T.H.M). Information on publication year, sample size, type of malignancy, average age 
(either median or mean), gender ratio, total radiation dose (mean or median), follow-up and outcome 
findings were extracted independently from every study. 
 
Results 
Study selection. From the original screening set of 7,329 papers, 766 were deemed suitable for abstract 
review, to which a further three papers were added from bibliographic review of review articles (Figure 
1). From the 176 papers reviewed, 38 contributed data to this analysis. 
Mediastinal irradiation for Hodgkin’s Disease. Twenty-one studies (1,659 patients), were identified 
as fitting inclusion criteria for investigation of long-term ventricular function after mediastinal 
irradiation for Hodgkin’s disease. Sixteen were over a decade post-publication and 5 were ≥30 years 
post-publication. Ten used transthoracic echocardiography (TTE) as the non-invasive imaging testing 
modality, eight used radionuclide angiography (RA), 2 utilized both TTE and RA, and one utilized 
cardiac MRI (CMR). The differing modalities, different endpoints and definitions of ventricular 
dysfunction precluded performance of a meta-analysis.  
 




Table 2-1: Summary of studies that have investigated systolic or diastolic function over 5 years after mediastinal radiotherapy for Hodgkin’s Disease 
First author, 
Year, (Ref.#) 





Groarke et al, 
2015 (65) 
Rest TTE 263 
(153 had 
TTE) 
30±12.4 years  
(mean±SD) 
54% 38 Gy (IQR 36-
40) 
19 years (median) Mean diastolic parameters for RT patients within reference range 
No comparison with control diastolic values. 
Chen et al, 
2014 (66) 
Rest/stress TTE 182 28.5 (median) 60% 39.6 Gy 15 years 26 (14%) had LVEF<55% 
Machann et al, 
2011 (67) 
CMR 31 21 (median) 
(range 6-41) 
42% 40 Gy (median) 24 years median 
(range 20-28) 
Mean LVEF 48±3%; 23% had LVEF<55% 
29% had LGE 
Tsai et al, 2011 
(68) 
TTE (LVEF, GLS 
and GCS) 
47 38 ± 9 (mean) 70% 41 ± 2 Gy 22 ± 2 years Mean LVEF 55.4%; Mean GLS -16.1±1.9% in RT + anthracyclines, vs -17.5±1.7% for RT 
alone; 20 (42.5%) had GLS<17% 
GCS -18.3± 3.2% for RT + anthracyclines, vs -17.8±3.6% for RT alone 
No difference in diastolic measurements (e.g. e’ 4.9±1.5 cm/sec vs 5.1±1.2 cm/sec) 
Busia et al 2010 
(69) 
TTE (M-mode, 2D) 147 38.2 (mean) 56% 34.3 Gy At least 5 years Mean LVEF 59.9% 
Mean LVEDD 4.35 cm 
Heidenreich et 
al, 2005 (70) 




50% 43.5 Gy 15 years (mean) Mild diastolic dysfunction in 9% 
Moderate diastolic dysfunction in 5% 
Salloum et al 
1999 (71) 
RNV 24 27 (median) 
(range 27-51) 
28% 23.4 Gy 6 years (median) Mean LVEF decline of 4.7%, but only 1 pt (4.2%) had LVEF<50% 
Normal diastolic function and LV volumes in all pts 
Glanzmann et 
al, 1998 (72) 
TTE (M-mode, 2D) 144 30.2 (range 4 -65 Not stated 30-40 Gy 14 years 
(mean, range 1.9-31.5 
years) 
LVEF ≥55% in 95% 
Normal diastolic function in pts without hypertension/CAD 
Constine et al, 
1997 (73) 
Rest/stress RNV 50 26.0±8.6 
(mean±SD) 
64% 35.1±7.8 Gy 
(mean) 
9 years (mean) Mean LVEF 59.6±6.2% 
PFR 3.46±0.88 
Lund et al, 
1996 (60) 
TTE (2D, M-mode) 116 28±7 42% 40.6 Gy 9 ± 3 years E/A 1.1 (vs 2.0 for controls). 
No significant difference in LV-FS or chamber size 
Kreuser et al, 
1993 (74) 
TTE (2D, M-mode 
and Doppler) 
31 35 (median) 
(range 15-38)) 
45% 20-30 Gy 5.4 years 
(range 2-10) 
18.4% had reduced LV-FS, 14% had reduced resting LVEF 
12% had dilated left atrium, No significant difference in diastolic parameters (E.A, DecT)  
Allavena et al, 
1992 (75) 
TTE (2D, M-mode) 73 29 
(median) 
35% 36.5 Gy 5 years 
(range 3-10) 
Mean LVEF 60% (range 51-75%), 4 pts (5.5%) had hypokinetic septum or apex 
1 pt (1.4%) had mildly dilated RV 
Gustavsson et 
al, 1990 (76) 
TTE (2D, M-mode) 
RNV 
26 38 (median) 
(range 21-45) 
35% 40 Gy 15 years (median) 
(range 4-20) 
44% had decreased LV fractional shortening 
50% had diastolic dysfunction (E/A<1.0) 




16 24.9 ± 6.2   9 ± 6 Mean resting LVEF 60 ± 7%, No abnormal LVEF measurements. 
Peak Filling Rate 3.5 EDV/sec, 2 (12.5%) had abnormally low PFRs 
Pohjola-
Sintonen et al, 
1987 (78) 
TTE (2D, M-mode) 28 23.3 (mean) 
 
Not stated 4130 rads 9 years (mean) (range 5-
14 
2 pts (7%) had resting LVEF<50% 
34% had RV thickness increased by >2SD  
Perrault et al, 
1985 (79) 
TTE 
(2D and M-mode) 
38 HD 
3 seminoma 
41 (median) 41% Not stated 12 years Resting LV systolic dysfunction in 13% (i.e. LVEF<50%) 
Morgan et al, 
1985 (80) 
RNV 25 20.1 ± 5.6 
(mean) 
40% Not stated 20 ±6 5% had resting LVEF<50%, 15% had <5% LVEF increase to exercise 
6 (30%) had RV dilatation 
Burns et al, 
1983 (81) 
RNV 21 44 ± 11 
(mean±SD) 
48% 3,589 ± 1,101 
rads 
14 ± 5 years Rest LVEF 68± 9.2, RVEF 43± 9.7 
Exercise LVEF 68±11, RVEF 40±12; Significantly reduced exercise RVEF response vs 
controls  




41 25 (mean) Not stated Total mid-plane 
dose 4,000 rads 
97 months (mean), 
range 37-172 
Mean resting LVEF 59%, 7 (17%) had LVEF<45% at rest, 
Exercise LVEF 69%; 7 (17%) had abnormal LVEF response to exercise, (increase <8%)) 
2 pts (4.2%) developed HF 
Gomez et al, 
1983 (83) 
RNV 55 24 
(median) 
Not stated 3,500 rads/d 
over 35 days 
(range 30-120 months) 21.8% had LVEEF<43%, 29.1% had LVEF in range 43-50% 
Applefeld et al, 
1982 (84) 
RNV 16 HD 22.9  
(mean) 
Not stated 3000-4000 radS 8 years (median) 25% abnormal resting LVEF (<45%) 
1 pt with HF 




CMR – cardiac MRI, IQR – Inter-quartile range, GCS – global circumferential strain, GLS – global longitudinal strain, HD – Hodgkin’s Disease, HF – heart failure, LGE – late gadolinium enhancement, LVEDD – LV end-diastolic dimension, 
LVEF – LV ejection fraction, LVFS – LV fractional shortening, RNV - Radionuclide ventriculography, RT – radiotherapy, RVEF – RV ejection fraction, TTE – transthoracic echocardiography




Systolic dysfunction. Mediastinal irradiation for Hodgkin’s disease shows diverse effects on ejection 
fraction, with studies providing contradictory findings and conclusions (Table 2-1) (60,65-84).  In 
general, LV ejection fraction was found to be significantly reduced in significant proportions in several 
studies. Publications showing >50% of subjects to have an LVEF<50% (83) and 44% with reduced 
fractional shortening (76) derive from over 20 years ago, when cumulative mediastinal RT doses were 
higher than are currently used. Nonetheless, other reports from a similar era report only a 14% 
prevalence of impaired EF (66), and a similar cumulative total radiation dose 95% of patients had a 
normal LVEF at 13.7 years post RT (72).  More recently, a normal resting LVEF has been reported in 
93% patients studied 8.6 years after therapy (78).  
Ejection fraction has recognized limitations for identifying mild or subclinical LV dysfunction, which 
is better measured using 2D speckle tracking strain. In a study of LV systolic dysfunction at an interval 
of 22 years after mediastinal RT(68), global longitudinal strain (GLS) was significantly impaired 
compared with age-matched controls (-17.5±1.7% vs 20.4±1.7%, p<0.05), and this difference was more 
pronounced for patients treated with both RT and anthracyclines (-16.1±1.9%, , p<0.05). No significant 
difference was seen in LVEF values between groups. 
In addition to the provision of highly accurate and reproducible cardiac chamber volumes, CMR has 
the benefit of providing tissue characterization, including the quantification of myocardial scar. In a 
study showing that 23% of asymptomatic screened patients had resting LVEF values <55% (mean 
LVEF 43±3%), Machann et al reported that 29% had late gadolinium enhancement that was not 
explainable by other etiologies (67). No specific anatomical pattern of LGE was discerned.  
Diastolic function. Of the 21 studies using noninvasive cardiac imaging in long-term HD survivors 
treated with RT, 10 (47.6%) included measurements of diastolic function. The results reported were 
inconsistent, with 6 studies demonstrating no significant long-term change in diastolic 
parameters(65,68,71-74), and 4 studies reporting abnormal diastolic function (60,70,76,77). The 6 
studies reporting no change comprised 4 echocardiographic studies and 2 radionuclide ventriculography 
studies, with a total of 450 patients followed after an average of 13.5 years and underwent an average 




of 36.9 Gy (mean of all 5 studies). These studies were relatively recent, with 5 of the studies published 
from 1997 onwards.  
In contrast, the 4 studies reporting significant change in diastolic function included 3 echocardiographic 
and 1 radionuclide ventriculography studies. Two studies (60,76) used solely an E/A ratio to define 
diastolic dysfunction, 1 used peak flow rate <2.54 EDV/sec as definition of abnormal (77), with 12.5% 
termed abnormal, and one study used composite of E/A, deceleration time (DecT) and pulmonary 
venous flow velocity systolic/diastolic ratio to grade diastolic function (70). These 4 studies (n=440 
patients) were generally older than the studies reporting no diastolic change, with 3 published earlier 
than 1997 (73,76,77) and 1 in 2005 (70). Their follow-up was incrementally shorter (12.2 years) 
compared with the 6 negative studies (13.5 years) and involved greater doses of mediastinal irradiation 
(41.4 Gy, averaged over three studies that reported average radiation dose). The largest of these studies, 
Heidenreich et al, consisted of 64% of the patients in these 4 studies, had the longest follow-up (mean 
15.4 years) and the highest average radiation exposure (43.5 Gy). It reported 14% prevalence of 
diastolic dysfunction (9% mild, 5% moderate, none severe), and compared these findings with 
Rochester community published data suggesting an expected prevalence of 6.4% in this age group (85). 
All patients underwent stress echocardiography, with 28% of the diastolic dysfunction patients 
demonstrating inducible myocardial ischemia, compared with 11% of patients with normal diastolic 
function. Two studies (76,77) used treadmill exercise testing to exclude ischemic heart disease as a 
cause of diastolic dysfunction, with neither study demonstrating ischemia in their small patient groups, 
and the fourth study (60) not using any test for ischemic  heart disease. 
Right ventricular size and function. Of the 20 identified studies, only 5 (25%) assessed right ventricular 
(RV) size or function in post-irradiated Hodgkin’s survivors (75,78-81). One study (75) included a 
reference of “slight RV dilatation” in a cohort of 73 patients, inferring but not explicitly stating that RV 
size  was normal in the remaining subjects, and did not provide any tabulated RV data. The remaining 
four studies (20%) consist of two echocardiographic and two radionuclide ventriculography studies 
with an average follow-up of 13.7 years. Small numbers of patients were recruited (mean number of 
subjects per study was 28), and notably all four studies were published approximately 30 years ago 




(time period 1983-1987). Two studies (79,80) did not specify the average dose of radiation 
administered, and for the remaining two the mean dose was 3,860 rads. All four studies found a high 
prevalence of abnormal RV findings. Two studies examined solely RV structure, with one (78)  finding 
34% had RV wall thickness increased above 2 standard deviations and another (80) finding that 24% 
had resting RV dilatation. Neither of these studies had a non-irradiated control cohort. Of the two studies 
that assessed RV systolic function (79,81), one reported 39% prevalence of RV dilatation or 
hypokinesis, and the other reported a significant difference in RVEF response to exercise compared 
with healthy controls (resting RVEF 43±9.7% vs 37±5.1% with p=NS, exercise RVEF 40±12% vs 
53±12%, p<0.005 for irradiated patients and controls respectively). 
 
Mediastinal irradiation for breast cancer 
Systolic function:  The majority of noninvasive cardiac imaging studies in long-term breast cancer 
survivors were focused on investigating ischemic heart disease and described ventricular findings in the 
context of inducible perfusion defects. Once these were excluded, only 4 studies were found that fitted 
the inclusion criteria (Table 2-2) (67,86-88). Three used echocardiography (86-88) and 1 utilized 
radionuclide ventriculography (67), and together, they totaled 253 patients, followed over an average 
of 10.6 years, with total radiation doses from 20-50Gy. The study that demonstrated systolic 
dysfunction (87) found that 5% of irradiated patients had resting LVEF<50%. This study involved a 
small number of patients (37 breast cancer survivors, mean age 65 years) but had the longest follow-up 
of all four studies (median 18.4 years). Although the mean total radiation dose in this study was not 
specified, it was the oldest of the four (published in 1994), and hence likely involved a higher radiation 
dose than the more contemporary studies. This study also found increased LV wall thickness in 30% 
(defined as end-diastolic wall thickness > 11mm), whereas for the two other studies that reported LV 
wall thickness and mass (67,88), no significant abnormalities were reported.  
 



















First author Method n Age at RT  Women (%) Total Radiation Follow-up Findings 
Magne et al, 
2009 (67) 
RNV 64 48 (median) 
(range 29-65) 
 
100% Not stated 6 years 
(median) 
No significant change in LVEF for any pt (mean LVEF69%, range 63-74%) 
Pistevou-
Gompaki et 
al, 2008 (86) 
TTE (2D, M-mode) 62 56  
(mean) 
(range 48-64) 
100% 50 Gy 5 years No significant change in LVEF, EDV or LV wall thickness 
Gyenes et al, 
1994 (87) 
TTE 37 (20 treated with XRT) 65.1 (mean) 
(range 54-72) 




5% had LV systolic dysfunction (LVEF<50%) 
40% had LV diastolic dysfunction used multiple parameters) 
30% had LVH (end-diastolic wall thickness >11mm) 
Gustavsson et 
al, 1999 (88) 
TTE (2D, M-mode) 90 (34 left-sided XRT, 35 right-
sided XRT,23 no XRT) 
57.2 (median) 
(range 45-64) 
100% 20 Gy (received by 
anterior LV wall)) 
13 (median) All had normal systolic function (defined as LV-FS>25%) 
E/A lower in RT pts (1.05 vs 1.2, p=0.04) 
No difference in LV mass, LVEDD or LA size. 




Table 2-3: Summary of studies that have investigated the risk of developing symptomatic heart failure after radiotherapy. 
First 
Author 










2524 HD 27.3 (median) 45.7% 37 Gy (median) 20.3 years 
(median) 
HR for HF 2.7, (95%CI 1.6-4.8) 
SIR 6.8 (95%CI 5.9-7.6) compared with general population 





(27.7% treated with XRT) 
 




100% Not stated 8 years Left-sided XRT HR 1.04 (95%CI .53-2.03) 
Right-sided XRT HR 0.83 (95%CI 0.34-2.03) 
Boerman et 








100% Not stated 9 (median) 
(range 5-57) 
2.2% all XRT patients developed HF 
HF HR 0.5 (95%CU 0.2 – 1.8) for XRT vs no XRT 
Left vs right XRT HR 0.98 (95%CU 0.3 – 3.6) 
Bouillon et 




(68.2% treated with XRT, 
62.2% treated with XRT alone) 
55 (mean) 
(range 22-90) 
100% Not stared 28 years 
(median) 
In XRT group, HF deaths were 2.9% of all deaths; XRT HF HR 2.39 (95%CI 1.41 – 4.03) 




34,825 BC 56%<50 y.o. 
39%>70 y.o. 
100% 6.3 Gy applied 
to heart for left-
sided tumors 
2.7 Gy for right-
sided tumors 
5-30 years 1.8 % developed heart failure (compared with 2.9% non-irradiated BC pts) 









100% 56.6 Gy 8.2 years 
(median) 
2 (1.6%) developed HF 





(59.5% treated with XRT) 
73  
(median) 
42.6% Not stated 8-19 years In XRT group: 
Cardiac dysfunction HR 1.54 (95%CI 1.29-1.83) 
Cardiomyopathy 0.46 (95%CI 0.25-0.80) 
HF 1.06 (95% 0.96 1.18) 
Myrehaug et 
al, 2008 (94) 
Data-linkage 
study 




SIR 0.9 (95%CI 0.1 to 2.5) in RT-alone group for HF hospitalization. 
Hooning et 




(86.5% treated with XRT) 
49  
(median) 
Not stated Not stated 17.7 years 
(median) 
In XRT group: 
HF HR1.47 (95%CI 1.04 – 2.08) 
Increased with longer follow-up, e.g. >20 years FU, 
HR 2.1, p<0.001 





(84% treated with XRT) 
25.7 46.4% Not stated 18.7 years 
(median) 
SIR 25-year cumulative incidence of HF after XRT and anthracyclines 7.9% 







2,491 testicular cancer patients 
(51.9% treated with XRT) 
33.9  
(median) 
0% Not stated 18.4 years 
(median) 
Cumulative incidence HF 66 pts (2.6%), SIR0.93 (95%CI 0.71 to 1.20) 
HF HR 3.1 (95%CI 1.7 to 4.7) 








Not stated Not stated 9.5 years 
(median) 
(range 0-15) 
9.7% cumulative incidence for HF hospitalization 
For left vs right XRT: 
HF HR 1.05 (995%CU 0.95 – 1.17) 
 
Hancock et 
al, 1993 (99) 
Data-linkage 
study 
2232 HD 28% aged 
<10 y.o. 
42% aged > 
40 y.o. 
59% Not stated 9.5 years 10 pts (0.45%) developed heart failure 




Diastolic function. Two of the four studies examined left ventricular diastolic dysfunction after RT for 
breast cancer (87,88). Gyenese et al found diastolic dysfunction in 8 patients (40%), determined by 
composite of E/A ratio, DecT and IVRT. However, this prevalence was not different from a non-irradiated 
breast cancer control group, which had a diastolic dysfunction prevalence of 53%.  Gustavsson et al found 
lower resting E/A ratio in irradiated breast cancer survivors after a median 13 years of follow-up (E/A 1.05 
vs 1.2, p=0.04), but found no significant difference between irradiated a non-irradiated patient in regards 
to LV mass, wall thickness or left atrial size. To date, no studies have been identified that have used 
advanced imaging modalities for assessing LV diastolic function in long-term breast cancer survivors (e.g. 
tissue Doppler imaging, diastolic speckle strain). 
There were no identified studies examining right ventricular size and function after mediastinal irradiation 
for breast cancer. There were also no identified studies using advanced non-invasive cardiac imaging 
techniques (e.g. 2D speckle-tracking strain, three-dimensional echocardiography, CMR) for investigating 
long-term myocardial performance after irradiation for breast cancer. 
 
Mediastinal irradiation for other malignancies  
No clinical studies were identified fitting the inclusion criteria for other malignancies, including 
esophageal, lung cancers and seminomas. 
 
Heart failure after mediastinal irradiation 
A total of 12 studies (Table 2-3), (55,58,89-96,98,99) were identified that investigated the incidence of 
cardiac failure after irradiation in survivors of long-term malignancy, including those with Hodgkin’s 
disease (58,94,96,99), breast cancer (55,89-92,95,98) and non-small-cell lung cancer (93). The majority 
were based on data-linkage and one was a retrospective cohort study. These studies included a total of 




112,149 patients followed up for a total average of 14.3 years. Females accounted for 73% of the patients 
due to the high proportion of breast cancer trials included. There was a diverse range of age groups 
represented, with a median age of 25-35 years old in the HD studies, 49 to 66 years old in the breast cancer 
studies, and 73 years in the NSCLC study. The average radiation dose could not be determined in most 
studies. Of the 12 studies, most (83%) were published in the past 10 years, thereby reflecting radiotherapy 
practice mainly over the last 25 years. 
In the earliest study of HD (99), the cumulative incidence of HF mortality of 0.45% over a follow-up of 9.5 
years. Although no information on nonfatal HF events was included, another study (94) examined the 
incidence of HF hospitalization, and found that RT alone had a standardized incidence ratio (SIR) of 0.9 
(95% 0.1 to 2.5), suggesting no significant association. In contrast, studies with longer follow-up found 
increased risks of developing HF with mediastinal RT. Aleman et al (96) investigated 1474 HD survivors 
with a median of 18.7 years post-treatment, and found HF was associated with RT with a SIR of 4.9, 
resulting in 25.6 excess cases of HF per 10,000 patient-years. In comparison with HD survivors not treated 
with RT, RT was significantly associated with HF (HR 7.37, 95%CI 1.81 to 30.0). The second study (58) 
investigated 2524 HD survivors at median 20.3 years post-treatment and found an increased incidence of 
HF (SIR 6.8, 95% 5.9 to 7.6) resulting in 58 excess HF cases per 10,000 patient-years. The observed 
incidence was higher in patients treated at younger ages, with 18-24-year age group demonstrating SIR 18.7 
(95%CI 14.5 – 23.6) and 40-50 year age group demonstrating SIR 2.7 (95%CI 2.0 to 3.7). Mediastinal RT 
also conferred increased risk for HF (HR 2.7, 95%CI 1.6 to 4.8).  
Seven studies (55,89-92,95,98) examined the association of RT for breast cancer with HF, six using a data-
linkage design and one using a retrospective cohort design (92). Together they totaled 71,095 patients 
followed up for an averaged 13.4 years. It was not possible to estimate the mean radiation dose from 
information provided.  Five studies provided median ages, for which the mean was 56.2 years. All studies 
had been published in the past 10 years. The retrospective cohort study (92) found a low cumulative 
incidence of 1.9% of HF in 129 BC patients treated with mean 56.6 Gy RT with median follow-up of 8.2 




years. A data-linkage study (90) found no significant association between RT and newly diagnosed HF (HR 
0.5, 95%CI 0.2 to 1.8) after following 561 BC patients for median of 9 years. One study (89) followed 
10,444 BC patients (28% treated with mediastinal RT) and found no significant association of RT with HF 
for left-sided disease (HR 0.83, 95%CI 0.34 to 2.03) or right-sided disease (HR 0.87, 95%CI 0.45 to 1.67)  
when compared with surgery alone. Another (55) investigated 34,825 patients and did not find an increased 
incidence of hospitalized HF (1.8% in RT arm, vs 2.9% in non-irradiated arm). Amongst irradiated patients 
who developed HF, there was no association with laterality of disease (left vs right incidence ratio 0.95, 
95%CI 0.81 to 1.11). In contrast, three other studies suggested an association between RT and HF. One 
study(98) investigated 16,270 patients, all treated with RT and followed-up for median 9.5 years, and found 
9.7% cumulative incidence of HF hospitalization, with laterality having no effect (left vs right HR1.05, 
95%CI 0.95 to 1.97). Two other studies which contained non-irradiated cohort patients that could serve as 
controls demonstrated significantly increased hazard ratios for CF after RT, with one (95) investigating 
4410 BC patients followed up over 17.7 years (HR 1.47, 95%CI 1.04 to 2.08) and another (91) following 
up 4456 BC patients over 28 years for HF deaths (HR 2.39, 95%CI 1.41 to 4.03). 
A single study (93) was identified that examined 34,209 patients treated with RT for NSCLC and found no 
significant association with HF (HR 1.06, 95%CI 0.96 to 1.18).  Another study investigated 2,491 with 
testicular cancer, 51.8% treated with mediastinal radiotherapy, and found HF was significantly associated 
(HR 3.1, 95%CI 1.7 to 4.7) (43).  
 
Discussion 
The studies selected for this systematic review display a large degree of heterogeneity, both in terms of 
study characteristics and findings. Notably, a large number of studies (17 of 40) were published over 20 
years ago, and many consist of cohorts with small numbers of patients. It is therefore difficult to reach 
definitive conclusions regarding the etiology and presentation of radiation-induced myocardial disease, 




despite RT being used as a therapeutic modality for almost a century. However, it is possible to consider 
new steps in researching radiation-induced cardiomyopathies. 
Ventricular dysfunction. Current contemporary opinion of radiation-induced cardiomyopathy emphasizes 
diastolic dysfunction (56,59), a highly prevalent finding in the elderly. Evidence for diastolic dysfunction 
attributable to RT is predominantly based on autopsy findings of increased fibrosis (100) and a cohort study 
conducted 20 years earlier (70). However, the autopsy studies were conducted decades earlier when RT 
delivered higher dosages, and likely represent a selection bias with over-representation of patients with 
severe RT complications. The use of population-derived values as a comparator in the retrospective cohort 
study might be confounded by a lower rate of hypertension and smoking than in the cancer population. Our 
review suggests that most studies that examined diastolic function did not find significant long-term 
changes, although many had methodological limitations. There therefore still remains need to characterize 
long-term diastolic function in RT patients. 
LV systolic dysfunction was prevalent in half of noninvasive imaging studies conducted on HD and BC 
survivors and was detectable in more contemporaneous studies using advanced imaging techniques (e.g. 
speckle-tracking strain, CMR). This is relevant as unlike diastolic dysfunction, treatments (e.g. ACE 
inhibitors, β-blockers) for systolic dysfunction have been shown to alter the condition’s natural history even 
in the pre-symptomatic stage, and therefore potentially support the concept of screening of asymptomatic 
RT patients. Determining the risk of LV systolic dysfunction after RT, and the benefits of screening and 
cardioprotection represent interesting research strategies. 
In contrast to the previous entities, RV dysfunction was commonly found in studies that specifically 
investigated the issue. This may not be unexpected as RV is the most anterior cardiac chamber and may 
have less functional reserve due to lower mass. RV dysfunction is an independent adverse prognostic 
marker in heart failure (101) and accounts for a large proportion of symptomatic burden. Whether regular 
screening of RV function in long-term RT survivors may be beneficial is unclear. 





Heart failure. Recent advances in data-linkage research has allowed very large groups of patients to be 
investigated for infrequent complications without the cost or difficulties associated with cohort studies. 
Excellent studies have reported associations between RT and ischemic heart disease (57), cardiovascular 
mortality (102) and combined cardiac events (103),  but few studies have used congestive cardiac failure as 
a specific endpoint. Although the associations reported in this systematic review were varied, there was a 
trend for the larger, more recent studies that included patients not treated with RT (58,91,93,95) to 
demonstrate significantly increased HF risk, with HR values ranging from 2.7 to 7.4 for Hodgkin’s 
lymphoma, and 1.5 to 2.4 for breast cancer. In total, these findings support the current guidelines for 
evaluating cardiovascular complications after RT (63), which currently recommend screening 
echocardiogram 10 years after RT, with further echocardiograms every 5 years onwards if no pathology is 
detected.  
Limitations. The selection criteria for this review sought to focus the data on the population most likely to 
be suitable for screening. Due to biological differences in tissue response to injury in different age-groups 
and the much higher prevalence of malignancies in the adult population compared to the pediatric 
population, we excluded studies that predominantly investigated children or adolescents. A minimum of 
average 5-year follow-up period was chosen because by convention the initial 5 years represents the period 
of highest mortality risk from malignancy or acute treatment complications, and also because current 
guidelines (63) define  a five-year period as the onset of increased cardiac risk, and recommend screening 
in 5-year intervals. Because our aim was to investigate specifically myocardial diseases, which have distinct 
disease manifestations and treatments, papers either examining non-myocardial diseases alone (e.g. 
coronary artery disease, pericardial disease, valvular disease) or failing to specify myocardial outcomes 
were excluded. No statistical meta-analytical techniques could be performed due to the significant 
heterogeneity in malignancies, imaging modalities and endpoints studied.  




A challenge for further researchers is to determine the post-RT cardiovascular risk in malignancies besides 
HD and BC, including esophageal cancer, lung cancer and seminoma. It is likely that differences in 
population characteristics (e.g. older age and smoking in esophageal and lung cancers) and treatment 
differences may make results from HD and BC trials non-generalizable. However, despite using a broad-
based search strategy, this systematic review did not identify any long-term cardiovascular imaging studies 
in these subgroups. Ideally, optimal screening regimens could be individualized based on malignancy, but 
there is currently insufficient scientific information to adopt such an approach. 
 
Conclusions. With successful advances in contemporary cancer treatment, clinical challenges are slowly 
pivoting from increasing 5-year survival to managing chronic health conditions in cancer survivors. This 
vulnerable population requires further research to develop strategies for identifying patients at high-risk for 
RT-induced myocardial disease and provision of early and effective treatment. 
 
Postscript 
This thesis demonstrated that the majority of studies assessing imaging endpoints of long-term cardiac 
function after chest-directed radiotherapy found that left ventricular function worsens and raises the 
possibility of significant right ventricular long-term effects. The next thesis chapter will assess the 
relationship between chest-directed radiotherapy and the clinical endpoint of heart failure.  
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The previous chapter of this thesis demonstrated the differing phenotypes of cardiac dysfunction resulting 
from chest-directed radiotherapy for cancer. These findings were clinically significant as phenotypes of 
systolic and diastolic cardiac dysfunction have different treatment paradigms, as does right and left 
ventricular cardiomyopathy. Therefore, there is a discordance between the traditional definition of anti-
cancer treatment cardiac dysfunction, which is defined by an absolute decrement in LVEF with or without 
the presence of symptoms, and the clinical reality of a derangement of multiple axes of cardiac 
homeostasis with different CTRCD patients displaying differing degrees of involvement for each axis. 
This provides a rationale for using more than one cardiac imaging modality for selected patients so to 
further characterise their dysfunction.  
The next thesis chapter changes the focus from cardiac imaging findings to the patient’s clinical 
characteristics and an endpoint that is more significant for the patient, namely that of heart failure. The 
aim of this chapter is to quantify the risk of heart failure secondary to chest-directed radiotherapy. As over 
50% of cancer treatments involve radiotherapy administration, if a significant association is seen then a 
cogent argument can be made that CTRCD is a predictable complication of anti-cancer therapy and merits 














Background: This investigation sought to identify and quantify any increased risk of long-term heart 
failure after thoracic radiotherapy for cancer and identify any population covariates that corresponded with 
increased risk. 
Methods: Electronic databases were systematically searched for studies reporting relative risk, odds ratio 
and hazard ratio for symptomatic heart failure more than 5 years after radiotherapy administration. Clinical 
characteristics, study design, univariable effect sizes and associated 95% confidence intervals were 
extracted. Univariable effect size was pooled and computed in a meta-analysis using random-effects models 
weighted by inverse variance. 
Results: Six studies (45,669 patients) with weighted median follow-up duration of 13.9 years were 
included, each data-linkage study that reported hazard ratios for heart failure. Pooled hazard ratio for long-
term heart failure was significant (HR 1.83, [1.09 to 3.08], p = 0.022), with significant between-study 
heterogeneity (Q 43.38, df 5, p<0.001, I2 88.47%). Statistical significance was lost when excluding studies 
of malignancies other than breast cancer or haematological malignancies, and excluding studies with 
Newcastle-Ottawa scores <8, but the direction of effect and magnitude remained approximately the same. 
Subgroup analyses and meta-regression demonstrated that study differences in age at time of radiotherapy 
administration and duration of follow-up explained approximately 80% of observed heterogeneity. Earlier 
publication date was associated with increased heart failure risk. Other variables, including female 
proportion, proportion of adjuvant chemotherapy use and sample size did not significantly impact the 
conclusions. 
Conclusions: In conclusion, radiotherapy approximately doubled the long-term risk of heart failure. This 
finding was associated with younger age at time of radiotherapy and longer follow-up duration, which 
explained approximately 80% of inter-study variability. 





Heart failure (HF) affects approximately 1-2% of population in developed countries, with 
prevalence rising to >10% in persons aged ≥70 years(33). Radiotherapy (RT) treated patients represent a 
rare group with a clearly identifiable onset of risk for myocardial injury, and as such may represent an 
attractive target for preventative screening and treatment. However, consensus guidelines by professional 
medical societies have been inconsistent in their recommendations. According to recent HF 
guidelines(61), previous chemotherapy represents a HF risk factor and confers a stage A HF status, but no 
specific guidance is given for patients treated with RT. The European Society of Medical Oncology 2010 
guidelines(104) states that “RT-induced risk is lifelong and requires long term follow-up”, but also note 
that “follow-up protocols are based on departmental or personal experience”. Expert consensus from the 
American College of Cardiology and European Association of Cardiovascular Imaging suggest 
echocardiography at ten years post-RT, with subsequent echocardiograms every 5 years (63), but further 
guidance regarding high-risk populations, disease manifestations and prevalence are needed to optimally 
guide cardiac screening. Thus, we performed this systematic review and meta-analysis to quantify the 
long-term risk of HF after thoracic RT for malignancy. 
 
Methods 
We followed the Preferred Reporting Items for Systematic Reviews and Meta- 
Analyses (PRISMA) guidelines(64) for reporting the systematic review. The search strategy was defined 
prospectively and listed in the PROSPERO database (registration number CRD42015020508). Citations 
and details were stored in a database (EndNote X7.4, Thomson Reuters, New York, NY). A liberal search 
strategy was employed to increase sensitivity. Two reviewers conducted a literature search of 
Medline/PubMed and EMBASE that investigated cohorts of patients treated with thoracic RT for HF for 




all years from inception to July 2015. HF was defined as the clinical syndrome associated with 
insufficient cardiac function to meet the body’s demands. 
Publications were limited to those published in English. References of publications and relevant 
papers were also searched for further reports. The search excluded studies of paediatric populations to 
prevent confounding of results, as a child’s heart appears to be more susceptible to chronic RT adverse 
effects than an adult’s heart(105), as evidenced by recognition of younger age at RT being a risk factor 
for cardiotoxicity(106) in addition to experimental evidence demonstrating greater biological 
susceptibility to RT in developing hearts(107). Publications in peer-reviewed, English-language journals 
evaluating long-term HF were included in this study if they met the following inclusion criteria: 1) 
average patient age (either median or mean) of ≥18 years at time of RT administration, 2) administration 
of adjuvant RT therapy (either tangential or mediastinal) for cancer, 3) measure of risk of HF reported as 
a binary outcome, either as hazard ratio, risk ratio or odds ratio and 4) presence of a time interval of at 
least 5 years between RT and determination of HF status. Exclusion criteria included 1) studies not 
meeting all of the inclusion criteria, 2) non-human studies and 3) abstracts or conference proceedings. No 
restrictions were applied to the types of patients, study’s country of origin or institution type where 
outcome was determined. 
  Relevant studies were selected from literature searches by 2 review authors (M.N. and D.R.), who 
also extracted relevant data. Discrepancies between review authors were resolved by consensus or, if 
necessary, by a third author (T.H.M.). Information on publication year, sample size, follow-up duration, 
average age (either median or mean), gender ratio, RT dose and use of concurrent chemotherapy were 
extracted independently from each study.  
















Reported measures of risk, including odds ratio (OR), hazard ratio (HR) or risk ratio (RR), were 
pooled and analysed using a random-effects model weighted by inverse variance as described by 
DerSimonian and Laird. Assumption of heterogeneity was tested by using Q, and between-study 
heterogeneity was quantified using the I2 value. Sensitivity analyses were performed by removing studies 
with following characteristics; studies examining cancers other than breast cancer or haematological 
cancers, studies with Ottawa-Newcastle quality score <8, and studies with low sample size. Subgroup 
analyses were performed using mixed-effects model with pooled τ2 estimates. Meta-regression was 
performed using random effects model. Publication bias was assessed visually by funnel plots of effect 
estimates and by Begg statistical test. If the number of studies assessed was <10, then further assessment 
Figure 3-1: Flow diagram for study search and selection 




of possible publication bias would be undertaken with Orwin’s fail-safe N and Duval and Tweedie’s Trim 
and Fill test. Statistical analysis was performed by Comprehensive Meta-Analysis® software, version 2. 
 
Results 
The study selection process (Figure 1) initially identified 7,329 individual studies, of which 6 
satisfied our selection criteria (Table 3-1). All 6 were data-linkage studies, using population-level 
electronic databases to match very large numbers of patients with desirable baseline characteristics (in 
this case, treatment with thoracic RT) with hospital-record diagnoses of HF. Two of the studies 
investigated breast cancer patients, two investigated Hodgkin’s disease patients, one investigated lung 
cancer patients and another metastatic testicular cancer. Of the 6 studies, a total of 45,669 patients were 
enrolled. Of these, 58.8% also received concomitant chemotherapy. Weighted mean age of the selected 
studies was 65.1 years with weighted mean follow-up of 13.9 years. 46.8% of subjects were female. Mean 
Newcastle-Ottawa observational cohort quality score was 8 (Table 3-2). Due to the data-linkage nature of 
the studies, specific information on RT dose, anthracycline administration and anthropomorphic 
information or ethnicity data were unavailable in the majority of published studies. Of the studies 
selected, 5 originated from the Netherlands.  
RT was found to increase the long-term risk of HF (HR 1.83, [1.09 to 3.08], p = 0.022). Test of 
heterogeneity was applied using Q, with Q value of 43.38 with 5 degrees of freedom, p<0.001 (Figure 2). 
This indicated significant heterogeneity not explained by random sampling error. I2 value was 88.47%, 
suggesting a high degree of inter-study variability. We hypothesised that this inter-study variability could 
potentially be explained by differences in either study population characteristics or study design. 
Sensitivity analyses (Table 3-3) revealed that restricting meta-analysis to studies involving breast cancer 
or haematological malignancies did not meaningfully alter the effect estimate, but it did fail to reach 
statistical significance. Removing studies with Newcastle-Ottawa scores <8 reduced the effect estimate 




and removed statistical significance. Removing studies with sample size <2000 subjects’ participants did 




Subgroup analyses were performed on the following study variables; i) median age less than 50, 
ii) follow-up less than 15 years, iii) female proportion less than 50% and iv) year of RT administration 
before 1981 (Table 3-4). For studies with median participant age ≤ 50 years old, there was increased RT 
effect on HF which was statistically significant, whilst no significant effect was seen with studies with 
median age > 50 years, with test of difference in risk between two subgroups (Q = 5.39, df =1, p=0.02) 
suggesting that impact of RT likely does vary with median age. For studies with less than or equal to 15 
years follow-up, there was no significant association between RT and HF but a significant association was 
seen if more than 15 years of follow-up occurred, with test of difference (Q = 5.39, df = 1, p = 0.02) 
suggesting that impact of RT likely does vary with length of follow-up. Trials with median age ≤50 years 
were an identical subset to that of trials with ≤15 years follow-up, explaining the identical pooled point 
Figure 3-2:  Forrest plot for pooled Hazard Ratio for HF after mediastinal radiotherapy 




estimate and test of difference findings. Subgroup analysis based on female proportion >50% 
demonstrated no effect of RT on HF. Studies with female proportion ≤ 50% did demonstrate an 
association, however the test of difference in effects (Q = 1.639, df=1, p=0.20) provided no evidence that 
impact of RT significantly depends on female proportion. Subgroup analysis of studies with RT 
administered before median weighted year 1981 showed an increased effect estimate while studies with 
RT applied after median weighted year 1981 did not have a statistically significant effect, with test of 
difference (Q=1.099, df=1, p = 0.294) suggesting that impact of RT does not vary with publication year. 
Therefore, of the four subgroup analyses, excluding studies based on median age and duration of follow-
up significantly varied effect estimate between groups, however female proportion and median weighted 
RT-administration year did not. 
Meta-regression analysis was performed to assess impact of study characteristics as continuous 
rather than binary variables (Figure 3). Study covariates utilised for meta-regression included i) female 
proportion, ii) length of follow-up, iii) median age at RT administration, iv) proportion of patients 
receiving adjuvant chemotherapy, v) publication year and vi) sample size. The following two 
characteristics did not have statistically significant impact on effect estimate slope; female proportion (β -
0.387, p = 0.13) or proportion in each trial receiving chemotherapy (β -0.855, p=0.08). Follow-up 
duration significantly predicted effect estimate outcome (β 0.146, p <0.001). Both median age (β -0.023,  
p <0.001) and publication year (β -0.076, p = 0.016) demonstrated significant inverse associations. 













Figure 3-3: Meta-regression models for following covariates plotted against log hazard ratio: a) female 
gender (%), b) length of follow-up (years), c) median age at RT administration (years), d) proportion of 
patients receiving chemotherapy (%), e) publication year and f) sample size. 




Goodness of fit analysis was applied to meta-regression models for age (unexplained τ2 0.051, Qresid 4.8 at 
4 degrees of freedom, R2= 83%) and follow-up duration (unexplained τ2 0.07, Qresid 4.4 at 4 degrees of 
freedom, R2 = 77%). Thus, patient age and duration of follow-up each accounted for approximately 80% 
of observed between-study heterogeneity. The individual R2 values sum to over 100%, most likely 
because age and follow-up duration are not independent of one another and the same variance source is 
captured twice. 
The risk of publication bias was assessed by funnel plot, shown in Figure 4, with visual 
inspection not revealing any obvious asymmetry and Begg’s test not demonstrating evidence of bias. 
However, these tests have low power due to small number of studies. If one assumes that publication bias 
did exist, Orwin’s fail-safe N test revealed an additional 15 studies with mean HR of 1.0 would be needed 
for cumulative effect estimate to become trivial (defined as HR <1.05). To assess the robustness of study 
conclusions against publication bias, Duval and Tweedie’s Trim and Fill test demonstrated an adjusted 
HR (HR 1.11, [1.02 to 1.22], p =0.022), which was reduced in magnitude from the observed values (HR 
1.83, 95%CI 1.08 to 3.08, p=0.020) but remained statistically significant. 
 
Discussion 
The main findings of the present study are the following: firstly, that thoracic RT approximately 
doubles the risk of long-term HF (as defined by clinical HF), and secondly that covariates associated with 
increased HF risk included younger median age at time of RT, longer follow-up duration, and earlier 
publication year. The present meta-analysis is the only study that pools long-term risk of HF after RT in 
adult cancer survivors. Our results broadly agree with a systematic review of increased HF in 
children(108), as well as observed increased rates of coronary heart disease(57) and valvular heart disease 
in adults(109) and is broadly consistent with research findings in the field. 
  








Figure 3-4: Funnel plot for assessing publication bias. 





To date, the understanding of radiation-induced myocardial disease has lagged behind 
improvements in the knowledge base of radiation-induced coronary and valvular dysfunction. Current 
reviews suggest that RT is associated with increased prevalence of diastolic dysfunction, however this 
conclusion is based on small studies performed without appropriate comparator groups. A systematic 
review conducted by the authors suggested that either systolic or diastolic dysfunction may characterise 
late HF associated with prior mediastinal RT(110). Histological examination of explanted hearts exposed 
to RT demonstrates widespread inflammation, microvascular obstruction and intimal proliferation of 
myofibroblasts(111), and agents designed to protect endothelial function have demonstrated utility in 
small animal studies(112). These findings support a proposed “two-hit” hypothesis(113), where cancer 
therapy causes subclinical myocardial damage in majority of patients, which reduces myocardial reserve 
for future cardiovascular risk factors. This hypothesis is in keeping with our finding of increased long-
term HF risk in studies that had younger patients and longer durations of follow-up and suggests potential 
benefit for prolonged cardiovascular surveillance of cancer survivors. Current guidelines suggest 
screening echocardiogram in high-risk patients 5 years after RT and after 10 years for low-risk patients, 
with repeat echocardiography every 5 years afterwards(63). The results of our meta-analysis broadly 
support these recommendations; however we note that in contemporary practice only a minority of 
patients may actually receive recommended monitoring even in the short-term setting(114).  
We also note that cardio-protection against anthracycline and trastuzumab-mediated 
cardiotoxicity is a rapidly developing field of research, with several randomised controlled trials recently 
being published(52,115). No comparable research exists for radiation-induced cardiotoxicity, and this 
study adds to the case that such research is needed to reduce HF prevalence in the community. 
There are several important limitations in our present study. Firstly, we acknowledge that we 
primarily recruited data-linkage publications, which carry specific advantages and disadvantages. The 
advantages of this approach are that large numbers of patients can be studied over a longer time period 




than would be impractical using randomised controlled trials or observational cohorts. However, the 
observational nature of data-linkage studies means we cannot exclude possibility that RT-treated group 
differed from comparison group in important aspects. Long-term randomised trials to resolve this point 
would be very challenging to perform and are not likely to eventuate in the foreseeable future. Secondly, 
we note that our results yielded a large degree of heterogeneity amongst trials. We used advanced meta-
analytical results to account for sources of heterogeneity and note that significant residual heterogeneity 
may be unavoidable for such a diverse clinical field. Thirdly, the number of studies recruited was small, 
which reflects the real-world complexity of accessing historical data of infrequent adverse effects over 
long time periods. Of the 6 studies selected, 5 originated in the Netherlands, which has an administrative 
register which contains near-complete and high-quality national hospitalization data from 1995 onwards 
for the entire country, making such studies possible. It is hoped that other health-care systems will follow 
the Netherlands lead in the future, to enable publication of further relevant studies. We also acknowledge 
that the small number of studies reduce the statistical power of subgroup analyses and meta-regression 
techniques, and therefore consider that these findings should be considered hypothesis-generating at 
current time. Fourth, due to the data-linkage aspect of the studies, aspects of patient demographics and 
treatment could not be provided, including proportion and cumulative dose of anthracycline use and RT 
technique and dose. Of the six studies analyzed, only 2 reported hazard ratios for heart failure associated 
with anthracycline administration; 1 study reported HR 3.0 (95%CI 1.9 – 4.7)(116) and 1 study reported 
HR 2.81 (95%CI 1.44 – 5.49)(96). Because the second study was confounded by the fact that 
anthracycline-treated patients had significantly shorter follow-up times than non-anthracycline treated 
patients, a decision was made not to perform meta-analysis on the 2 studies. Lastly, a fifth limitation was 
that we could not exclude the possibility of publication bias due to reduced statistical power due to low 
number of studies, however further testing suggested that it is unlikely that sufficient number of 
investigations were unpublished to alter this meta-analysis’s conclusions.  
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Postscript 
Despite current attention to the cardiotoxicity associated with chemotherapy and the identification 
of cardioprotective strategies, there has been little work done on risk protection from the cardiac 
consequences of radiotherapy. The work in the last two chapters identifies the magnitude of this problem 
and the features of the patients who are most at risk. Further studies are needed to improve protection 
against these cardiac sequelae.  
The initial chapters of this thesis have focused on the cardiac consequences of cancer therapy. 
However, the association of cancer with cardiac disease also arises because the two illnesses share 
aetiologic agents. In the next chapter, I sought to understand the relative magnitude of these joint risk 
factors, as a potential target for intervention.  



















Part of the research in this chapter has been published as(117): 
 Nolan MT, Marwick TH, Plana JP, Zhenghong L, Ness KK, Joshi VM, Srivistava D, Green DM, 
Robison LL, Hudson MM and Armstrong GT. Effect of Traditional Heart Failure Risk Factors 
Relative to Cardiotoxic Therapy for Impairment of Myocardial Function in Adult Survivors of 











The preceding chapters have demonstrated that CTRCD can occur relatively frequently in response to 
either chemotherapeutic or radiotherapeutic treatment strategies, and that cardiac monitoring in the peri-
treatment setting is a reasonable strategy for reducing burden of cardiomyopathy in the cancer survivor 
population. However, many adverse cardiac events are delayed until up to many years after completion of 
anti-cancer therapy, and even subclinical cardiac dysfunction may lead to heart failure if left untreated for 
prolonged periods of time. Two separate strategies for reducing heart failure burden in this population 
include 1) extending cardiac monitoring to beyond anti-cancer treatment completion with commencement 
of heart failure medications if cardiac dysfunction is detected and 2) aggressively treating traditional heart 
failure risk factors on the basis that cancer survivors represent an at-risk population of heart failure. 
This chapter aims to quantify the incremental risk of cardiac dysfunction due to traditional heart failure 
risk factors in the childhood cancer survivor population, and to compare the effect sizes of traditional risk 
factors with those of cancer-therapy-related risk factors. 





Background: Treatment of childhood malignancies is associated with risk for late-onset cardiac 
dysfunction.  
Objectives: To determine the relative contribution of traditional heart failure risk factors (HFRFs) and 
cardiotoxic therapy to impairment of myocardial function and functional capacity in adult survivors of 
childhood malignancies. 
Methods: We recruited 1807 adult survivors of childhood cancer (48% female, median age 31.6 years, 
range 18 - 62) with a median interval of 22.6 years (range 10.4 – 48.3 years) from treatment with 
anthracyclines (57.7%), chest-directed radiotherapy (16.8%) or both (25.5%.) Assessment included 
comprehensive echocardiographic examination (including two- [2D] and three-dimensional [3D] left 
ventricular ejection fraction (LVEF), global longitudinal strain (GLS) and diastolic grading). HFRFs 
included hypertension, insulin resistance, obesity and smoking history. Functional capacity was assessed 
by six-minute walk test (6MWT). Logistic models were used to adjust for the effects of known risk factors 
(including sex, age and anthracycline and radiotherapy dose). 
Results: Among 1807 participants with an evaluable echo, 13% had abnormal 2D-LVEF, 15% had 
abnormal 3D-LVEFs, 29% had abnormal global longitudinal strain and 46% had diastolic dysfunction. 
Presence of hypertension (OR 1.81, 95% confidence interval [CI] 1.25–2.62) was associated with an 
abnormal 3D-LVEF.  Insulin resistance (OR 1.72, 95%CI 1.30–2.28) and obesity (OR 1.58, 95%CI 1.19-
2.11) were associated with abnormal GLS. Diastolic dysfunction was associated with insulin resistance 
(OR 1.44, 95%CI 1.08–1.92), obesity (OR 1.92, 95%CI 1.42–2.58) and hypertension (1.41, 95%CI 1.03–
1.94). Smoking status was not associated with changes in myocardial functional indices. Effect size (ES) 
of insulin resistance on GLS (ES 1.09x10-2, p=0.002) was greater than traditional risk factors of age at 
assessment (ES 0.20x10-2, p=0.05) and cumulative anthracycline dose (ES 0.06x10-2, p=0.17). Obesity 
was the only HFRF associated with abnormal 6MWT results (OR 2.06, 95%CI 1.45 – 2.94). 
Conclusions: The effects of traditional HFRFs on echocardiographic markers of myocardial dysfunction 
are similar to those of treatment-related variables. HFRFs may be appropriate targets for active clinical 
intervention in childhood cancer survivors. 






The five-year survival rates from childhood malignancies have increased to over 80% (105), and as a result 
the number of adult survivors of childhood cancer is growing. Compared with the general population, this 
group has a higher lifetime risk of cardiovascular disease, including heart failure (HF), with up to 32% 
developing subclinical left ventricular dysfunction (LVD) at a median of 23 years from cancer diagnosis 
(118). Cardiac late-effects of cancer therapy are considered the cause of this increased risk; the majority of 
these survivors have a history of anthracycline or chest-directed radiotherapy treatment. Indeed, up to 86% 
of patients treated with anthracyclines will have myocardial histopathological changes (119). While this 
irreversible myocardial damage predisposes to HF, the delay of decades before HF onset suggests that it is 
not itself sufficient for HF development.  
The risk of non-ischemic HF is linked to a number of HF risk factors (HFRFs). It may be that exposure to 
cardiotoxic therapy reduces the heart’s tolerance for other cardiometabolic risk factors, culminating in the 
eventual progression to cardiomyopathy. There are no specific recommendations for optimal management 
of these HFRFs in the cancer survivor population (120), and thresholds for their treatment in the survivor 
population may be similar to the normal population. It is possible that this approach poorly serves the 
survivor population due to depleted LV functional reserve. However, there is currently a paucity of research 
assessing the additional impact of traditional HFRFs on cardiac dysfunction in the survivor population. 
Therefore, we sought to determine the relative impact of conventional HFRFs and the presence and intensity 
of potentially cardiotoxic therapy on echocardiographic measures of myocardial function and exercise 
tolerance in survivors of childhood cancer. 
 
Methods 
Participant recruitment. Subjects were participants from the St Jude Lifetime cohort study (SJLIFE).  
Inclusion criteria included; i) treatment for childhood cancer at St Jude Research Children’s Hospital, ii) 
received anthracycline and /or chest-directed radiotherapy, iii) 18 years of age or older and iii) at least 10 




years distant from treatment. Recruitment was completed by April 2013. Further details of SJLIFE 
recruitment and study design have been published previously (121). The local Institutional Review Board 
approved the study. 
Demographic and Exposure variables. Demographic and treatment data, including cumulative 
anthracycline dose and chest-directed radiotherapy radiation dose was obtained by abstraction of 
participants’ medical records. Patients completed a questionnaire and attended a clinical assessment for 
direct assessment of current medical conditions and presence of risk factors. Height and weight were 
recorded. Seated resting blood pressure was recorded three times, with the lowest reading selected for 
analysis. Blood samples were collected after an overnight fast.  
The following HFRFs were included in the current analysis, based on established association with incident 
HF in the non-cancer survivor population (122): presence of hypertension (defined as systolic blood 
pressure (BP) >140 mm Hg or diastolic BP > 90 mm Hg or self-reported history of hypertension or current 
treatment with anti-hypertensive medications), insulin resistance (defined as homoeostatic model 
assessment for insulin resistance (HOMA-IR) > 2.86), obesity (defined as body mass index [BMI] > 30 
mg/m2) and smoking status (defined as self-reported current, former or never).       
A 6-minute-walk test (6MWT) was performed indoors by experienced technician with a 6MWT distance 
of <490m considered abnormal (123). 
Echocardiographic Assessment. All echocardiographic examinations were performed by experienced 
sonographers using a standard echocardiographic system (Vivid 7, GE Medical Systems, Milwaukee, WI).  
LVEF and left ventricular morphology were measured using techniques outlined in American Society of 
Echocardiography (ASE) 2015 guidelines (124), with LVEF threshold of <53% designated as abnormal for 
both 2D and 3D-LVEF techniques. Given that formal thresholds for HF treatment are based on LVEF alone, 
abnormalities of 2D or 3D-LVEF were described as clinical cardiac dysfunction, and abnormalities in GLS 
or diastolic dysfunction without HF symptoms were described as subclinical cardiac dysfunction.   
Diastolic echocardiographic assessment included measurements of peak mitral inflow velocity (E), mitral 
septal and lateral early diastolic tissue velocities (e’), the ratio of these variables using the medial e’ velocity 




as the denominator (E/e’) and indexed left atrial volumes calculated using biplane orthogonal 
measurements. Diastolic grade was determined using criteria described in ASE 2016 guidelines (125). 
Diastolic dysfunction was defined as a binary variable with grade 1 or higher constituting dysfunction.  
The apical 2-chamber, 3-chamber and 4-chamber views were obtained for offline global longitudinal strain 
(GLS) measurement, with temporal resolution of 50-60 fps for image optimization. GLS was assessed using 
peak systolic strain measured by 2D-speckle tracking by EchoPAC version 10.0 software (GE Medical 
Systems). 2D-speckle strain measurements were considered abnormal if ≥ 2 standard deviations from age-
specific and sex-specific values from normal controls, extrapolated from the JUSTICE cohort of 817 
healthy volunteers (126). All measurements were performed in a core laboratory at the Cleveland Clinic. 
Statistical analyses. Baseline demographic and treatment characteristics of participants and nonparticipants 
were described using percentages for categorical variables and means ± standard deviations for continuous 
variables, with a chi-square test to assess for significant differences between groups. HFRFs were evaluated 
using Bayesian model averaging to automatically select the final logistic regression model for testing. All 
variables underwent univariable analysis, and variables with p≥0.1 were included in multivariable analysis; 
variables associated with abnormal cardiac function (gender, anthracycline cumulative dose, chest-directed 
radiotherapy, time since diagnosis, age at diagnosis) were included in all models. Each cardiac outcome 
variable was modelled independently. Multivariable odds ratios (OR) and 95% confidence intervals 
(95%CI) were estimated using models adjusted for treatment exposure. The final model with the lowest 
Akaike Information Criterion was selected for interpretation of findings. Standardised β coefficients were 
calculated by subtracting the mean from the variable and dividing by the standard deviation. Effect sizes 
were calculated using the semi-partial omega-square method to measure the adjust effect as proportion of 































Clinical features. Of 4575 patients assessed for eligibility for inclusion in SJLIFE cohort, 3209 were 
confirmed to have received anthracyclines and/or chest-directed radiotherapy for childhood malignancy 
(Figure 1). Echocardiographic assessments were completed in 1820 subjects; after exclusion of 13 due to 


























from diagnosis 22.6 years) were included in the final analysis. Compared with 1209 non-participants, 
participants were more likely to be female (44.4% vs 48.0%, p < 0.0001) and more likely to be non-
Caucasian (15.8% vs 20.1%, p = 0.01), with no other significant differences in baseline characteristics 
(Table 4-1).  
Associations with cardiac dysfunction. On echocardiographic assessment, 13% were found to have 
abnormal 2D-LVEF, 15% had abnormal 3D-LVEF, 29% had abnormal GLS and 46% had abnormal 
diastolic function. Of patients with abnormal diastolic function, 98% had grade 1 dysfunction, 1.3% had 
grade 2 dysfunction and 0.7% had grade 3 dysfunction. 
Baseline demographic factors had significant associations with systolic, diastolic and morphological 
echocardiographic parameters of cardiac dysfunction. Systolic dysfunction was independently associated 
with male gender, age >15 years at diagnosis and time since diagnosis. Chest-directed RT and anthracycline 
co-treatment was associated with greater change in LVEF, compared with treatment with anthracyclines 
alone. Diastolic dysfunction was independently associated with male gender and chest-directed 
radiotherapy. 
The associations of HFRFs with abnormal LV functional parameters are shown in Table 4-2. Insulin 
resistance (defined as HOMA-IR > 2.86 mmol/L) and obesity were associated with abnormal GLS and 
abnormal diastolic grade, but not with abnormal cardiac morphology. There was no association between 
CAD and any abnormal echocardiographic parameters.  
Standardized coefficients were calculated in order to compare the effect sizes for HFRFs and other features 
associated with HF (Figure 4-2) (Table 4-3). The greatest effect on GLS appeared to originate from HOMA-
IR, and this (together with age) had the greatest effect on LAVi. In contrast, LVMI was influenced strongly 
by hypertension. The effect of anthracycline dose had a minor effect on each of these variables and was the 
most important effect only for 3D-LVEF. HOMA-IR was sole HFRF that affected diastolic function (as 
measured by LAVi). 
 






Figure 4‐2: Effect sizes of impact of treatment-related risk factors and conventional HFRFs on A) Systolic function 
(GLS) and B) diastolic function (LAVi). Anthracycline refers to cumulative anthracycline dose.  
BMI – Body mass index; CD-RT – Chest Directed Radiotherapy; CTR-RF – Cancer-Therapeutic-Related Risk 
Factor; GLS – Global Longitudinal Strain; HFRF – Heart Failure Risk Factor; HOMA-IR – Homeostatic Model 
Assessment Insulin Resistance; HTN – Hypertension. 




6MWT was performed in 1635 participants (90.5%), with 326 (18.0%) achieving <490 metres. Obesity was 
the only HFRF associated with abnormal 6MWT distance (Table 4-4). Chest-directed RT alone was 
associated with abnormal 6MWT distance, but anthracyclines and chest-directed RT together was not. 
 
Association with functional capacity. Clinical systolic dysfunction (2D-LVEF, 3D-LVEF), subclinical 
systolic dysfunction (GLS), diastolic dysfunction and changes in cardiac morphology all significantly and 




The current study indicates that traditional HFRFs are associated with novel echocardiographic markers of 
myocardial dysfunction in childhood cancer survivors. Furthermore, effect sizes for HFRFs were frequently 
on the same order of magnitude as baseline demographics of age and cumulative anthracycline dose.   
Effect of HFRFs. It is generally accepted that aggressive treatment of HFRFs in the non-oncological setting 
may delay or prevent development of symptomatic HF to a degree similar to pharmacological therapy (127). 
However treatment of HFRFs remains suboptimal; 32% of population attributable risk of incident HF is 












Table 4-1: Demographic and Treatment Characteristics of Adult Survivors of Childhood Cancer 
    
 Eligible Nonparticipants Participants 
 (n= 3029) (n= 1209) (n= 1820) 
 n % n % n % 
Sex         
   Male 1684 55.6 946 52.0 738 61.0 
   Female 1345 44.4 874 48.0 471 39.0 
Race       
   Non-Hispanic White 2499 82.5 966 79.9 1533 84.2 
   Non-Hispanic Black 417 13.8 195 16.1 222 12.2 
   Non-Hispanic Other 37 1.2 18 1.5 19 1.0 
   Hispanic 76 2.5 30 2.5 46 2.5 
Therapeutic Exposure       
   Anthracycline alone 1765 58.3 715 59.1 1050 57.7 
   Chest-directed RT alone 510 16.8 204 16.9 306 16.8 
    Anthracycline + chest-                  
directed RT 
754 24.9 290 24.0 464 25.5 
Age at Diagnosis, years       
      0 – 4 1023 33.8 404 33.4 619 34.0 
      5 – 9 718 23.7 296 24.5 422 23.2 
    10 – 14 731 24.1 286 23.7 445 24.5 
    15 – 19 530 17.5 210 17.4 320 17.6 
>19 27 0.9 13 1.1 14 0.8 
Time since diagnosis (years)       
    10 – 20 - - - - 664 36.5 
    21 – 30 - - - - 738 40.6 
    31 – 40 - - - - 365 20.0 
    41 – 50 - - - - 53 2.9 
Age at Assessment, years       
    ≤30 - - - - 859 47.2 
    31 – 40 - - - - 654 35.9 
    41 – 50 - - - - 268 14.7 
    51 - 60  - - - - 38 2.1 
    >60  - - - - 1 0.1 
Anthracycline Cumulative Dose, 
mg/m2 
      
    0  511 16.9 205 17.1 306 16.9 
    1     – 100 784 26.0 296 24.6 488 26.9 
    101 -  200  882 29.2 364 30.3 518 28.6 
    201 – 300 336 11.1 141 11.7 195 10.8 
   301 – 400 332 11.0 107 8.9 225 12.4 
  401 – 500 100 3.3 41 3.4 59 3.3 
   501 – 600 23 0.8 5 0.4 18 1.0 
   >600 48 1.6 43 3.6 5 0.3 
   Missing 13 0.4 7 0.6 6 0.3 
Chest-directed RT (Gy)       
   0 1765 58.33 715 59.2 1050 57.8 




   1  – 19.9 362 11.96 144 11.9 218 12.0 
  20 – 29.9 474 15.66 182 15.1 292 16.1 
  ≥30 425 14.04 167 13.8 258 14.2 
  Unknown 3 0.1 1 0.1 2 0.1 
Diabetes Mellitus       
   Yes - - - - 108 6.8 
   No - - - - 1490 93.2 
   Missing - - - - 222 - 
HOMA-IR       
   >2.86 - - - - 821 45.8 
   < 2.86 - - - - 971 54.2 
   Missing - - - - 28 - 
Hypertension       
   Yes - - - - 367 21.0 
   No - - - - 1379 79.0 
   Missing - - - - 74 - 
Dyslipidemia (TC/HDL > 3.5 
mmol/L) 
      
  Yes - - - - 143 8.1 
  No - - - - 1629 91.9 
  Missing - - - - 48 - 
Obesity       
   Yes - - - - 602 33.2 
   No - - - - 1210 66.8 
   Missing - - - - 8 - 
Coronary Artery Disease       
    Yes - - - - 107 5.9 
    No - - - - 1713 94.1 
Smoking status       
    Never - - - - 1162 64.7 
    Ex-smoker - - - - 210 11.7 
    Current smoker - - - - 424 23.6 









Table 4-2: Multivariable Association Between Cardiovascular Risk Factors and Echocardiographic Abnormalities  
                 
 2D-LVEF <53% 3D-LVEF <53% Abnormal GLS Diastolic Dysfunction 
Grade 1-3 
LAVI >35 mL/m2 
 OR 95%CI p OR 95%CI p OR 95%CI p OR 95%CI p OR 95%CI p 
Therapeutic 
Exposure 
               
   Anthracycline 
alone 
1.0 - - 1.00 - - 1.00 - - 1.0 - - - - - 
   Chest-directed 
RT alone 
1.32 0.9 – 2.0 0.19 1.09 0.70-1.71 0.69 1.11 0.78-1.59 0.55 2.54 1.78-3.62 <0.0001 - - - 
   Anthracycline 
+ chest-directed 
RT 
1.44 1.01 – 
2.06 
0.04 1.30 0.91-1.87 0.15 1.37 1.03-1.82 0.03 1.82 1.36-2.44 <0.0001 1.0 - - 
HOMA-IR                
  >2.86 -* - - 1.09 0.75-1.56 0.63 1.72 1.30-2.28 0.0002 1.44 1.08-1.92 0.01 1.0 - - 
  <2.86 - - - 1.00 - - 1.0 - - 1.0   - - - - - 
Hypertension                
   Yes 1.19 0.83-1.71 0.35 1.81 1.25-2.62 0.002 1.34 0.98-1.82 0.06 1.41 1.03-1.94 0.03 1.82 0.47-6.98 0.38 
   No 1.00   1.00   1.0 - - 1.0 - - 1.0 - - 
Dyslidipemia                
   Yes - - - 1.27 0.76-2.13 0.37 1.07 0.69 –1.66  1.94 1.19-3.17 0.01 2.52 0.58-10.96 0.22 
   No - - - 1.00 - - 1.00  0.76 1.94 - - 1.0  - 
Obesity                
   Yes - - - 1.47 1.02-2.12 0.04 1.58 1.19-2.11 0.002 1.92 1.42-2.58 <0.0001 - - - 
   No - - - 1.00 - - 1.00 - - - - 1.0 1.0   
                 - 
CI – Confidence Interval; GLS  -Global Longitudinal Strain, HOMA-IR – Homeostatic Model Assessment Insulin Resistance; LAVI – Indexed Left Atrial Volume; LV – Left Ventricular; 
LVEF – Left Ventricular Ejection Fraction; 
OR – Odds Ratio; RT – chest-directed radiotherapy 
*Absence of calculated OR indicates that dependent variable did not produce p value ≤0.1 on univariable analysis, and hence were not included in the multivariable analysis.  








There are several reasons to think that effects of HFRFs on cardiac function are accentuated in the childhood 
cancer survivor population. First, survivors have a high risk of undetected cardiac dysfunction, and 39% of 
childhood cancer survivors have subclinical cardiac dysfunction (118). These findings suggest that a sizable 
proportion of survivors may meet criteria for stage B HF. Second, asymptomatic cardiac dysfunction is 
under-treated in the non-oncological population - 50% of newly diagnosed patients in the hospital setting 
do not receive appropriate pharmacological treatment (129) – and it is likely that initiation of appropriate 
treatment may be even lower in the relatively younger cancer survivors.   Additionally, the younger age of 
cancer survivors indicates that HFRFs may have a larger time window to exert a cumulative myopathic 
effect. Hypertension and obesity precede the diagnosis of HF by 10-16 years (128) and cancer survivors 
may become victims of a confluence of adverse risk factors at a younger age than the general population. 
The prevalence of cancer survivors is projected to increase by 29% by 2016 (130), which suggests that an 
active approach to preventing incident HF in the cancer survivor population should be undertaken to prevent 




Table 4-3:  Standardized Coefficients and Effect Sizes of Cardiovascular Risk factors on Abnormal Echocardiographic Findings. 
                     
 3D-LVEF  Abnormal GLS  LVMI  LAVI 
 B SE p Effect 
size 
 B SE p Effect 
size 
 B SE p Effect 
size 




0.04 0.03 0.09 0.0016  0.02 0.01 0.05 0.002  -0.03 0.08 0.73 -
0.0006 
 
0.09 0.03 0.002 0.0070 




0.01 0.001 <.0001 0.0151  0.001 0.001 0.17 0.0006  0.001 0.004 0.66 -
0.0006 
 
-0.003 0.001 0.04 0.0025 
                    
HOMA-IR 0.64 0.38 0.09 0.0015  0.71 0.17 <0.0001 0.0109  -1.02 1.18 0.39 0.0002  -1.23 0.43 0.004 0.0058 
                       
                    
Hypertension 1.25 0.45 0.01 0.0055  -0.62 0.20 0.002 0.0059  -6.30 1.33 <0.0001 0.0151  -0.83 0.49 0.09 0.0015 
                    
                    
BMI                    
   <25 1.22 
 
0.72 0.09 0.0017  -1.10   0.31 0.0004 0.098  -0.19 2.09 0.93 0.0051  -0.006 0.76 0.94 
0.0059 
  25-29 1.26 
 
0.71 0.07   -1.00 0.31 0.001   3.63 2.03 0.07   
1.32 0.74 0.08  
  30-35 0.37 
 
0.71 0.60   -0.84 0.31 0.01   2.40 2.04 0.24   
0.60 0.75 0.42  
  35-49 0.49 0.79 0.53   -0.24 0.35 0.49   2.19 2.33 0.35   1.10 0.89 0.20  
                    
Smoking                    
  Ex-smoker 0.43 0.50 0.39 0.0010  0.06 0.22 0.78 0.0009  0.65 1.54 0.67 0.0054  0.75 0.56 0.18 0.0013 
                    
   Current 
     smoker 
0.17 0.37 0.65   0.14 0.17 0.39   3.53 1.13 0.002   
0.67 0.41 0.11  
BMI – Body mass Index; GLS – Global Longitudinal strain; HOMA-IR – Homeostatic Model Assessment Insulin Resistance;  LAVI – Indexed Left Atrial Volume; LVEF – Left Ventricular Ejection Fraction; 
LVMI – Indexed Left Ventricular Mass; SE – Standard Error 






On an individual HFRF level, our results broadly agree with previously published findings in non-
oncological populations. Hypertension is associated with subclinical cardiac dysfunction, and the 
population attributable risk for HF is 20% (128). Recent large clinical trials such as SPRINT suggest there 
are patient subgroups who may benefit from aggressive HFRF management (131).   
Although there is a clear appreciation of the relationship between diabetes and both clinical and subclinical 
HF (132), the relationship between insulin resistance and subclinical myocardial dysfunction is less well-
known. HOMA-IR has been associated with abnormal GLS and LVH (133). These findings broadly agree 
with our findings of subclinical cardiac dysfunction associated with elevated HOMA-IR and suggest that 
insulin resistance should be considered a therapeutic target in childhood cancer survivor population.  
Associations between obesity and subclinical cardiac dysfunction are recognized in the non-oncological 
population; reported OR 1.60 (95%CI 1.06 – 2.41) for diastolic dysfunction, are similar to our observed 
value (OR 1.92 (95%CI 1.42 – 2.58)) (134). This association is manifest with diastolic dysfunction and 
LVH rather than 2D or 3D-LVEF, and this was confirmed in our study. Childhood cancer survivors are 
14% more likely to be obese than their healthy peers (134,135), again supporting the need for active 
intervention to prevent and treat obesity in this group. 
Smoking is a HF risk factor. Nonetheless, the lack of association of smoking status with systolic or 
subclinical systolic or diastolic cardiac dysfunction is broadly in agreement with previously published 
findings in participants free of hypertension and diabetes (136). 
  








Table 4-4: Standardized coefficients and effect sizes of echocardiographic parameters on exercise capacity 
        
 Abnormal 6MWT (< 490 m) 
 β  SE  P  Effect size 
        
3D-LVEF  2.00  0.57  0.0005  0.0076 
        
GLS -6.95*  1.08  <0.0001  0.0260 
        
LVMI 0.46  0.16  0.004  0.0044 
        
LAVI 1.92 
 
 0.45  <0.0001  0.0107 
 
6MWT = 6 minute walk test; 3D-LVEF = 3D Left Ventricular Ejection Fraction; GCS = Global Circumferential Strain; GLS = Global 
Longitudinal Strain; LAVI = Left Atrial Volume Indexed; LVMI = Left Ventricular Mass Index; Se = Standard Error  
*Note that as 2D speckle-tracking strain measurements within reference range are reported as negative values, the standardized coefficients 
will also  be negative  
 
  




Comparison of echocardiographic techniques for assessing myocardial function. Our results confirm a 
hierarchy of imaging modalities for detecting effects of myocardial consequences of HFRFs that 
corresponds to previously published reports of sensitivity for earlier phenotypes with different techniques 
(137).  Three HFRFs were associated with abnormal GLS and diastolic dysfunction, and two HFRFs 
associated with abnormal 3D-LVEF, but only one factor was associated with 2D-LVEF decline. The lack 
of association of HFRFs with the traditional method of 2D-LVEF may reflect the late onset of LVEF 
decline, which may not have had time to develop in our cohort. Current guidelines suggest periodic 
echocardiographic follow-up for adult survivors of childhood cancers (105,120). However, several of the 
echocardiographic parameters recommended, such as fractional shortening, wall stress and velocity of fiber 
shortening corrected for heart rate, are no longer widely measured, and the empiric basis for LVEF 
monitoring was established 25 years ago (138). Our results suggest that an emphasis should be placed on 
subclinical LV dysfunction preceding LVEF decline, and recognition of such changes should be followed 
by search for modifiable HFRFs. 
Each of the HFRFs modelled significantly increased the risk of diastolic dysfunction, even after correcting 
for baseline risk of anthracycline and chest-directed-RT treatment. Because it is a continuous variable, 
LAVI was used as an outcome rather than diastolic grade for quantifying the effect size of HFRFs on 
diastolic dysfunction. Only one HFRF, elevated HOMA-IR, was associated with increased LAVI. This may 
be because the majority of patients with diastolic dysfunction were in grade 1, which is not associated with 
elevated left atrial pressures. 
GLS has been reported to demonstrate a greater association with mortality than 2D-LVEF (139). It is 
unclear as to whether this difference reflects an inherent problem with EF, or whether it simply reflects the 
ambiguity of echo measurement of EF. The limitations of single-point LVEF measurements are widely 
recognized (140), and GLS is recognized to have lower intra- and inter-observer variability (141).  
Functional Capacity. Despite the association of HFRFs with echocardiographic findings of subclinical 
systolic and diastolic dysfunction, there was no association between the majority of HFRFs and abnormal 
6MWT, with the sole exception of obesity. However, reduction in 6MWT distance is frequently due to 




disturbance of multiple physiological systems so potential contributions to 6MWT distance by improving 
HFRFs may be masked by the real-world complexity of exercise physiology. Nonetheless, it is of interest 
to measure the effect of echocardiographic markers of cardiac dysfunction on 6MWTD for several reasons. 
First, 6MWTD has been demonstrated to an equally strong and independent mortality predictor as LVEF 
in HF patients, so demonstrating association would provide a prognostic context for the effects of HFRFs 
on echocardiographic markers. Second, exercise testing has been demonstrated to facilitate earlier diagnosis 
of cardiac dysfunction in patients without a diagnosis of HF (142), indicating that exercise intolerance may 
be an early phase in the evolution of HF. Third, although studies have been performed demonstrating that 
GLS is more closely associated with reduced cardiopulmonary exercise function than is LVEF (143) in 
patients with symptomatic HF, there is limited evidence of the association of GLS and exercise tolerance 
in patients with HF risk factors. Our study’s findings that echocardiographic markers of cardiac dysfunction 
were significantly associated with reduced 6MWTD is novel and clinically important and adds further 
support to the concept that HFRFs should be actively managed if cardiac dysfunction is present. GLS had 
the strongest association with 6MWTD, which is in keeping with prior studies in HF patients (143). The 
pathophysiological mechanisms underlying this finding remain uncertain.   
Limitations. Several limitations should be taken into account when assessing the implications of our results. 
First, the cross-sectional study design meant that historical data was not collected contemporaneously, and 
it is possible that baseline information may contain inaccuracies. Second, of all eligible subjects recruited 
into the SJLIFE cohort, 43% did not have an echocardiographic assessment, and it is possible that these 
excluded subjects differed from participants in unmeasured characteristics. Third, given the relatively 
young age of our cohort, we are unable to assess hard cardiovascular outcomes such as HF incidence, 
although such analyses may be possible in the future as the cohort ages. Fourth, participants had only a 
single echocardiogram, and it is possible that sequential echocardiographic studies may have detected 
decrements in cardiac function over time while remaining within normal reference ranges. Fifth, 
echocardiography is operator-dependent and it is possible that other centres may not reproduce findings 
with similar accuracy, although it should be noted that the newer echocardiographic modalities used in our 




study, including GLS and 3D-LVEF, have superior intra-observer and inter-observer reproducibility 
compared to 2D-LVEF measurements.  Last, thresholds for abnormal GLS measurements were derived 
from reported normal reference ranges derived from a large population of Japanese healthy volunteers and 




The results of the current study have added new information on the effects of traditional HFRFs on novel 
echocardiographic markers of myocardial dysfunction in survivors of childhood cancer. The effect sizes for 
HFRFs were larger than that of cumulative anthracycline dose. Guideline recommendations for frequency 
and extent of monitoring, and thresholds of treatment and management of HFRFs are based on expert 
consensus derived from studies and guidelines from the non-oncological population (120).  This approach 
may not be ideal for the childhood cancer survivor population, in whom HFRFs may be appropriate targets 
for aggressive clinical interventions.  
 
Postscript 
Despite a focus on cancer therapy as a cause for HF, the results of the current study show that traditional 
HFRFs are at least as important (if not more so) than cumulative anthracycline dose as determinants of 
myocardial dysfunction in survivors of childhood cancer. In addition to cardioprotection at the time of 
chemotherapy, ongoing detection and management of classical HFRFs appear to be important and should 
be considered as part of guidelines.  
 



























The first section of this thesis demonstrated that CTRCD is a significant source of morbidity and 
mortality in the cancer survivor population and requires sequential monitoring using cardiac imaging due 
to variable onset of cardiac dysfunction. Effective therapeutics for cardiac dysfunction exist, but targeted 
use is only possible in the context of cardiac imaging at appropriate time-intervals to successfully identify 
patients prior to irreversible dysfunction. Presently CTRCD is defined by significant decrement in LVEF 
from a baseline value. Although many modalities are available for measuring LVEF, values are not 
interchangeable between them(145). Therefore the choice of imaging modality directly affects the 
physician’s ability to diagnose CTRCD, and the modality with highest accuracy, reproducibility and 
predictive value should be prioritized. 
Currently cardiac tests for cancer patients can be ordered by either the patient’s treating 
oncologist or haematologist, or alternatively by a cardiologist who has been invited to participate in the 
patient’s care. For purposes of simplicity, further reference to oncologists will include physicians with 
specialist accreditation in either oncology or haematology. In practice, the two most common techniques 
for assessing cardiac function in cancer patients are MUGAs and echocardiography. Alternative non-
invasive techniques, such as CMR and positron-emission tomography are not reasonable first-line choices 
due to reasons of cost and variable regional availability of services. Since oncologists and cardiologists 
may have differing training and treatment goals (e.g. cancer remission versus long-term cardiovascular 
risk), it is possible that one modality maybe considered more appropriate than the other. Whether each 
modality has recent technological advances that could potentially improve diagnostic performance could 
also be taken into account. 
     The next section of this thesis is concerned with comparing the most commonly used techniques for 
measuring LVEF and exploring potential avenues for optimising their diagnostic and predictive yield in 
cancer populations, so that the test with the greatest utility can be recommended at a societal level.  
  





Background: Previous studies has suggested that sequential cardiac imaging modalities in patients treated 
with chemotherapy are discordant with recommendations in international guidelines, possibly related to 
issues of access and cost. It is unknown if this difference affects rates of cardiotoxicity diagnosis or has 
treatment implications. 
Objectives: To perform a prospective cohort study comparing real-world practice predominantly using 
MUGA scans at an Australian regional tertiary hospital with a strategy utilizing sequential novel 
echocardiographic techniques.  
Methods: Patients were recruited from a single center if they had been identified by their treating 
oncologist or hematologist as scheduled for treatment with potentially cardiotoxic chemotherapeutics. 
Patients underwent concurrent MUGA-based cardiac imaging by treating team and echocardiographic-
based cardiac imaging by researchers. Conventional strategy was MUGA screening as intervals deemed 
appropriate by the treating team. The echocardiographic strategy was performed in all patients at timepoints 
advised by international society guidelines. Outcomes included adherence to society recommendations, 
agreement between MUGA and echocardiographic LVEF measurements and detection of cardiac 
dysfunction (defined as >5% LVEF decrement from baseline by 3D-LVEF). A secondary endpoint was 
accuracy of global longitudinal strain in predicting cardiac dysfunction. 
Results: 35 patients were recruited, including 15 breast cancer patients, 19 hematological malignancy 
patients and 1 gastric cancer patient. MUGA and echocardiographic LVEF measurements correlated poorly 
with limits of agreement of 30% between 2D-LVEF and MUGA-LVEF and 37% for 3D-LVEF and 
MUGA-LVEF. Only 1 case (2.9%) of CTRCD was diagnosed by MUGA, compared to 12 (34.2%) cases 
by echocardiography. Four patients had >10% decrement in 3D-LVEF that was not detected by MUGA. 
GLS at 2 months displayed significant ability to predict CTRCD (AUC 0.75, 95% 0.55 – 0.94).   
Conclusions:  MUGA correlates poorly with echocardiographic measurements with substantial 
disagreement between MUGA and echocardiography in CTRCD diagnosis. MUGA and 
echocardiographic imaging strategies should not be considered equally appropriate for imaging cancer 
patients. 





Cardiac dysfunction after potentially cardiotoxic chemotherapy for cancer can cause cancer-therapy-related 
cardiac dysfunction (CTRCD) in up to 20% of patients (146). CTRCD is associated with significantly 
increased adverse cardiac event rates, with higher rates observed in patients treated >2 months from 
chemotherapy administration(22). Contemporary oncological guidelines recommend LVEF measurement 
prior to starting cardiotoxic chemotherapy at baseline, every 3 months during treatment and at 12 and 18 
months after the initiation of treatment (104). However recent studies have demonstrated that adherence to 
guideline-directed cardiac monitoring can be as low as 46% (147).  
Older cardiological and oncological guidelines have recommended that LVEF measurements may be 
performed by either echocardiography or multiple-acquisition-gated nuclear (MUGA) scans. Recently 
concerns have been raised regarding the accuracy of MUGA for detecting baseline cardiac dysfunction(46) 
and paucity of evidence demonstrating improved cardiac outcomes with MUGA screening(148).  However, 
in many centres around the world, LVEF monitoring by MUGA is the most frequent modality ordered by 
oncologists(149), often due to accessibility and cost concerns regarding echocardiography.  
We performed a head-to-head study comparing traditional oncologist-directed cardiac imaging at our local 
institution, where MUGA screening is standard practice, and advanced echocardiographic techniques, 
including 3D-LVEF and global longitudinal strain (GLS). Our goals were the following; 1) to compare 
agreement between MUGA-LVEF and echocardiographic measures of LVEF, 2) to compare rates of 




Patients and Data Collection. The study sample consisted of patients referred prospectively from Royal 
Hobart Hospital between May 2014 and November 2015. Inclusion criteria included 1) age ≥ 18 years; 2) 




planned anthracycline or trastuzumab chemotherapy (as determined by treating oncologist); 3) ability to 
provide written informed consent; 4) recruitment within three months of commencing anti-cancer therapy. 
Exclusion criteria included 1) life expectancy <12 weeks, 2) history of myocardial infarction in prior 3 
months and 3) unwillingness to comply with study and follow-up procedures. Pre-existing left ventricular 
dysfunction was not a contraindication to treatment. All patients underwent concurrent cardiac screening 
for cardiotoxicity with standard institutional practice and advanced echocardiographic imaging. 
Ethics approval was granted by the Tasmanian Human Research Ethics Committee (approval number 
H13115). All patient contact and data collection was conducted in compliance with the second Declaration 
of Helsinki. Written informed consent was obtained from all patients prior to enrolment. 
Conventional Cardiac Imaging. All patients underwent cardiac imaging as decided by their treating 
oncologist. The most common practice was to order a baseline multiple-gated acquisition scan (MUGA 
scan) prior to administration of potentially cardiotoxic anticancer treatment, with need for subsequent 
sequential cardiac imaging at the discretion of the oncologist. The MUGA scan report described the LVEF 
but diastolic function, as assessed by nuclear peak filling rate, was not routinely assessed. 
Echocardiographic Imaging. All patients underwent baseline history physical examination, including 
blood pressure, heart rate, height and weight measurements. Standard transthoracic 2-dimensional and 
Doppler echocardiographic studies were performed using standard equipment (GE Vivid E9; Vingved, 
Norway) in accordance with contemporary echocardiographic practice. LV peak global longitudinal strain 
was (GLS) measurements were obtained from gray-scale recorded images in the apical 4-chamber, 2-
chamber and long-axis views. Strain was analyzed using commercial speckle-tracking software (Echopac, 
GE Medical Systems). GLS was measured by averaging strain from regions of interest from 3 apical views.   
Patients underwent transthoracic echocardiographic imaging at baseline, and at 2 months after treatment 
(which is usually in the period after anthracycline or other chemotherapy agents are completed, but prior to 
trastuzumab administration for breast cancer patients). 




Echocardiographic studies were performed in accordance with professional society guidelines and included 
cine imaging of biventricular function from multiple planes, diastolic interrogation and colour Doppler 
imaging of valvular function. 2D-LVEF was calculated by Simpson biplane technique. Global longitudinal 
strain used left ventricle-focused images at 50-70 frames/second. Images were discarded if ≥2 segments 
were uninterpretable. 
Outcomes. First outcome was agreement between MUGA and echocardiographic measurements, as 
described by correlation coefficients and limits of agreement.  Second outcome was detection of changes 
in LVEF per patient that may meet criteria for CTRCD. Because current position statements suggest that a 
5% decrement in LVEF from baseline is the smallest change that can justify diagnosis of CTRCD and 
merits clinical assessment, we used this threshold. Third, we assessed prognostic ability of global 
longitudinal strain to detect later decrements in LVEF >5% (CTRCD-3D). We chose 3D-LVEF decrements 
≥5% because 3D-LVEF has 95% confidence interval limit of temporal variability of 5% with greater 
decrements unlikely to be due to test imprecision and hence represent true pathological change(150). 
Multiple-Gated Acquisition Scanning (MUGA). MUGA scans were performed per standard 
recommendations to quantify LVEF(151). Erythrocyte labelling using technetium 99-m labelled blood cells 
was employed with the modified in vitro method with activity of 11 to 13 MBq/kg. Images were acquired 
using a Siemens e-cam dual-head gamma camera (Siemens, Erlangen, Germany) equipped with a parallel 
hole, low-energy high-resolution collimator, with energy window of 15% symmetrically placed over a 
photopeak of 140 keV. Acquisition times were adjusted to achieve a minimum of 200,000 count per frame. 
LVEF analysis was performed by nuclear physicians with 2-10 years’ experience. Clinically reported LVEF 
analyses were used, and analyses were not remeasured for the study.  
Statistical analysis. Continuous data was expressed as mean ± standard deviation, and categorical data was 
expressed as numbers and percentages. Correlation between continuous variables was expressed using 
Pearson’s correlation coefficient and Bland-Altman analyses. All data was first assessed first for normality 
by visual inspection and by Kolmogorov-Smirnov test. No transformations were necessary. Comparisons 




of means were performed using paired or unpaired t-student’s test as appropriate, and one-way ANOVA 
was used to compare means of >2 groups. If the assumption of normality was not held, then Wilcoxon’s 
paired or unpaired test was used. Longitudinal data analysis was performed using generalized linear mixed 
models with individual patients used as random-effect models and timepoint used as in fixed-effect models 
with singular covariance matrix with Cholesky parameterization. Receiver-operating curves were 
calculated to assess predictive accuracy. Statistical analysis was performed using R statistical software 
(Vienna, Austria) and the lme4 package(152). P values ≤ 0.05 were considered significant. 
 
Results 
Study sample. Patient characteristics of the 35 patients were recruited between May 2014 and November 
2015 are described in Table 5-1. Four patients died from their cancers during the study period (2 patients 
with AML, 1 patient with NHL and I patient with lymphoproliferative disease). 
Follow-up. Of the 15 breast cancer patients, 14 received trastuzumab therapy over 12 months, with median 
4 MUGA scans per patient (range 1 to 5). A single metastatic breast cancer patient treated with doxorubicin 
had a single baseline MUGA scan. Amongst the trastuzumab-treated patients 8 (62%) received sequential 
LVEF monitoring during treatment every 3 months (as recommended by oncology guidelines) but did not 
undergo post-treatment LVEF monitoring (i.e. 8 had total of 4 MUGA-LVEF measurements). Only 3 
trastuzumab-treated patients (21%) had baseline, 3-monthly and post-treatment MUGA-LVEF 
measurements (i.e. 5 MUGA scans over 14 months). 
The 19 patients with haematological malignancy had a median of 1 MUGA-LVEF measurement (range 0 
to 3). Only 7 patients (37%) with haematological malignancy had both baseline and post-treatment MUGA-
LVEF measurements. One patient did not receive any MUGA test. A single patient with gastric cancer had 
a baseline MUGA scan only. In total, 37% of patients received both baseline and post-treatment LVEF 




assessment by MUGA monitoring. None of the 35 patients were admitted to hospital with diagnosis of heart 
failure during study duration. 
In comparison, of the 14 trastuzumab-treated patients, 11 (78.5%) completed all 5 planned 
echocardiographic assessments at the planned 3-monthly intervals. One patient missed her baseline TTE 
study due to medical illness, 1 patient had 4 TTE exams but could not attend her final scan and 1 patient 
dropped out from the study after her third study. Haematological malignancy patients had a median of 4 
TTE assessments (range 1-5). 16 patients (84.2%) had both baseline and post-treatment TTE scans.  
 
Comparison between MUGA and echocardiographic LVEF. Among all 35 patients, there was a total of 
73 MUGA-LVEF measurements, 131 2D-LVEF measurements and 117 3D-LVEF measurements. 
Feasibility of 2D-LVEF measurement was 100%, and feasibility of 3D-LVEF measurement was 89%. 
There was median of 10 days between echocardiographic and MUGA examinations (range 0 – 85 days). 
No significant correlation was seen between MUGA-LVEF and 2D-LVEF (r = 0.15, 95%CI -0.09 to 0.37, 
p = 0.22) (Figure 1). There was little bias between the measurements for MUGA-LVEF and 2D-LVEF but 
the limits of agreement were wide (Bias = 0.2%, LoA = 37.0%, 95% range -18.4 to 18.7%). A weak albeit 
significant correlation was seen between MUGA-LVEF and 3D-LVEF (r = 0.33, 95%CI 0.1 to 0.53, p = 
0.0053), with small bias towards higher LVEF values with MUGA-LVEF and wide limits of agreement 
(Bias = +1.8%, LoA = 29.9%, range -13.1% to 16.8%). A stronger association was observed between 2D-
LVEF and 3D-LVEF (r = 0.65, 0.48 to 0.77, p < 0.0001), with small bias towards higher LVEF values with 
2D-LVEF and limits of agreement were narrower (Bias = +2.1%, LoA = 23.2%, range -9.5% to 13.7%) 
compared to comparisons with MUGA-LVEF. Overall, MUGA-LVEF did not correlate with 2D-LVEF 
and only weakly with 3D-LVEF measurements, and limits of agreement between MUGA and either 2D or 
3D echocardiographic LVEF measurements were ≥30%. 




Detection of Cancer Treatment-Related Cardiac Dysfunction (CTRCD). Ten patients were determined 
to have new cardiac dysfunction by 2D-LVEF (29%), as were 6 (17%) patients by 3D-LVEF. 5(15%) of 
patients had cardiac dysfunction diagnosed by both 2D-LVEF and 3D-LVEF. In contrast, only 1 patient 
demonstrated new cardiac dysfunction by MUGA, which was also detected on 2D-LVEF (3D-LVEF could 
not be measured in this patient at this timepoint due to image artifact from radiation-induced skin changes). 
By using a combined echocardiographic approach (i.e. ≥5% LVEF decrement from baseline as measured 
by either 2D-LVEF or 3D-LVEF or both ), 11 additional cases of cardiac dysfunction (31.4%) were 
detected by regular echocardiography compared to MUGA, which may have prompted cardioprotective 
treatment.  Inter-rater agreement for significant cardiac dysfunction was non-significant between MUGA-
LVEF and 2D-LVEF (κ= 0.14, p =  0.11) and MUGA-LVEF and 3D-LVEF (κ = -0.51, p = 0.61). However 
there was significant inter-rater agreement between 2D-LVEF and 3D-LVEF (κ = 0.46, p = 0.01). Notably 
4 patients were found to have >10% decrement in 3D-LVEF by 3D-TTE, none of which were detected by 
MUGA screening approach. 
GLS prediction of CTRCD. Relative changes in GLS at 2 months, 5 months and using the greatest 
decrement of either timepoint were used to predict CTRCD (Figure 1). Change in GLS at 2 months was 
modestly predictive of CTRCD (AUC = 0.74, 95%CI 0.55 to 0.94), with threshold of 10.4% decrement 
from baseline in GLS demonstrating greatest accuracy. There was no significant predictive ability of change 
in GLS at 5 months (AUC = 0.51, 95%CI 0.28 to 0.74) or using the greatest decrement of either timepoint 
(AUC = 0.57, 95%CI 0.35 – 0.80).   
  

















Figure 5‐1: Receiver-Operating Curves to assess the predictive accuracy of relative changes in GLS for 
predicting CTRCD. A) Relative reduction in GLS from baseline at 2 months as predictor variable; B) 
Relative reduction in GLS from baseline at 5 months as predictor variable; C) using greatest decrement at 
either 2 or 5 months as predictor variable  




Sequential LVEF change over time. There was no significant change in LVEF over time as measured by 
2D-LVEF (β = -0.61 p = 0.17) or 3D-LVEF (β = -0.53 p = 0.15) (Figure 5-2). In contrast, a significant 
decline in MUGA- LVEF was observed (β = -0.76, p = 0.03). However, this finding was confounded by 
small numbers of MUGA scans (8 scans) performed at 8 month and 14-month timepoints, with no 
significant change seen between average MUGA-LVEF values at baseline and 2 months (p=0.29) or 







Figure 5‐2: Trajectories of LVEF change over time with different modalities. A) Absolute change 
in LVEF over time for each modality. B) change relative to Baseline LVEF over time. 





Table 5-1: Patient Baseline Demographics 
  
Age (years) 55.0 ± 13.0 
Female 24 (68.6%) 
BMI (mg/m2) 29.9 ± 7.2 
Cancer  
           Breast 16  (45.7%) 
           NHL 13   (37.1%) 
           AML 3     (8.6%) 
           Hodgkin’s 1     (2.9%) 
           Lymphoproliferative 1     (2.9%)  
           Gastric 1     (2.9%)  
Diabetes Mellitus 2 (6.3%) 
Obesity 13 (37.1%) 
Hypertension 8 (22.9%) 
Family History 7 (20%) 
Heart disease 8 (22.9%) 
SBP (mm Hg) 133.8 ± 21.0 
DBP (mm Hg) 79.7 ± 10.2 
HR (bpm) 79.7 ± 13.7 
Abbreviations: AML – Acute Myeloid Leukemia; BMI – Body Mass Index; DBP – Diastolic Blood 




This study has demonstrated three important findings; 1) that there was poor correlation between LVEF 
measured by MUGA scans and by echocardiography, 2) that use of MUGA-LVEF measurements would 
have led to missing up to 28% of patients that could potentially benefit from cardioprotective therapy as 
assessed by echocardiography and 3) relative change in GLS at 2 months was predictive of later 3D-
LVEF decrement as measured by echocardiography. 
Nuclear and echocardiographic imaging. Our finding that LVEF measurements by MUGA correlate 
poorly with echocardiographic measurements and that up to 28% of patients had a ≥5% decrement in their 
LVEF that was missed by MUGA raises the question of which cardiac imaging modality is optimal for 
the cancer patient. Scientific studies assessing the use of MUGA in the cancer populations are lacking. 




However anecdotally MUGA has been favoured by Australian oncologists due to reported difficulties in 
accessing quality echocardiographic services within a time-frame that does not risk delaying 
commencement of potentially life-saving chemotherapy. Additionally, oncologists understandably place 
greater value on cardiac imaging parameters that directly influence choice of cancer treatments, 
principally LVEF, and may be less inclined to incorporate other dimensions of cardiac function available 
from echocardiography, including strain, diastology and valvular function, into their treatment strategies.  
However, several concerns have been raised recently regarding the use of MUGA scans for monitoring 
chemotherapy. Firstly, quoted studies demonstrating utility of MUGA scanning used different modalities 
of MUGA imaging than used in current day practice. The number of published studies on utility of 
MUGA in cancer peaked in approximately 1992, when MUGA used single-headed, small field of view 
cameras that allowed separation of photon counts between the cardiac chambers, so that the left ventricle 
could be measured without contamination from atria or right ventricle(153). Contemporary single photon 
emission cameras are two- and sometimes three-headed cameras that allow greater photon collection, but 
concerns have been voiced over the accuracy of this method for volumetric analysis, given that the spatial 
resolution of contemporary gamma camera is approximately 7-9 mm, and that LV volume measurements 
may be confounded by photons from adjacent chambers(148). A second concern is the unavoidable 
exposure to radiation, for which the typical dose from a MUGA scan is 6-7 mSv. This especially becomes 
an issue when sequential LV monitoring is required, such as for cardiac monitoring. In our study, 2 
patients had a total of 5 MUGA scans each, which approximates a total radiotherapy dose of 30-35 Gy. 
This dose represents a third of the lifetime total medical radiation dose that is considered reasonable. A 
third concern is that, as seen in this study and confirmed in other studies(145), LVEF measurements 
between cardiac modalities are not inter-changeable. This creates the risk that if cardiac dysfunction 
develops, the MUGA modality would need to be continued to allow for comparison to baseline. This 
would result in loss of additional relevant clinical data, such as diastolic and valvular function, as well as 
increased cumulative radiation dose. 




 Our finding that 31% of patients had significant LVEF declines detected echocardiographically, 
of which one was detected by contemporary oncologist-directed monitoring, raises the issue of whether 
MUGA has adequate sensitivity for cardiotoxicity. An alternative consideration is whether 
echocardiography is nonspecific, resulting in excessive numbers of false-positive results. The difference 
between modalities likely cannot be attributed to technical differences alone, as it is probable that higher 
cardiac dysfunction rates would have detected by MUGA is monitoring adherence had been higher. 
However, as 60% of oncology-directed patients had ≥2 sequential MUGA scans, it is very likely that 
significant inter-modality differences also contribute to the disparate findings of cardiac dysfunction. One 
attribute of MUGA scanning that contributes towards uptake is reported superior reproducibility(45) with 
the underlying principle being that changes in accuracy may not be clinically important so long as the 
changes between LVEF between time-points is accurately quantified. This has become more debatable in 
past years, as recent publications have demonstrated that anthracycline-treated patients with LVEF in the 
“low-normal” range of 50-54% have a 6.7-fold increased risk of cardiac dysfunction(154). A head-to-
head comparison of LVEF values derived from MUGA and the gold-standard of CMR found minimal 
bias, however the limits of agreement were wide at 35%(46). In practice, this means that for an individual 
with a MUGA-derived LVEF of 55%, we can be 95% confident that their CMR-derived LVEF would be 
between 37% and 71%. In contrast, the limits of agreement with CMR-LVEF with 3D end-diastolic 
volume and end-systolic volumes as calculated by echocardiography has been reported as 4.4% and 7.9% 
respectively(155), suggesting that echocardiographic measurements may indeed be superior to MUGA in 
terms of accuracy. The evidence for superior reproducibility of MUGA is also less settled in the author’s 
view than described in recent review publications. The claims for superior reproducibility predominantly 
quote a study of 73 anthracycline-treated patients, which compared an LVEF derived from visual 
inspection of echocardiographic images to LVEF derived from automated software analysis of MUGA 
images with minimal operator intervention(156). The comparison of automated software to visual 
estimation likely reflects differences between machine and human estimation which would mask true 
inter-technique differences. It is possible that advances in nuclear camera technology may have improved 




temporal variability, but the peak number of publications of MUGA-LVEF studies was in 1992, and there 
has been a precipitous decline in number of studies published since(153). If MUGA scans are to remain a 
first-line test for cancer-therapy-related cardiac dysfunction, then there is an urgent need for new research 
to determine the applications and limits of this technology. 
Limitations. Several significant limitations of this study need to be addressed. Firstly, the incidence of 
heart failure was not quantified in a systematic manner, and therefore the predictive ability of either 
imaging strategy for heart failure cannot be assessed. However, our observed rates of cardiac dysfunction 
by echocardiography were similar to rates observed in other prospective clinical studies(44,157). 
Secondly as the echocardiographic reports were made available to the treating oncologist or 
haematologist, this may have affected their ordering MUGAs at intervals as advised by international 
guidelines, and this may have on turn affected their sensitivity for CTRCD diagnosis. Appropriate steps 
were taken during patient recruitment to emphasise that oncologist-guided monitoring should be 
independent of echocardiographic monitoring, and it would been ethically inadvisable to withhold 
information from echocardiographic studies from the treating physicians. Thirdly, we did not use a gold 
standard comparator of CMR-LVEF to determine accuracy. In contemporary clinical practice, CMR is 
difficult to access due to cost, local availability and frequent contraindications amongst patients. Hence 
our study reflects what can be reasonably achieved in majority of hospitals. Lastly, we did not measure 
biomarkers (e.g. troponin) for predicting or diagnosing cardiac dysfunction. Presently the evidence base 
for use of biomarkers in this setting is not concordant, and this is reflected in their delegation to second 
tier monitoring strategy behind cardiac imaging in contemporary guidelines(148). 
Conclusions. 
MUGA correlates poorly with echocardiographic measurement of LVEF with substantial disagreement 
between MUGA and echocardiography in CTRCD diagnosis. MUGA and echocardiographic imaging 
strategies should not be considered equally appropriate for imaging cancer patients. 





 This chapter has demonstrated that there are clear differences in real-world clinical performance 
between MUGA and echocardiography. Differences in choice of cardiac imaging and suboptimal 
adherence to guidelines may be related to the makeup of physicians caring for the cancer patient and 
highlight the need for implementing cardio-oncology services in Australian hospitals. Additionally, there 
does not appear to be any patient-level variables that make one test preferable to the other in different 
patient populations, save perhaps for the desire to avoid the unavoidable radiation dose in younger 
patients. Therefore it would be reasonable to uniformly advise one test over another. This chapter has 
demonstrated increased sensitivity and earlier CTRCD detection properties of echocardiography over 
MUGA, which may potentially be counteracted by reduced specificity. Given the potential consequences 
of either false negative or late diagnosis of CTRCD and relatively benign implications of false positive 
result, keeping in mind that disruption of chemotherapy should be reserved for severe CTRCD cases 
where diagnosis is unlikely to be incorrect, it seems reasonable to state the echocardiography should be 
the initial cardiac imaging modality of choice. From this point on, this thesis will focus on 
echocardiography as the appropriate cardiac imaging modality. Subsequent chapter in this thesis will 
focus on strategies to improve specificity and reduce the rate of false negatives from echocardiography.   












Strategy for Improving Echocardiographic 
Measurement Accuracy  
 
 
Part of the research in this chapter has been accepted for publication as: 
 Nolan MT, Thavendiranathan P. Automation in Echocardiography. J Am Coll Cardiol Img 2019; 
12(6): 1073-92.  
  





The first four chapters of this thesis provided evidence that CTRCD is a significant source of morbidity 
and mortality amongst cancer survivors. In addition, it was demonstrated that there were significant 
performance differences between MUGA, the technique most commonly used by oncologists and 
hematologists at the single centre sampled, and echocardiography. If one also includes the additional 
health risks from the unavoidable radiation exposure and lack of additional information regarding 
valvular and pericardial function associated with MUGA, then it may be considered likely that 
echocardiography is a more appropriate modality and should be by default the first-line cardiac imaging 
test for chemotherapy-treated patients. It is notable that recently published cardio-oncology clinical 
guidelines from Spain explicitly advise against the use of MUGA for screening for CTRCD(12). 
Echocardiography does also have significant limitations that may impair performance in guiding 
cardioprotective therapy. Notably the temporal variability of 2D-LVEF measures can be as high as 11%, 
which is a greater absolute change than that required for CTRCD diagnosis. This raises the likelihood that 
if echocardiography is used solely to diagnose CTRCD, then a large number of CTRCD diagnoses might 
be false positives attributable to measurement imprecision. There is therefore an unmet clinical need for a 
strategy to improves accuracy of echocardiographic measurements. One approach is to utilize novel 
echocardiographic technologies with demonstrated reductions in temporal variability, such as use of 
three-dimensional datasets. However this approach requires substantial hardware and software changes, 
incurs additional financial and time costs and therefore may not be available to all providers. An 
alternative strategy is to use automated measurements, which may potentially provide the advantages of 
reduced inter-observer variability. The next chapter will examine the evidence base for utilising 
automation for echocardiographic measurements and will advance a proposed plan for cardio-oncology 









Echocardiography has become the primary method for non-invasive imaging of the heart. The use 
of echocardiography has significantly increased from 1990s with echocardiograms comprising 11% of all 
U.S. Medicare spending on imaging services in 2010, with $1.2 billion in annual spending(158). 
Approximately 20% of Medicare enrollees receive at least 1 echocardiogram annually, accounting for 7.1 
million echocardiograms in the U.S. each year(159).   
 Due to the progress in echocardiography (Figure 6-1), the echocardiography examination has 
become longer over time due to routine addition of multiple newer parameters. A good example of this is 
the patient receiving cancer therapy where a clinical examination has evolved from bi-plane left 
ventricular ejection fraction (LVEF) only to now including 3D LVEF, diastolic function assessment, and 
myocardial strain analysis. Overall, this growth in echocardiography has added stress to echocardiography 
labs, increased time for studies to be performed and reported and potentially results in delays in diagnosis. 
Time restraints combined with multiple manual analyses also introduces a source of variability between 
successive tests (150,160).   
 Automation of echocardiographic measurements has the potential to change the landscape of 
echocardiography. Potential benefits of automation include time and cost savings associated with 
streamlining of image acquisition, rapid analysis and reporting, and greater accuracy and reproducibility 
of measurements. The possible drawbacks of a strategy of widespread automation adoption include 
increased costs of software upgrading and staff training and erroneous results, which would be more 
likely if baseline image quality was not assessed or if automation was applied to patient groups lacking a 
supporting evidence base.  In this manuscript we describe some of the promising advances with 
automated quantification in echocardiography and how these methods could be incorporated into 
echocardiography laboratories.  We have used the term “semi-automated” to describe methods where the 
user needs to define regions of interest or anatomical landmarks, but the measurement process is 
automated and “fully-automated” to describe methods where the software automatically identifies the 




landmarks and initiates measurements. However, even in the latter scenario manual adjustments can be 
made by the user if necessary.  
 
Chamber and Doppler Quantification 
A complete echocardiography study involves multiple measurements of chamber dimensions and Doppler 
spectra. In most cases a single measure is obtained, and the lack of routine use of an average of multiple 
measurements despite current guideline recommendations(124) is due to the limited time in busy 
echocardiography laboratories. Regardless of underlying rhythm, there is likely an added benefit to using 
an average of multiple measurements as opposed to a single measurement for determining chamber size 
or quantification of velocities, gradients, or stroke volumes. Automation makes it possible to rapidly 
obtain multiple measurements(161,162) and is now a reality for quantification of chamber dimensions and 
Doppler spectra from multiple heart beats with some vendors. These measurements have been shown to 
be accurate (R2 0.90-0.98)(161) when compared to expert annotations, add time savings and may 
contribute to improved reproducibility of the measurements.




















Figure 6-1: Temporal progression in automated quantification in echocardiography. Description of the 
progression in automated quantification in echocardiography over the past 33 years 
 




Assessment of myocardial function 
Automated Measurements of 2D LV Volumes and Function 
Non-invasive measurement of LVEF was first performed by one-dimensional (M-mode) 
measurement in late 1960’s, but computer technology of the time was insufficient to automatically 
analyze images on a frame-by-frame basis. Contemporary automated software use intelligence technology 
with “knowledge base” gained from large datasets of echocardiographic images to improve detection of 
endocardial borders. Multiple imaging companies are now marketing automated 2D-LVEF measurement 
software that is gain-independent and accurate (e.g. eSie Left Heart by Siemens, AutoEF by General 
Electric, AutoLV by Tomtec, a2DQAI  by Philips). In early studies (Table 6-1) of automated 
analysis(163,164) correlation with 2D-LVEF and accuracy for grading cardiomyopathy severity was sub-
optimal(163). However multiple studies using software from several vendors involving >1300 patients 
have now shown high feasibility (83-100%) for bi-plane 2D-LVEF measurements and excellent 
agreement with core-lab measurements or other external reference standards such as CMR (Table 6-
1)(165). The fully automated methods have no inter-observer variability (ICC=1.0)(165,166) when 
repeated on same echocardiographic images, while semi-automated methods have better reproducibility 
than manual methods (Table 6-1).  Furthermore automated methods reduce the gap in reproducibility 
between expert and novice readers and improve accuracy and reproducibility in multicenter settings for 
2D LVEF measurements. (163,165) The analysis time is shortened by >50% with fully automated 
analysis providing the greatest time savings (as short as 10 seconds analysis time(165)) when compared to 
semi-automated(163), manual, or even CMR methods(167-171). Therefore, given the existing data, 
bringing automation of 2D-LVEF measurements into the echocardiographic laboratory is now a reality 
and may be considered by all centers
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(Bias±LOA) 
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92%  Manual Simpson 
Biplane 2D-LVEF and 
CMR LVEF 
Manual 2D-LVEF 
r=0.98 / 0±2.9%% 
CMR-LVEF 
r=0.95 / -0.3±6.0% 
Automated 2D-LVEF:48 
± 26 sec;  
Manual 2D-LVEF: 
102 ± 21 sec 
Automated 2D-LVEF: 1.3 ± 
1.7%, Manual 
2D-LVEF 
2.9 ± 2.1% 
Maret et al 
2008(163) 
60  Auto EF 
(Siemens) 
100% Manual Simpson 
Biplane 2D-LVEF 
Uncorrected Auto-EF: 
r=0.81 / +2.2±12.1% 
Corrected Auto-EF r=0.89 
/+0.8±10.5% 
 
Uncorrected Auto-EF: 79 
± 5 sec;  
Corrected Auto-EF: 
159±46 sec;  
Manuel 2D-LVEF: 177 ± 
66 sec 
Uncorrected Auto-EF no 
variability,   
Corrected Auto-EF: 
ICC=0.88,  
Manual EF: ICC=0.74 
Rahmouni et al 
2008(164) 
92  Auto EF 
(Siemens) 
100% Manual Simpson 







Szulik et al 
2011(171) 
81 (hospitalized)  AutoEF 
(GE) 
90% Average of 4 visual 
LVEF measurements 
and 2CMR reads 
Manual 2D-LVEF: 
r=0.80/-0.66±10.4% 
AutoEF :r = 0.77 / 
-1.88±11.6% 








Aurich et al 
2014(167) 
47  AutoEF (GE) 
 
100% Manual Simpson 
Biplane 2D-LVEF  
CMR LVEF  
2D-LVEF; 
 r=0.85 / +3±12%,  
CMR  
r=0.74 / +9±17% 
AutoEF: 74±18 secs, 
Manual 2D-LVEF; 
113 ± 30 secs, CMR; 
139 ± 18 secs 
Auto LVEF:  
CoV = 12% 






AutoLV (TomTec) 98% Manual Simpson 
Biplane 2D-LVEF; 







8 ± 1 sec 





2D-LVEF, Visual ICC=0.87 
Frederickson et 
al 2015(169) 
102 pts AutoEF 
(GE) 
83% Manual Simpson 
Biplane 2D-LVEF, 
Visual LVEF  
2D-LVEF, Simpson: 
r=0.82 / NA; 2D-LVEF 
Visual: r = 0.82 / 0±19% 
Automated: 






184 pts A2DQ 
(Philips) 
100% Manual Simpson 
Biplane 2D-LVEF 
ICC=0.93/ +0.4±15.3 Automated: 




Abazid et al 
2018(172) 
268 pts AutoEF 
(GE) 
89.5% Visual LVEF  






Abbreviations: BA – Bland-Altman; CMR – Cardiovascular Magnetic Resonance; CoV – Coefficient of Variance; GE – General Electric;  ICC – Intraclass Correlation Coefficient; LoA – Limits of 
Agreement (2SD); LV – Left Ventricle; LVEF – Left Ventricular Ejection Fraction; TTE – Transthoracic Echocardiogram ; NA: Not available.  
 




Automated measurements of 3D left ventricular volumes and function 
Three dimensional (3D)-LVEF with echocardiography is a more accurate and reproducible 
method of measuring LV function than 2D-LVEF(173), with test-retest variability approximating half that 
of 2D-LVEF(150). However, acquisition and manual post-processing takes 3-5 minutes per study 
(174,175). Despite recommendations for routine use of 3D-LVEF in contemporary guidelines(176,177), 
time restraints and need for analysis expertise have remained bottlenecks for widespread uptake. 
Automated analysis removes some of these limitations and can lead to significant potential benefits for 
busy echocardiography laboratories.  
Several vendors have produced fully-automated software (e.g. eSieLVA, Siemens and 
HeartModel, Philips) that requires minimal user interaction other than initiation of the analysis package. 
eSieLVA offers single-click analysis of the left ventricle, whereas HeartModel provides single-click 
analysis of all four cardiac chambers although only the left sided analysis is clinically available. Most 
studies have demonstrated >90% feasibility for fully- or semi-automated 3D-LVEF measurements (Table 
6-2).(174,175,178-181) with single beat fully-automated measurements taking <30 seconds(175,182,183) 
and 3-5 consecutive beats taking 30-60 seconds depending on volume rates(184). Using HeartModel 
(Philips®) the time required for 3D LVEF and atrial volumes for a single volume is <30 seconds.(175) 
Overall fully-automated methods have been shown to reduce analysis times by >75% compared to semi-
automated or manual methods.(174,175,181,185) For a busy echocardiographic department that reports 
80-100 studies daily, >4-5 hours (assuming 3 minutes per study) may be spent performing manual 3D-
LVEF measurements, and in ideal circumstances full-automation could potentially save over 3-4 hours of 
post-processing.  
The agreement of the automated methods for 3D-LVEF measurements have ranged from r=0.75-
0.98 compared to manual 3D methods or CMR(186). Interestingly there appears to be small 
improvements in agreement with reference method with manual adjustment of automated contours made 
by expert readers, but not novice readers, when compared to fully-automated 
measurements.(175,180,186-188) However, fully-automated 3D-LVEF measurements offer the advantage 




of significantly reducing or eliminating measurement variability, as measurements are deterministic and 
outcomes are invariable for a given study regardless of the user experience.(186) This results in decreased 
inter-observer and test-retest variability (174,175,181,185,187), likely leading to more uniform clinical 
decision making. Therefore unless there are major errors in full-automated contours and adjustments are 
made by experienced observers, contour adjustments should be minimized.     
 Another contemporary challenge for accurate 3D-LVEF measurement is in patients with 
irregular rhythms due to substantial beat-to-beat variation in their LVEF. Current guidelines recommend 
averaging of sequential LVEF measurements over 5 beats(177). Use of single-beat 3D acquisitions 
followed by automated 3D-LVEF measurements in 5-10 consecutive beats(189) has the potential to 
substantially improve workflow. Automated analysis with eSieLVA using multiple 3D datasets from 
multiple consecutive heart beats demonstrated average 3D-LVEF measurements similar to individual beat 
2D measurements.(189) Additionally, automated 3D-LVEF measurements from single index beats 
correlate with manually-measured averaged beats with absolute reductions of time to analysis of 22 
minutes per study(190).This suggests that automated single-beat 3D-LVEF measurement may be a 
reasonable approach in patients with AF and possibly other arrhythmias





Studies Patients Software 
(Company) 
Feasibility Comparator Correlation / Agreement 
(Bias±LOA) 
Time Cost Inter-Observer 
Variability 




100% Manual 3D LVEF / 
CMR LVEF  
Corrected contours:  
3D-LVEF (Manual): 
r=0.95 / -0.1±4.9% 




CMR: r = 0.64 / -1.5±12.5% 
Automatic: 
142 ± 30 sec, Manual: 
226 ± 114 sec 
 
4DAutoLVQ 
r=0.98, 6.5±6.0%  
3D-LVEF(Manual): 
r = 0.98, 4.6±4.3%  
 
Barbosa et al 2013 (179) 24  BEAS 
algorithm 
100% Manual 3D LVEF  r=0.91 / -1.0±9.8% Automatic: 






Thavendiranathan et al 
2012(189) 




71.1% LVEF as measured 
by CMR for SR, 
and manual 2D 
LVEF for AF 




30 – 60 secs 
eSie LVA: 0.4±4.5%; 
CMR: 
1.0 ± 2.0%; Test-Retest: 
r=0.98, 0.4±2.8% 
Shibiyama et al 
2013(174) 
44  eSie LVA 
(Siemens) 




r = 0.89 / -5.5±15.4% 
CMR: r=0.90 / -1.0±15.1% 
 
Fully automated: 
37 ± 8 sec;  
Semi-automated: 







Aurich et al 2014(167) 
 
 
268  3D AutoLVQ 
(GE)  





CMR; r = 0.73 / +9.0±17 
 
3D AutoLVQ; 
261 ± 93 secs; 
Manuel EF 113 ± 30 
secs; CMR 139 ± 18 
secs 
3D AutoLVQ: 
COV = 11% 
Tsang et al 2016(175) 
 
159  HeartModel 
(Philips) 
90.5% Manual 3D-LVEF 












Fully automated  
26±2 sec; Semi-







8 ± 9%; Semi-automated; 
8 ± 8% 




















COV = 3.8%;  
ICC = 0.99 
 
Levy et al 2017(184) 
 
63  HeartModel 
(Philips) 




NA r=0.90; CoV=5% 
Test-retest: 
r=0.91, CoV=6% 
Medvedofsky et al 
2017(187) 
180  HeartModel 
(Philips) 
90% LVEF as measured 
by manual 3D-
LVEF 









9±11% , Semi-automated: 
14±9% 









3D-LVEF: r=0.88 / +7.3±12.9%;  
CMR: r=0.79 / +4±20% 
HeartModel: 
29 ± 10 sec; 
3D-LVEF: 




ICC = 0.98 
For LVESV: 
CoV = 10.7% 
ICC = 0.97 
Spitzer et al 2017(185)  67 HeartModelTM 
(Philips) 















CoV = 6.9% 
Sun et al 2018(188) 103 HeartModel 
(Philips) 






1.1 ± 0.3 min;  
Manual: 
4.9 ± 2.4 min  
Fully Automated: 


















CMR LVEF (35 
patients) 
AutoLVQ: r = 0.80 / -2.0±12%; 3DQ 
ADV: 
r = 0.79 / -1.6±14% 
eSieLVA  r = 0.77 /   
-0.4±14% 
AutoLVQ = 224±29 sec 
3DQ ADV = 358±36 
sec 












Abbreviations: AF – Atrial Fibrillation; BEAS – B-Spline Explicit Active Surfaces; CMR – Cardiovascular Magnetic Resonance; CoV -Coefficient of Variation; GE – General Electric; LoA – Limits of 
Agreement; LVEF – Left Ventricular Ejection Fraction;  SR – Sinus Rhythm;  AF-Atrial fibrillation; TTE – transthoracic Echocardiogram;  
 




Automated Strain measurements 
Assessment of myocardial mechanics, referred to as strain imaging, has many strengths, including 
detection of subclinical cardiac dysfunction(137,191)and has superior ability to predict mortality 
compared to traditional 2D-LVEF measurements(137,192). Although strain imaging was introduced 20 
years ago(193), clinical uptake was initially delayed by suboptimal reproducibility of manual 
measurements. With advancements enabling high frame rate images, successful implementation of semi-
automated strain measurements using speckle tracking methods achieved similar accuracy to manual 
measurements, allowing time savings of up to 82% and positioned semi-automated 2D-speckle strain for 
widespread clinical uptake.(194) Today very few physicians need to undertake manual strain analysis. 
Given that 2D-speckle tracking based strain measurements were introduced clinically as a semi-
automated technique and were validated using sonomicrometry(195), there is limited literature comparing 
the accuracy and reproducibility of automated versus manual methods (Table 6-3).(194,196-198)  
Currently strain measurements are made using vendor specific software - AFI (General 
Electric®) and QLAB (Philips®) – and vendor neutral software – AutoSTRAIN (TomTec), VVI 
(Siemens), and EchoInsight (Epsilon Imaging®). These programs require manual identification of certain 
ventricular landmarks followed by specification of the width of the region of interest, which is then 
automatically tracked through the cardiac cycle(199). Although some degree of manual input may 
introduce variability, contemporary analysis packages have demonstrated excellent inter-observer 
reproducibility for semi-automated GLS measurements compared to manual methods (Table 6-
3)(165,197). For example, one study of 546 patients analyzed with AFI reported an inter-observer ICC of 
0.92  for GLS compared with ICC of 0.80 for 2D-LVEF.(192) Similarly in a multicenter setting semi-
automated measurement of GLS have been shown to be more reproducible that 2D LVEF.(141) As 
opposed to GLS, regional strain measurements are less reproducible(195) and currently not encouraged 
for routine clinical practice. More recently, fully-automated GLS strain measurements are now possible 
with some vendors (165). Whether this will likely further improve the reproducibility of the global and 
segmental strain measurements and optimize workflow remains to be seen. 




Currently clinical strain measurements are limited to systolic GLS and are obtained using 
multiple 2D left ventricular apical images. Small studies have demonstrated that semi-automated 3D-
LVstrain is feasible and reproducible(200), but larger studies are required to quantify clinical benefit. It is 
likely that further advances in automation and efforts in standardization of strain measurements between 
vendors may allow GLS to supersede LVEF as the primary measure of left ventricular systolic function 
and enhance its use in point-of-care imaging. 





Table 6-3: Studies Assessing Automated Echocardiographic Measurements of Myocardial Strain 















Accuracy speck tracking 
method = 95.8%, 
manual method 96.2% 
Automated: 
2 min; manual: 
11 min 
 
CoV Automated 15%, 
Manual 30% 
Delgado et al 
2008(197) 
222 (CAD) AFI 
(GE) 
100% (GLS) 2D-LVEF 
 
r=0.83 NA ICC=0.92; -0.2± 2.6% 
Belghiti et al 
2008(199) 




97% (GLS) LVEF as 
measured by 2D-
LVEF 
r=0.87 (experience did 
not affect correlation), 
r=0.96 between expert 
and beginner (LOA 
3.4%) 




2D LVEF 14.5% 
Brown et al 
2009(196) 
62 (prior MI) 4D analysis 
(TomTec) 






r=-0.69  Strain: 
132 ± 30 sec; CMR: 




Fernandez et al, 
2012(198) 
59 QLab (Philips) 91% amongst expert, 
89% amongst non-
experts (GLS) 
NA  NA -0.09±4.45 (experts) 
0.66±7.68 (expert vs 
non-expert) 




98% (GLS) Manual Biplane 
Longitudinal 
Strain 
ICC = 0.83 /  
+0.7 (95%CI 0.1-1.3)% 
NA Automated ICC=0, 
LOA 0 
Manual ICC=0.88, LOA 
9.6% 




93% (GLS) Manual Biplane 
LVEF 
NA GLS 1 minute, 2D 
LVEF 2 minutes 
GLS r=0.98, 2D EF 
r=0.91. Minimal impact 
of reader experiences on 
GLS, FF ICC 0.89, GLS 
0.98  
Abbreviations: AFI – Automated Function Imaging; AS – Aortic stenosis; CAD – Coronary Artery Disease; CoV – Coefficient of Variance; DCM – Dilated Cardiomyopathy; MI – Myocardial 
Infarction; TDI – Tissue Doppler Imaging; TTE – Transthoracic Echocardiography; NA - not reported 
 




Assessment of Valvular Heart Disease 
Automated measurement of stroke volume and regurgitant volume  
The American Society of Echocardiography’s Valvular Regurgitation Guidelines recommend the 
use of the volumetric techniques to quantify valvular regurgitation severity(201). However this is not 
routinely performed due to concerns of  wide inter-observer measurement variability from squaring of 
measurements leading to exaggeration of imprecisions and time demands with multiple  measurements 
taking up to 4-6 minutes(202).  
Semi-automated measurement of stroke volume using real-time 3D color Doppler datasets allow 
measurement of velocities over the entire orifice (e.g. mitral or tricuspid annulus) of interest to provide a 
measure of stroke volume(202-204). The benefits of this approach are avoidance of assumptions of orifice 
geometry, rapid simultaneous stroke volume measurements at multiple valves and improved accuracy and 
reproducibility(Table 6-4).(202-204) Stroke volume calculations are determined by fully-automated 
detection of the relevant landmarks using an expert-annotated database of sample images, followed by 
placement of hemispheric velocity-sampling planes and automated de-aliasing for Doppler velocity 
ambiguity. Measurements of stroke volume have been shown to be feasible in >85% of the patients with 
good agreement with CMR phase-contrast imaging(202) and take <60 seconds without manual 
adjustments, whereas manual methods may take 4-5 minutes(202). Notably, these studies excluded 
patients with multi-valvular disease, significant arrhythmia and poor images, and it is possible that 
accuracy, reproducibility, and time-efficiency may be reduced in these patient subgroups.  
 A promising application of automated 3D color Doppler stroke volume technique is 
quantification of valvular regurgitation. Mitral or aortic regurgitant volume can be calculated indirectly as 
difference in mitral inflow and aortic outflow stroke volumes using the same cardiac cycle(205,206). For 
functional mitral regurgitation for example, the time required to obtain automated mitral and aortic stroke 
volume for 3-5 cardiac cycles has been reported to be 30-60 seconds, and the calculated regurgitant 
volume had excellent correlation and agreement with CMR and was superior to that for 2D manual 




methods(205). The value of the automated 3D color Doppler technique for regurgitation quantification 
has now been consistently illustrated in multiple studies, including for the assessment of aortic 
regurgitation(206). The strength of this technique is particularly notable in patients with eccentric jets and 
multiple jets. The clinical applicability of this automated method is currently limited by its vendor 
specific nature and limited awareness. 
  















Matthews et al 
2010(207) 




100% CO as measured by 
PA catheterization 
Cardiac Output; R2 = 0.71/ 
0.09±1.3L 
 
NA  Not reported 





93.8% PC-CMR for MR 
severity 
RV r = 0.85 / -5.7±33.6ml  
 
NA ICC = 0.89 








100% PC-CMR, 2D 
Manual Stroke 
volume method 
CMR vs Auto 3D SV: MV: 
r=0.91/ 1.1±18.9ml ; AV SV: 
r=0.93 / -0.7±17.8ml 
CMR vs 2D SV: MV r=0.66 / 






2D manual = 4-6 
minutes 
Automated 3D MV r=0.97, 
AV 0.95, 2D manual MV 
r=0.79, AV 0.92. 2D 
manual MV 
Thavendiranathan et al 





100% PC-CMR for MR 
severity 
RV r=0.91/ -1.6±17.0ml; RF 
r=0.92 / -0.3 ±14.6% 
30-60 seconds RV 0.9 ±11.5ml, CCC 
0.96;  RF 0.2±10.9%; CCC 
0.93; Test re-test RVol 
1.2±8.8ml, RF 1.6±9.7% 
Gruner et al 2014(209) 27 ( post mitral 
clip for MR) 
Unnamed 
(Siemens)  
89% Visual MR 
classification 
3D Automated Color Doppler 
better agreement with visual MR 
than 2D manual method 
NA ICC 088 for MV SV 0.86 
of AV SV 




93.8% PC-CMR for AR 
severity 
AR RV r=0.93, LOA 9.5ml, AR 
severity agreement k=0.94 
5.6 ±2.0 min 
 
RV ICC=0.96 
Heo et al 2017(210) 152 (MR) Unnamed 
(Siemens) 
97.4% PC-CMR for MR 
severity (37 patients) 
MR Rvol volume: 
r=0.94, 2D Volumetric method 
r=0.56 
Automated: 
4.3 ± 2.2 min 
ICC = 0.87 automated , 2D 
manual ICC 0.93 
 
Kato et al  2018(211) 34 Children 





92% for AV 
97% for MV 
80% for PV 
92% for TV 
Qp : Qs calculated 
via Fick method 
PV/AV ratio 
r=0.84; TV/MV ratio: 
r=0.87 
Automated: 
3 – 5 min per 
valve 
MV:  CoV 12.6% 
TV: CoV 8.9%  
AV: CoV 13.2% 
PV: CoV 8.2% 
Abbreviations: 3D RT-VCFD – Three -Dimensional Real Time Volume Color Flow Doppler; ASD – Atrial Septal Defect; AR – Aortic Regurgitation; AV – Aortic Valve; CO – Cardiac Output; CoV – 
Coefficient of Variation; ICC – Intraclass Correlation Coefficient; MR – Mitral Regurgitation; MV - Mitral Valve; PA – Pulmonary Artery; Qp:Qs – Pulmonary-Systemic Flow Ratio; PC-CMR – Phase 
Contrast Cardiovascular Magnetic Resonance; PV – Pulmonary Valve; RV – Regurgitant volume; RF – Regurgitant Fraction; SV – Stroke Volume; TV – Tricuspid Valve;   
 
 




Automated Proximal Isovelocity Surface Areas Measurements 
Semi-Automated analysis of the 3D proximal isovelocity surface area (PISA) to estimate 
effective regurgitant orifice area (EROA) and regurgitant volume (RVol) offers a novel approach to 
directly quantify regurgitation severity. Manual quantification of EROA and RVol using 2D-PISA makes 
assumptions regarding the shape of the proximal flow convergence region resulting in significant inter-
observer disagreement for severity classification(212).  The use of manual 3D-PISA avoids the need to 
make specific shape assumptions offering improved accuracy compared to the 2D-PISA 
technique(213,214), but is laborious and impractical(213). Semi-automated software can take advantage 
of large and information-rich 3D color Doppler datasets to quantify the 3D PISA (205) over the entire 
cardiac cycle (“integrated PISA”) accounting for the dynamic nature of the regurgitant orifice.(215)  
Semi-automated 3D-PISA measurements have been demonstrated to be accurate and reproducible 
in both in vitro models(205) and when applied to patients with functional MR using CMR as a reference 
standard (Table 6-5). Use of integrated 3D-PISA technique provides further incremental benefit in 
functional mitral regurgitation, as evidenced by superior agreement with CMR for RVol(205). These 
multiple measurements of the 3D-PISA over the cardiac cycle are only practical with semi-automated 
methods and not manual methods due to superior time efficiency (~15±4 seconds per cardiac cycle).(205) 
The reduced variability in effective regurgitant orifice area measurement by 3D-PISA compared with 
traditional 2D-PISA methods has been replicated in two other larger studies of >300 patients with both 
organic and functional MR(216,217). Similar results have been observed for quantification of tricuspid 
regurgitation severity (218).  
To date, studies examining semi-automated measurement for stroke volume or regurgitant 
volume quantification have consistently demonstrated improvements in accuracy, reproducibility and 
analysis speed. Further improvements in these automated algorithms are likely with growing vendor 
interest. 





Table 6-5:  Studies Assessing Automated Echocardiographic Measurements of 3D-Proximal Isovelocity Surface Area  
Studies Patients Software Feasibility Comparator 






et al 2013(205) 
30  pts with 






CMR RV  
 
RV by CMR: 




1.7±0.7 min;  
Automated Peak 
PISA: 15±4 sec 





De Agustin et al  
2012(219) 
33 pts  
(25 primary MR;  







EROA; r=0.99 / 
0.0±0.1cm2 









3D PISA ICC 
0.92 
2D PISA ICC NA 








3D VCA Vs VCA 3D PISA r=0.97 
/ 0.01±0.12cm2, 2D PISA 
r=0.89 / 0.1±0.27cm2 
2-3min for 3D 
PISA, 3-4 min for 
2D PISA 
3D PISA ICC 
0.88, 2D PISA 
0.79 
Schmidt et al 
2014(216) 
93 pts 









EROA: r= 0.93 
 
Not reported Not reported 
Choi et al 
2014(217) 
221 pts (111 primary; 










4.6 ± 2.0 min 
3D PISAICC 0.97 
2D PISA ICC 
0.95 
Abbreviations: CMR – Cardiac Magnetic Resonance; EROA – Estimated Regurgitant Orifice Area; ICC – Intraclass Correlation Coefficient; MR – Mitral 
Regurgitation; PC-CMR – Phase Contrast Cardiac Magnetic Resonance; PISA – Proximal Isovelocity Surface Area; RV – Regurgitant Volume; RF – Regurgitant 
Fraction 




Guidance for intervention 
Automated measurement of aortic annulus and root 
Clinical outcomes of transcatheter therapies for aortic valvular disease depend on accurate 
measurements of AV landmarks. Measurements of aortic annulus size using 2D-TEE under-estimate 
aortic annular area due to incorrect geometric assumptions. Although 3D-TEE-based measurements offer 
incremental improvement, they still underestimate area by ~9% compared with multi-detector CT 
(MDCT)(220). Currently MDCT is the recommended imaging modality for accurate aortic annulus and 
root dimensions prior to transcatheter aortic valve implantation (TAVI) but is limited by risk of 
nephrotoxicity from contrast use, radiation exposure, limited temporal resolution, and susceptibility to 
calcium blooming artifact obscuring true annular border. Automation of 3D-TEE measurements may 
avoid these undesirable effects and lead to safer, accurate and reproducible measurements.  
Several vendors have now produced automated software specifically designed for measuring 
aortic annular and root measurements from 3D-TEE datasets with good feasibility, accuracy, and 
reproducibility (Table 6-6)(221,222). These software allow fully automated analysis, but also allow for 
manual adjustments(221). For TAVI assessment, the bias of automated 3D-TEE measurements for 
annular diameter, perimeter, and area appears small (approximately -1.2% to -2.2%) and agreement with 
MDCT for selection of device size has been excellent (κ = 0.90)(222). Time required for automated aortic 
root measurements from 3D-TEE datasets has  ranged from 2.3 ± 0.6 minutes(221) to 4.2 ± 1.0 
minutes(222), with longer times required if excessive calcium or poor image quality present. Smaller 
studies have demonstrated similar promising results in terms of accuracy in comparison to 
MDCT(220,223,224).  
Beyond the annulus, automated modeling of aortic root and valve is now feasible using software 
based on learned-pattern recognition(221), with cross-sectional diameter measurements displaying good 
agreement with MDCT(221). Additionally, several published studies display similar reproducibility to 
MDCT measurements with ICC for intra- and inter-observer variability ranging from 0.91-0.98 (Table 6-




6). This reproducibility is particularly important in longitudinal follow-up to determine timing of surgical 
intervention(221,222,225).  
 Automated 3D-TEE appears to be a viable strategy for enhancing the precision and 
reproducibility of future aortic measurements. Larger studies using clinical endpoints are required prior to 
widespread clinical use.




Table 6-6: Studies Assessing Automated Echocardiographic Measurements of Aortic Annulus and Root 
Studies Patients Software Feasibility Comparator 





Calleja et al 
2013(221) 
69 pts (20 healthy 
volunteers, 14 severe AS, 








0.5±5.87 mm Automated: 
1.1–3.4 minutes 
ICC=0.90 to 0.93 
Garcia-Martin et 
al 2016(223) 




88.6% Manual 3D-TEE 
measurements 
Aortic Annular diameter: ICC 
0.85; Aortic Annular Area: 
ICC 0.74 
NA Aortic Annular diameter: 
ICC=0.94;  








90% MDCT Aortic Annular Area: r=0.92; 
Aortic Annular perimeter: 
r=0.91 
NA Aortic Annular Area: ICC 
0.70;  
Aortic Annular Perimeter: 
ICC 0.72 







100% for aortic 
annular dimensions; 
89% for aortic root 
dimensions 
MDCT Aortic Annular area: 
r=0.91; Aortic annular 
perimeter:  
r=0.83 
Automated Aortic root 
measurements: 
4.2 ± 1.0 min 
ICC 0.93 
Queiros et al 
2018(226) 
101 pts Specqle 3D 
(KV Leven) 
92.1% MDCT Fully Automated: 
ICC 0.78; Contour correction: 
ICC 0.83 
Automated: 




Podlesnikar et al 
2018(227) 
83 pts (severe AS 
Separated into high and 
low aortic valve calcium 
(AVC) 
4D Auto AVG 
(GE-
Vingmed) 
97.6% MDCT For selecting prosthesis size 
Low AVC: Κ= 0.93;  
High AVC: Κ=0.71 
NA Perimeter ICC 0.96; Area: 
ICC 0.97 






93.5% MDCT Automated 
annular area: 
r = 0.86; Semi-automated 
annular area: r= 0.94Manual 
annular area: r=0.93 
 
Automated 3D-TEE: 




Manual 3D-TEE; 81.8 
± 18.5 sec 
Automated; ICC 0.99,LoA 
-28.6 to 26.7; Semi-
automated; ICC 0.96 
LOA -22.7 to 66.8 
Manual; ICC = 0.95 
LOA -47.0 to 81 
Abbreviations: AS – Aortic Stenosis; AVC – Aortic Valve Calcium; CoV – Coefficient of Variance; ICC – Intra Class Correlation Coefficient; LOA - Limits of Agreement;  MDCT – Multi Detector 










Automated measurement of mitral valve anatomy 
The use of 3D echocardiography has significantly enhanced our understanding of the mitral valve 
and annular anatomy.  Specifically, the ability to generate parametric maps has improved the accuracy of 
identifying mitral valve pathology, has been validated surgically and has the potential to guide surgical 
planning(229-233). However they are currently not practical for routine echocardiography.  
3D mitral valve parametric maps can now be generated using automated software from several 
vendors, and can be either fully- or semi-automated(Table 6-7). For example, semi-automated analysis in 
patients with degenerative mitral valve disease has demonstrated that quantitative annular circumference 
was associated with implanted annuloplasty band length, while posterior mitral valve leaflet segment 2 
length and area was associated with performance of intraoperative leaflet resection(230,234). Similar to 
automation in other areas of echocardiography, intra-and inter-observer variability for semi-automated 
measurements have been reported to be good with ICC ranging for 0.83-0.99 depending on the structure 
being measured(234). Also fully-automated methods result in >75% reduction in the time for analysis 
compared to manual methods. 




Table 6-7: Studies Assessing Automated Echocardiographic Measurements for Assessing Mitral Valve Anatomy 
Studies Patients Software Feasibility Comparator Correlation / 
Agreement 
Time Cost Inter-observer 
Variability 
Grewal et al 
2010(230) 
32 pts (moderate-to-
severe primary MR) 
Q-Lab MVR 
(Philips) 
100% Direct surgical 
measurement 
Mean difference in aortic 
annulus measurement: 
0.1 ± mm, 95%CI ±4.4 
mm 
NA Antero-posterior diameter 
CoV 5.7% 
BA 95%CI ±5.1mnm; 
Inter-commissural distance 
CoV 4.3%; BA 95%CI ±2.3 
mm  
Pouch et al 
2014(235) 
20 pts pre cardiac 
surgery (6 normal MV, 






100% Manual 3D-TEE 
measurements 
Mean distance between 
manual and automatic 




Kagiyama et al 
2015(236) 
74 pts ( 15 functional 






100% Manual 3D-TEE 
measurements 
Agreement using 
Cronbach’s alpha: 3D 
annulus circumference: 
α =0.88; Antero-posterior 
diameter:α=0.90  
Automated: 
260 ± 65 sec;  
Manual: 
381 ± 68 sec 
Inter-observer 
agreement using 
Cronbach’s alpha: 3D 
annulus circumference: 
α =0.97; Antero-posterior 
diameter: 
α=0.96 
Calleja et al 
2015(234) 











predicted and implanted 










ICC = 0.99 
 
Aquila et al  
2016(219) 
36 pts 
-referred for 3D-TEE 
for any reason 
eSie Valves 
(Siemans) 
59% Manual 3D-TEE 
measurements 
Mitral annular area: 
r=0.94; Inter-commissural 
distance: r=0.84 





















144 ± 24 sec; 
Manual: 





Abbreviations: BA – Bland-Altman; CoV – Coefficient of Variation; ICC – Intra-class Correlation Coefficient; MV – Mitral Valve; MR – Mitral Regurgitation; MVP Mitral 
Valve Prolapse; TEE – Trans-Oesophageal Echocardiogram;   
 




Adoption of Automated Methods in Routine Echocardiography 
We have summarized evidence for the use of automated techniques and provided 
recommendations for its use in Table 6-8. We believe that there is adequate evidence to support the 
clinical use of semi- or fully-automated analysis of 2D LVEF, 3D LVEF, and measurements of global 
longitudinal strain. Prior to use of automated 2D LVEF or strain measurements it is prudent to ensure 
adequate image quality including adequate endocardial definition, non-foreshortened views, minimal to 
no drop-out or artifacts. For GLS measurements, acquisition of all 3 apical views sequentially with 
similar heart rates and frame rates (>40 frames per second) is essential. For automated 3D LVEF, in 
addition to good image quality, volume rates should exceed 20 volumes per second. Once the automated 
algorithm is applied for LVEF or strain measurements, it is important to visually assess tracking quality 
and make contour adjustments if necessary. LVEF techniques should be avoided in scenarios in which 
they have not been adequately assessed.  
An approach for echocardiography laboratories to incorporate automated techniques as part of 
their workflow has been outlined in Figure 6-2. The types of automated quantification techniques 
available will depend on the vendor and the version of the echocardiography machines being used. Each 
lab should establish practice guidelines by identifying patient subsets that should be included and 
excluded from automated quantification. Analysis of the acquired data should ideally be performed 
immediately so that additional images could be obtained in case of poor tracking. Physicians and 
sonographers should be trained on 20-30 echocardiographic datasets with the focus on what constitutes 
adequate automated analysis. Echo templates may need to be modified to accommodate the automated 
measurement. It is also important to use the same vendor’s automated techniques for longitudinal follow-
up of EF or strain measurements as there are limited data on inter-vendor comparisons with 2D LVEF and 
there are known vendor differences with GLS measurements(228). Interestingly, for 3D LVEF, a recent 
study comparing 3 vendors using semi-automated algorithms has demonstrated good inter-vendor 
agreement.(181) Therefore inter-vendor differences may be less of an issue for 3D LVEF measurements. 
It is also important to ensure that the echocardiography image data is stored in a format (e.g. 




uncompressed format) that could be re-analyzed by the reporting physician if there is disagreement with 
the automated analysis. Finally, labs should incorporate a local quality assurance program to verify robust 
automated analysis processes and to ensure that any software upgrades are carefully considered especially 
if they will have an impact on measurement accuracy and reproducibility. 




Table 6-8: List of recommendations and assessment of evidence base for use of automated echocardiography 
2D-LVEF Moderate number of studies with moderate number of patients with uniform direction of effect 
 Use of automated 2D-LVEF measurements is reasonable for assessing left ventricular systolic function for purposes of improved time efficiency 
and reproducibility. 
 Use of software that has been validated in peer-reviewed literature is recommended 
 Tracking quality should be visually assessed, with contour adjustment as necessary 
 TTE report should specify that automated LVEF measurement was utilized 
 Caution is advised in cases of significant arrhythmia, LV aneurysm and congenital heart disease, as few published studies recruited these patients 
 
3D-LVEF Moderate number of studies with moderate number of patients with uniform direction of effect. 
 Use of automated 3D-LVEF measurements is reasonable for assessing left ventricular systolic function for purposes of improved time efficiency 
and reproducibility. 
 If available, preference for automated 3D-LVEF should be given over automated 2D-LVEF 
 All other recommendations for automated 2D-LVEF apply to automated 3D-LVEF 
 
Strain Moderate number of  studies demonstrating clear clinical utility 
 It is reasonable that automated strain measurements be used. 
 Commercial package that has been validated in peer-reviewed study should be used. 
 Manual strain measurements are not recommended for clinical use. 
 
Stroke Volume & 
Regurgitant Volume 
Small number of single-center studies suggestive of clinical utility   
 Use of automated stroke/regurgitant volume measurements for quantification of mitral regurgitant volume and trans-mitral stroke volume needs 
further validation before routine clinical use.  
 
PISA Small number of single-centre studies which included relatively small number of patients 
 Use of automated PISA measurements for quantification of mitral regurgitant volume and EROA needs further validation before routine clinical 
use. 
 
Aortic Annulus and 
Root 
Small number of single-centre studies which included moderate number of patients with uniform direction of effect 
 It would be reasonable to use automated aortic root and annulus measurements for purposes of improved time efficiency and reproducibility, 
however, further experience is needed before routine clinical use.  
 Automated measurements should only be taken using datasets obtained by 3D-TEE at present. 
 Caution should be exercised in cases of reduced image quality and high-grade annular calcification as manual contour adjustments are more likely 




Small number of single-centre studies with small number of patients that did not include variety of mitral valvular conditions 
 Use of automated mitral valvular dimensional measurements requires further validation before clinical use.   
 Automated measurements should only be taken using datasets obtained by 3D-TEE at present.  
Abbreviations:3D-TEE – 3-Dimensional Trans-Esophageal Echocardiogram; LVEF – Left Ventricular Ejection Fraction; PISA – Proximal Isovelocity Surface Area; TTE – 
Transthoracic Echocardiogram 





Although the described studies have demonstrated net benefit of automated measurements at the 
group level, it is likely that at an individual level automated accuracy may be substantially different from 
reported mean values of large groups. This may be due in part to two reasons; firstly, distinct populations 
such as those with arrhythmia, congenital heart disease, abnormal cardiac chamber configuration, and 
multi-valvular disease are poorly represented in studies to date; secondly, there is an inherent conflict 
between reproducibility and accuracy, as algorithms are restricted to a greater degree in the number of 
variables and approach to analysis than human beings are. Two strategies for increasing effective and safe 
widespread implementation of automation are expansion of the evidence-base and mindful incorporation 
of both subjective and automated variables into a holistic reporting process. 
  
We consider that the seven automative techniques described above can be divided into three strata based 
on their needs for future research before they replace manual measurements in clinical practices. The first 
strata includes 2D-LVEF, 3D-LVEF and GLS, and is characterized by several studies demonstrating 
feasibility and accuracy of specific patient groups with moderate number of patients. In order to facilitate 
uptake of these automated techniques, further studies are desirable to clearly quantify benefits and 
liabilities. This includes determination of inter-vendor agreement, assessment of multicenter 
reproducibility, comparison of the diagnostic and prognostic advantage of the automated techniques, and 
cost-effectiveness analyses. Distinct populations such as those with arrhythmia, poor-quality images 
secondary to obesity or post-surgical status, obesity, congenital heart disease, abnormal cardiac chamber 
configuration, and multi-valvular disease need to be studied. Additionally, the hypothesis of cost and time 
savings with automation should be confirmed in large observational studies of multiple busy echo labs 
that incorporate automated software. Ideally, large multi-centre randomized control studies that assess 
automated versus conventional echo measurements for management of cardiac disease using measurable 
clinical outcomes would be required for automated echo measurements to receive a Class I 




recommendation, but such studies would be challenging to conduct and are unlikely to be implemented in 
the foreseeable future.  
These analysis algorithms are now available with multiple vendors but inter-vendor comparisons 
do not exist.  The clinical utility of these methods will become apparent as percutaneous techniques and 
minimally invasive procedures for valve disease become more common practice.  
The second strata includes automated measurements of aortic annulus and root, for which large, 
multicenter studies with demonstration of efficacy in patients with greater diversity of aortic pathologies 
are required before being considered suitable for routine clinical use. The third strata includes the three 
automated techniques of automated stroke and regurgitant volume measurements, PISA measurements 
and mitral valve anatomy. Data supporting use of these techniques overall is based on small number of 
single-center studies with small sample sizes. These techniques are also only currently available with a 
single vendor with ongoing evolution of the analysis software, and requires large, multicenter studies 
demonstrating a uniform direction of effect of high levels of feasibility, accuracy and reproducibility 
before large clinical studies can be recommended. 
Significant advances in automated quantification in echocardiography are anticipated over the 
next decade, including improvement in spatial and temporal resolution, better contrast to noise and signal 
to noise ratios, and enhancement in 3D image visualization. With these advances, automated 
quantification will likely extend beyond a single chamber to provide simultaneous assessment of the size 
and function (ejection fraction and strain) of all cardiac chambers and great arteries simultaneously.  
However, physicians should be mindful that automation does not remove the need for physician review of 
all echocardiographic images, and automated measurements should be assessed in the context of a holistic 
appreciation of all available data.  Physicians retain the responsibility to visually assess all 
echocardiographic images, including automated tracking and border detection. If the automated 
measurements are discordant with other echocardiographic data, then the clinician should inspect 
automated tracking and border detection images for errors and consider manual measurement if errors are 




detected. If there remains clinical uncertainty, an alternative cardiac imaging modality may be utilized. 
Ideally there should be a process by which automated measurement errors are reported back to the 
software developer to allow for iterative algorithmic improvements.









Figure 6-2: Flowchart for steps required for Echo Lab to uptake routine automated measurements 
¶Vendor software company may provide de-identified datasets for automated measurement training 





Automated quantification in echocardiography has partially fulfilled its early promise and has led 
to successful and practical uptake of several echocardiographic technologies and affected many aspects of 
echocardiographic practice. It has consistently and successfully led to significant time savings and 
improvements in measurement reproducibility, and it is anticipated that further advancements will assist 
in improving patient outcomes and reining in healthcare costs.  Automated quantification will allow 
clinicians to focus less on the process of measurements and shift their attention to data quality, data 
synthesis, and diagnosis. To fully reach the potential of automation, innovative partnerships between 
physicians, technologists, software engineers, and industry need to be encouraged and supported. 















Secondary Cardiac Imaging for 
Indeterminate Cases of Cardiac Dysfunction 
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The two previous sections of this thesis have established the central importance of sequential cardiac 
monitoring to prevent and manage CTRCD and have demonstrated echocardiography is the most suitable 
first-line imaging modality. Improved national uptake of this proactive strategy may potentially decrease 
both acute and long-term burden of cardiovascular disease in the cancer population, with potential down-
stream savings in terms of both survival years and societal resources. It is probable that under-
appreciation of the benefits and suboptimal understanding of contemporary cardiac imaging may be a 
barrier to successful implementation amongst both oncologists and cardiologists. 
Up to this point in this thesis, the focus has been on identifying optimal strategies for cardioprotection at 
the population-based level. However, in practice all medicine is practiced at the individual level, where 
personal characteristics of patients and cancer treatments may lead to the need for an individualized 
imaging strategy for successful long-term management. Due to the excellent safety record of 
echocardiography and the substantial quality clinical information it provides, the number of cancer 
patients who would be unsuitable for echocardiography as 1st line imaging modality is likely to be 
vanishingly small. Therefore the next section of this thesis will focus on adjunctive imaging techniques 
that offer additional information not readily available by echocardiography.  
Echocardiography has several notable limitations which should be taken into account. It is dependent on 
obtaining quality acoustic windows, which may be challenging in patients who have undergone left-sided 
breast surgery or radiotherapy. Temporal variability of LVEF measurements can be as high as 11% even 
in the absence of changes in myocardial function(140). Echocardiography cannot reliably detect changes 
in myocardial tissue composition, such as edema or fibrosis. For these reasons, as well as for excluding 
significant differential diagnoses and co-existing myocardial diseases, there will be a subgroup of cancer 
patients who will require a 2nd line imaging test to assess myocardial function. Cardiac MRI is a strong 
contender for this role, as it is the gold standard technique for measuring left ventricle volumes and can 
reliably detect acute myocardial tissue changes. The next section of this thesis will assess the utility of 




CMR to firstly assess a cohort of CTRCD patients to determine if there are false positives with preserved 
contractility, and secondly assess a cohort of early breast cancer patients to determine if cardiac 
dysfunction can manifest as phenotypes other than that described solely in terms of LVEF decrement. 
Together, these chapters will expand our understanding of the role of CMR in cancer patients both with 











Background: There is concern that intravascular volume depletion (preload) mediated reduction in LVEF 
and GLS may result in incorrect diagnosis of cancer-therapy related cardiac dysfunction (CTRCD). 
Objectives: To explore the mechanisms underlying cancer-therapy-mediated reduction in left ventricular 
ejection fraction (LVEF) and global longitudinal strain (GLS).  
Methods: 112 consecutive women (50.6±9.7 years) with early stage HER2+ breast cancer, receiving 
sequential anthracycline and trastuzumab, were recruited prospectively. All had CMR pre-anthracycline, 
within one-month post-anthracycline and at six months. A subgroup of 83 patients had echocardiography 
with GLS measurements at identical timepoints. Significant change in LV volumes by CMR were 
defined as LV end-diastolic volume (LVEDV) reduction by >10ml or LV end-systolic volume (LVESV) 
increase by >5ml. CTRCD was defined either per the Cardiac Review and Evaluation Committee Criteria 
(CTRCD-LVEF) or a relative reduction in GLS by >15% (CTRCD-GLS). Sensitivity analysis were 
performed with any reduction in LVEF by >5% or GLS>11%. 
Results: Fifteen patients (13.4%) developed CTRCD-LVEF mediated by an increase in LVESV alone in 
12(80.0%), combined LVESV increase and LVEDV decrease in two (13.3%) and non-significant volume 
change in one patient. No patient had CTRCD-LVEF due to isolated reduction in LVEDV (reduced 
preload). A change in LVEDV was not predictive of CTRCD-LVEF (p=0.74), while a change in LVESV 
was (p=0.006). CTRCD-GLS occurred in 17 patients (20.5%) of whom one had a primary reduction in 
LVEDV with a non-significant increase in LVESV. Of the 53 patients (47.3%) with a reduction in LVEF 
>5% and 29(34.9%) with a reduction in GLS >11%, an isolated reduction in LVEDV was observed in 
seven (13.2%) and 4 (13.8%) patients respectively. 
Conclusions: The dominant mechanism of CTRCD in breast cancer patients receiving anthracycline 
based therapy relates to an increase in LVESV likely reflecting altered myocardial contractility. Preload 
reduction may play role in small reductions in LVEF or GLS not meeting criteria for CTRCD. 





Cancer therapy related cardiac dysfunction (CTRCD) is primarily defined as a threshold change in left 
ventricular ejection fraction (LVEF) between baseline and a subsequent follow-up(238,239). Often the 
recognition of CTRCD results in transient or permanent cessation of cancer therapy, additional cardiac 
investigations, and the initiation of heart failure medications. Myocardial dysfunction from CTRCD may 
potentially be detected earlier by the use of myocardial strain measurements.(137) Several studies have 
demonstrated that a reduction in peak systolic global longitudinal strain (GLS) during cancer treatment is 
associated with a subsequent reduction in LVEF and heart failure  providing an opportunity for earlier 
intervention.(240) 
Since LVEF is calculated as difference between left ventricular end-diastolic (LVEDV) and end-
systolic (LVESV) volumes divided by LVEDV, a reduction in LVEF can occur due to either a decrease in 
LVEDV, an increase in LVESV, or the combination. It is generally assumed that CTRCD is driven by 
myocardial injury affecting myocardial contractility with resultant increase in LVESV. However, during 
cancer therapy the potential for nausea, vomiting, and reduced oral intake can result in intravascular 
volume depletion and an associated reduction in LVEDV (preload) translating to a reduction in LVEF. 
The treatment for contractile dysfunction would include standard strategies for CTRCD,(238,239) whilst 
treatment for the latter would include hydration and treatment of nausea and vomiting. Treating patients 
with reduced preload with heart failure medications (e.g. ACE inhibitors and beta-blockers) could 
potentially result in adverse hemodynamic alterations and clinical symptoms. Recent cardiovascular MRI 
(CMR) studies of patients with multiple different cancers and treatment regimens demonstrated that 
CTRCD occurred due to isolated reduction in LVEDV in 19-26% of the patients.(241,242) Furthermore, 
a reduction in CMR measured myocardial strain (circumferential and longitudinal) was associated with a 
reduction in LVEDV. Consequently, additional work is necessary to confirm these findings and to 
explore the association between preload with GLS measured by echocardiography. 




In this study, using a uniform population of women with human epidermal growth factor receptor 
2 positive (HER2+) breast cancer receiving anthracycline and trastuzumab-based therapy, our objectives 
were to (i) quantify proportions of patients with CTRCD secondary to contractile dysfunction versus 
reduced preload using CMR-measured left ventricular volumes and ejection fraction and (ii) determine 
whether a reduction in GLS measured by echocardiography is associated with a reduction in preload. We 
hypothesized that changes in LVEF and GLS meeting CTRCD criteria will be related to myocardial 




One-hundred and twelve consecutive patients with early stage HER2+ breast cancer were recruited 
prospectively from outpatient clinics between January 2014 and April 2017 from the Princess Margaret 
Cancer Centre/University Health Network (UHN) or St. Michael’s Hospital in Toronto (N=83) and from 
February 2015 to February 2017 from the Libin Cardiovascular Institute of Alberta, Calgary, Canada 
(N=29). We included women ≥18 years of age with stage I-III, HER2+ breast cancer scheduled to 
undergo treatment with an anthracycline (Epirubicin or Doxorubicin) followed by a combination of 
trastuzumab and a taxane (paclitaxel or docetaxel). Exclusion criteria were (1) previous anthracycline 
therapy; (2) current or prior cardiovascular disease; and (3) general contraindications to MRI. Patient 
characteristics, cardiac risk factors, medications, cancer history, cumulative anthracycline doses, and 
other cancer treatment exposure were collected. At each visit all patients were weighed, vitals were 
recorded, and heart failure symptoms were elicited. The study was approved by the respective Research 
and Ethics Boards and all patients provided written informed consent. 
 
 




















Cardiovascular MRI (CMR): CMR studies were performed at three time points: prior to initiation of 
cancer therapy, within 1 month of anthracycline completion (~2-3 months from baseline), and 3 months 
later (~6 months from baseline and ~3 months after trastuzumab initiation). CMR scans were performed 
on 1.5T (Toronto) or 3.0T (Calgary) imagers (Magnetom Avanto Fit or Prisma; Siemens Healthcare, 
Erlangen, Germany), using dedicated array coil systems for optimized signal reception and retrospective 
electrocardiographic gating. After acquisition of multi-planar localizers (2, 3, and 4 chamber views), a 
short-axis stack of cine steady-state free precession (SSFP) slices were obtained for ventricular function 
analysis in consecutive end-expiratory breath-holds. Typical parameters for SSFP sequence were: TR 
Table 7-1: Clinical and demographic data of cohort. 
Demographics at Baseline: (N=112) 
 Age (years) 50.6 ± 9.7 
 Body weight (kg) 66.7 ± 13.9 
 Body surface area, (m2) 1.7 ± 0.2 
 Body Mass Index, (kg/m2) 25.6 ± 5.4 
 Heart rate (bpm) 71.3 ± 11.8 
 Systolic blood pressure (mmHg) 125.5 ± 21.0 
 Diastolic blood pressure (mmHg) 76.7 ± 14.0 
Cardiovascular Risk Factors at Baseline, n (%):  
 Hypertension 17 (15.0%) 
 Diabetes 4 (3.5%) 
 Hypercholesterolemia 10 (8.8%) 
 Smoking History, Any 30 (26.5%) 
 Coronary artery disease 0 (0%) 
Chemotherapeutic Regimen:  
   Epirubicin dose (mg/m2), n=110 308.7 ± 40.3 
   Doxorubicin dose (mg/m2), n=2 104.3 and 253.1 
Cardiac Medications at Baseline:  
 Beta-blocker 5 (4.4%) 
 ACE inhibitor / ARB 13 (11.5%) 
    Statins 7 (6.2%) 




2.8ms, TE 1.2ms, slice thickness 8mm, in-plain resolution 1.6-1.8 x 1.6-1.8mm, temporal resolution of 
35-40ms.  
CMR analysis was performed by three experienced readers (MN, MA and RH, 2-5-year 
experience) on a remote workstation using commercially available software (CVi42; Circle CVI, Calgary, 
Alberta, Canada). All CMR studies were de-identified and randomized to ensure that the analyst was 
blinded to all clinical data and imaging time points. Following predefined standard operating procedures 
for endocardial contouring, LV volumes, function and mass, were quantified, by semi-automatic tracing 
of endo- and epicardial contours with assignment of trabeculations and papillary muscles to the LV blood 
pool. Partial basal slice inclusion was based on built-in long axis cross referencing tools and close 
monitoring of SAX cine movie concurrently. For all patients arterial elastance (EaI) was calculated as 
end-systolic pressure (0.9 x brachial systolic pressure)/LV stroke volume indexed to BSA (243,244). 
Systolic blood pressure was measured just prior to the CMR study.  
 
Echocardiography: In the sub-cohort of patients recruited in Toronto (n=83), transthoracic 
echocardiography (TTE) was performed on average within 2 hours of each CMR exam. TTE studies were 
performed by experienced sonographers using commercially available GE ultrasound systems (Vivid 7 or 
E9). In each patient, apical 4, 3, and 2 chamber LV views at high frame rate (>55 frames per second) 
were acquired for 3 cycles for quantification of LV GLS. Measurement of GLS was performed offline 
using de-identified images using EchoPAC (GE, version 112) by an experienced dedicated research 
sonographer (3-year experience with strain) blinded to all clinical data using de-identified and 
randomized study identifiers. Blood pressure and heart rate (HR) were recorded at the time of each 
echocardiography study. GLS was measured using automated myocardial contours generated by placing 3 
seed points on each of the 3 long axis views.(150) Contour adjustment was performed as necessary; 
however, after 3 attempts, poorly tracked segments were excluded. 
 




CTRCD Definitions: The primary definition of CTRCD was as a reduction in LVEF by >10% and to 
<55% without symptoms or a reduction by >5% and to <55% with heart failure symptoms (referred to 
henceforth as CTRCD-LVEF).(245) If baseline LVEF was <55%, only >10% reduction in LVEF was 
used to define CTRCD. A secondary definition of CTRCD was based on a reduction in GLS of >15% by 
echocardiography between pre-cancer treatment at either of the 2 follow-up imaging time points as per 
the recent American Society of Echocardiography (ASE) recommendations (referred to from hereon as 
CTRCD-GLS).(239)  
A pre-defined sensitivity analyses was performed including a mild reduction in LVEF, defined as 
any reduction in LVEF of >5% as compared to pre-cancer therapy as a CTRCD event. This threshold was 
chosen based on data that an LVEF change of 5% is >2 standard deviations (SD) above inter-study 
variability of CMR measurements of LVEF reported in the literature.(246) A second sensitivity analysis 
was performed to examine a smaller reduction in GLS (>11%) a CTRCD event based or previous 
literature.(157)  
 
Definition of significant change in volumes: Significant changes in CMR measured LV volumes were 
defined to be consistent with published literature as LVEDV reduction >10 mL and LVESV increase >5 
mL(241).  These thresholds are also higher than the inter-study variability for these measurements 
reported in the literature.(246) 
 
Intra-observer variability:  
In 20 randomly chosen single time point CMR data sets, intra-observer reproducibility was assessed by 
repeated analysis (>3-month interval) with the same observer blinded to previous results.  
 
Statistical Analysis 
Data are summarized as mean (SD) or median (IQR) as appropriate. All data were first assessed for 
normality based on skewness, kurtosis, and the Kolmogorov-Smirnov test. No transformations were 




necessary. Comparison of means was performed using paired or unpaired student’s t-test as appropriate. 
Longitudinal data analysis was performed using linear mixed models with time point as the independent 
variable and subject as a random effect, which were then fit to examine the impact of time on the 
outcomes of interest (body weight, HR, systolic (SBP) and diastolic (DBP) blood pressures, EaI, LVEF, 
LVEDV, LVESV, LV mass, and GLS). The frequency of LVEDV declines or LVESV increases were 
calculated based on above criteria in those with CTRCD. Association between changes in LVEF and GLS 
was assessed using Repeated Measures General Linear Model with time as fixed factors, LVEF as a 
covariate, and patient identifier as a random variable. Univariable logistic regression models were used to 
examine associations between baseline CMR parameters and their changes (as continuous variables) and 
CTRCD.  Variables with p-values <0.1 were included in multivariate logistic regression models to test 
independence of association. Presence of collinearality was assessed by measuring variance inflation 
factors (VIFs), with values >4.0 deemed as demonstrating models with excess collinearality. Intra-
observer variability was calculated using co-efficient of variation (COV) and Bland-Altman analysis. A 
two-sided p-value <0.05 was considered significant. Statistical analysis was performed using SPSS 




Patient clinical characteristics are summarized in Table 7-1. Mean ± SD age was 50.6±9.7 years (range 
27–70 years). Amongst these patients, 110 received epirubicin (mean cumulative dose 308.7 ± 40.3 
mg/m2) and two patients received doxorubicin.  At least one cardiovascular risk factor (Table 7-1) was 
present in 45 patients (40.2%). Over the six month follow-up period there was no statistically significant 
change in SBP, DBP, and EaI (Figure 1). There was, however, a statistically significant increase in mean 
weight and HR (Figure 1) over the follow-up period (p<0.001). Mean baseline 71.3±11.8bpm, at 3 




months 77.7±10.6 bpm (p<0.001 vs baseline), and at 6 months 75.5±10.4 bpm (p<0.001 vs baseline). 
There was no change in the mean weight between baseline and 3 months (66.7 ± 13.9kg to 66.9± 14.0kg, 
p=0.99), but the weight increased significantly at 6 months (68.1 ± 14.3kg, P< 0.001).  
 
Changes in Left Ventricular Volume, Mass and Function 
CMR parameters at baseline and follow-up are summarized in Table 7-2. Mean LVEF at baseline was 
normal at 61.0 ± 4.9%, however, 12 patients had LVEF between 50-55% and one patient had a baseline 
LVEF of 47%.  These patients with a mild reduction in LVEF still received treatment since cardiac 
screening prior to cancer therapy was based on 2D echocardiography as per standard of care. Over the six 
month period there was an overall significant increase in LVEDV and LVESV and a significant reduction 
in LVEF (p<0.001 for all). Changes are summarized in Table 7-2 and Figure 7-2A. There was no change 
in LV mass over the follow-up period (Figure 1F). 
Changes in Global Longitudinal Strain 
Mean baseline GLS was 21.9 ± 1.9% in the subgroup of 83 patients who had echocardiography. There 
was a significant reduction in GLS over the follow-up period (p<0.001) (Table 7-2 and Figure 2B). The 
changes in GLS were significantly associated with changes in CMR measured LVEF (p<0.001) with a 
1.73% absolute change in GLS for every 10% change in LVEF.  
 
  











3 Months* P-value 
(0-3) 
6 Months&  P-value 
(0-6) 
Cardiac MRI Left Ventricular Parameters (n=112): 
 Ejection fraction, (%) 61.0 ± 4.9 59.3 ± 5.0 <0.001 56.3 ± 4.7 <0.001 
 End-diastolic volume, (ml) 125.7 ± 22.9 128.0 ± 24.9 0.06 137.2 ± 23.2 <0.001 
 End-diastolic volume indexed ml/m2 73.6 ± 10.8  75.1 ± 12.9 0.04 80.6 ± 12.5 <0.001 
 End-systolic volume, (ml) 49.4 ± 12.7 52.1 ± 13.0 <0.001 60.5 ± 13.7 <0.001 
 End-systolic volume indexed, (ml/m2) 28.9 ± 6.6 30.6 ± 7.1 <0.001 35.5 ± 7.7 <0.001 
 Stroke volume, (ml) 76.2 ± 13.0 75.4 ± 14.6  0.37 76.7 ± 12.2 0.59 
 Stroke volume indexed, (ml/m2) 44.6 ± 6.0 44.2 ± 7.4 0.40 45.1 ± 6.6 0.40 
 End-diastolic mass, (gm) 66.1 ± 15.2 65.8 ± 13.9 0.59 67.1 ± 13.8 0.13 
 End-diastolic mass indexed, (gm/m2) 38.5 ± 6.6 38.4 ± 6.1 0.73 39.3 ± 6.5 0.06 
Echocardiography (n=83): 
   Global Longitudinal Strain, (%) 21.9 ± 1.9 21.4 ± 2.2 0.02 20.2 ± 1.8 p<0.001 
Data presented as frequency mean ± standard deviation,  
*Within 1 month of completion of anthracycline, 
&Within 2-3 months of initiation of trastuzumab 

















Figure 7-2: Changes in LV volumes, LVEF, and GLS. (A) Changes in LV end-diastolic and systolic 
volumes and change in LVEF in 112 patients. (B) Change in LV peak systolic global longitudinal 
strain (GLS) by echocardiography and LVEF by cardiac MRI in 83 patients 
Figure 7-1: Changes in hemodynamic variables and LV mass over time. P-values calculated using 
linear mixed models. A) weight, B) heart rate, C) arterial elastance, D) systolic blood pressure, E) 









Cancer Therapy Related Cardiac Dysfunction  
Using our primary definition 15(13.4 %) patients developed CTRCD-LVEF (Table 7-3). This was 
identified in three patients at three months and 12 patients at six months. The LV volumetric changes that 
accounted for the development of CTCD are summarized in Figure 3A while its timing is summarized in 
Table 7-3. The predominant mechanism of CTRCD was an isolated increase in LVESV (80%). None 
developed CTRCD due to isolated reduction in LVEDV. Using the sensitivity definition for CTRCD, a 
>5% reduction in LVEF occurred in 53 (47.3%) patients (Table 7-3). Amongst these patients 42 (79.2%) 
had an isolated increase in LVESV, seven (13.2%) had isolated decrease in LVEDV, two had both, and 
two had neither (Table 7-3, Figure 3B). As an exploratory analysis we also used the recently published 
ASE CTRCD criteria(239)(LVEF reduction >10% to <53%) and identified seven (6.3%) patients who 
developed CTRCD; all seven patients had a significant increase in LVESV.  
In the GLS subgroup, 17 patients (20.5%) had a >15% relative reduction in GLS (Table 3); five (6.1%) 
occurred at between baseline and three months and an additional 12(14.6%) by six months. Amongst 
these patients 12(70.6%) had an isolated increase in LVESV while one (5.9%) had an isolated reduction 
in LVEDV (Figure 7-3C). This one patient with significant reduction in LVEDV also had an increase in 
LVESV of 4.9ml (just below significant threshold). When a lower threshold for strain change was 
considered (i.e. >11% reduction) 29 (34.9%) patients met criteria (Table 7-3). Amongst these patients, 17 
(59%) had an isolated increase in LVESV, 4(13.8%) had an isolated reduction in LVEDV, while the rest 
had non-significant changes.  
To examine the association between changes in LV volumes and GLS, we calculated GLS values 
at baseline and at the time of any >5% reduction in LVEF (our sensitivity outcome) (Figure 4). A 
statistically significant reduction in GLS occurred in patients who had an isolated increase in LVESV as 
the mechanism for reduction in LVEF, but not in those with an isolated change in LVEDV.  
  





Table 7-3: CMR Volumetric determinants of left ventricular ejection fraction decline categorized by 
different CTRCD definitions and the time of occurrence. 
EDV, end-diastolic volume; ESV, end-systolic volume; GLS, global longitudinal strain 
*CTRCD is defined by >5% Symptomatic drop in LVEF to <55%, or asymptomatic >10% drop in LVEF 
to <55% 
$GLS was measured in a subgroup of 83 patients  
#LVESV increased by 4.9ml; 
@LVEDV<-10ml, LVESV>5ml;  
 
  
CTRCD*@ 3 Month,  
n 
6 Month,  
n 
Entire Follow Up, 
n(%) 
   Isolated ESV increase 2 10 12 (10.7%) 
   Isolated EDV decrease 0 0 0 
   Combined ESV increase and EDV decrease 0 2 2 (1.8%) 
   No significant Change in ESV or EDV 1 0 1 (0.9%) 
      Total 3 12 15 (13.4%) 
GLS$@ decline >15%    
   Isolated ESV increase 3 9 12 (14.5%) 
   Isolated EDV decrease 0 1# 1 (1.2%) 
   Combined ESV increase and EDV decrease 0 1 1 (1.2%) 
   No significant Change in ESV or EDV 2 1 3 (3.6%) 
      Total 5 12 17 (20.5%) 
LVEF decline >5%@    
   Isolated ESV increase 18 24 42 (37.5%) 
   Isolated EDV decrease 3 4 7 (6.3%) 
   Combined ESV increase and EDV decrease 0 2 2 (1.8%) 
   No significant Change in ESV or EDV 2 0 2 (1.8%) 
      Total 23 30 53 (47.3%) 
GLS$@ decline >11%    
   Isolated ESV increase 5 12 17 (20.5%) 
   Isolated EDV decrease 1 3 4 (4.8%) 
   Combined ESV increase and EDV decrease 0 0 0 
   No significant Change in ESV or EDV 6 2 8 (9.6%) 
      Total 12 17 29 (34.9%) 




Association between changes in volumes and CTRCD 
Change in LVESV was associated with CTRCD-LVEF (OR 1.15, 95%CI 1.05 –1.28, p<0.001), with 
14.7% increase in odds of CTRCD-LVEF for each 1 mL increase in ESV (Table 7-4). In contrast, change 
in EDV was not significantly associated with CTRCD-LVEF (OR 1.01, 95%CI 0.96–1.05, p=0.74). 
Sensitivity analysis demonstrated that both change in ESV (OR 1.31, 95%CI 1.20 – 1.47, p<0.001) and 
change in EaI (OR 4.7, 95%CI 2.05 – 12.4, p<0.001) were associated with outcome of ≥5% LVEF 
decrease, however change in EDV was not (OR 1.00, 95%CI 0.98 – 1.03, p=0.87). Baseline ESV (OR 
0.95, 95%CI 0.91 – 0.98, p=0.002) was also associated with >5% LVEF decrease, but baseline EDV was 
not (0.99, 95%CI 0.98 – 1.01, p=0.51). On multivariable logistic modelling, both change in ESV (OR 
1.37, 95%CI 1.22 – 1.61, p<0.001) and change in EaI (OR 6.3, 95%CI 2.73 -85.4, p=0.004) demonstrated 
independent and significant associations, but baseline ESV (OR 1.02, 95%CI 0.94 – 1.08, p=0.20) and 
baseline LVEF (OR 1.03, 95%CI 0.92 – 1.17, p=0.65) did not.   
CTRCD-GLS outcome was significantly associated with change in EDV (OR 0.92, 95CI 0.87 – 0.94, 
p=0.003), however a stronger association was seen with change in ESV (OR 0.81, 95%CI 0.72 – 0.90, 
p<0.0001), with lower odds more predictive of pathology due to GLS measurements being in negative 
units. Multivariate logistic models demonstrated significant and independent association with change in 
ESV (OR 0.83, 95%CI 0.72 – 0.93, p=0.004), but no independent significant association was seen with 
change in EDV (OR 0.98, 95%CI 0.92 – 1.04, p = 0.61). Sensitivity analysis using a liberal GLS 
threshold of 11% decrement demonstrated similar findings as for CTRCD-GLS on both univariable and 
multivariable logistic modelling. No collinearality was detected in any multivariable logistic models (VIF 
range 1.33 – 1.41). 







Table 7-4:  Univariable logistic regression analysis of association between ventricular volume and function measurements and development of CTRCD 
   CTRCD-LVEF  CTRCD-GLS  LVEF decrement >5%  GLS decrement >11% 
  OR 95%CI p  OR 95%CI    p  OR 95%CI       p  OR 95% CI        p 
                 
                 
Baseline cardiac measurements             
EDV (mL)   1.00 0.98 – 1.02 0.94  1.02 0.96 – 1.05 0.11  0.99 0.98 – 1.01 0.51 1.00 0.98 – 1.02 0.71 
ESV (mL)   0.99 0.94 – 1.03 0.53  1.03 0.98 – 1.08 0.28  0.95 0.91 – 0.98 0.002 1.00 0.97 – 1.04 0.80 
LVEF (%)   1.07 0.09 – 1.20 0.24  1.01 0.09 – 1.16 0.87  1.41 1.24 – 1.64 <0.001 1.00 0.90 – 1.11 0.99 
LV mass (gm)   1.01 0.97 – 1.04 0.68  1.04 1.00 – 1.09 0.07  1.02 0.99 – 1.04 0.25 1.00 0.97 – 1.04 0.92 
                 
Changes in LV parameters              
∆EDV (mL)   1.01 0.96 – 1.05 0.74  0.92 0.87 – 0.97 0.003  1.00 0.98 – 1.03 0.87 0.91 0.85 – 0.95 <0.0
01 
∆ESV (mL)   1.15 1.05 – 1.28 0.006  0.81 0.72 – 0.90 <0.00
01 
 1.31 1.20 – 1.47 <0.0001 0.80 0.71 – 0.88 <0.0
01 
∆LVEF (%)   - - -  1.21 1.06 – 1.41 0.008  - - - 1.22 1.08 – 1.39 0.002 
∆EAI 
(mmHg/mL) 
  1.53 0.61 – 4.93 0.45  0.95 0.35 – 2.45 0.91  4.7 2.05 – 12.4 <.0001 0.89 0.39 – 1.98 0.78 
∆GLS (%),  0.97 0.89 – 1.05 0.42  - - -  1.02 0.97 – 1.07 0.51 - - - 
                
⁋All GLS measurements performed at single site 
CTRCD- Cancer Therapeutic Related Cardiac dysfunction; CTRCD-GLS - Cancer Therapeutic Related Cardiac dysfunction, GLS definition;  EAI – Arterial Elastance;  EDV – End-
Diastolic volume; ESV- End-Systolic Volume; GLS – Global Longitudinal Strain; LV – Left Ventricular; LVEF – Left Ventricular Ejection fraction. 
 













 Figure 7-3: Causes for reduction in LVEF and GLS. (A) CTRCD was defined as per CREC 
recommendations. (B) Any >5% reduction in LVEF at 3 or 6 months compared to baseline. (C) CTRCD 































Figure 7-4: Comparison of mean global longitudinal strain between baseline and at time of a reduction in 













Intra-observer variability measured as mean difference ± 2SD and COV was as follows:  0.2±3.5ml and 
1.5% (95% CI 0.9-2.0%) for LVEDV; 1.7±2.4ml and 3.4% (95% CI 2.4-4.4%) for LVESV; -1.3±1.6% 




In this cohort of consecutively-recruited HER2-positive breast cancer patients receiving uniform cancer 
treatment, CTRCD-LVEF at six months was seen in 13.4% of the patients. The reduction in LVEF was 
associated with a significant increase in LVESV in 93% of the patients. None of these patients had an 
isolated reduction in LVEDV, as would be seen with reduced preload. These findings are strongly 
suggestive of a reduction in myocardial contractility from cancer therapy as the primary mechanism of 
reduction in LVEF rather than isolated reduction in preload. Results were similar with CTRCD defined 
by echocardiography measured GLS reduction >15%. There was a significant association between 
CTRCD-LVEF and changes in LVESV over time but not LVEDV. In contrast, when a lower threshold 
was used to define significant change in LVEF (>5%) or GLS (>11%), a minority of patients attained 
these changes solely due to a reduction in preload (13.2% and 13.8% respectively). However these 
changes would not usually trigger interventions for CTRCD.(239)  When a definition of CTRCD derived 
from GLS measurements was used, change in ESV demonstrated a significant and independent 
association, but change in EDV was not significantly associated if effect of change in ESV was included 
in model. 
 
Relationship between ventricular volumes and CTRCD 




Using a well-established criterion for cardiotoxicity(245), 14 out of 15 (93%) patients in our study 
developed CTRCD association with an increase in LVESV. None had an isolated reduction in LVEDV. 
Even using the ASE criteria(239) all patients who developed CTRCD had an increase in LVESV. Our 
findings were further confirmed by the logistic regression models where a change in LVESV as a 
continuous parameter showed predictive value for development of CTRCD but this association was not 
seen with LVEDV. Our work therefore suggests that currently used definitions for CTRCD based on 
LVEF appear to identify patients who have associated reduction in myocardial contractility. However, 
some of these patients may also have co-existing reduction in preload as demonstrated by the fact that two 
(13%) of our patients who met criteria for CTRCD also had a >10ml reduction in LVEDV along with a > 
5ml increase in LVESV. A sensitivity analysis using LVEF decrements >5% to define CTRCD identified 
a larger proportion of patients (13.2%) with a reduction in LVEF due to reduced preload. Association of 
EaI with smaller decreases in LVEF is likely mediated by increased peripheral resistance causing earlier 
equalization of ventricular-arterial pressures with consequent reduction in ejection time. 
 
Ventricular Volumes and Global Longitudinal Strain  
When CTRCD was defined by a GLS reduction of >15%, our findings were similar. The reduction in 
GLS was primarily associated with an isolated increase in ESV. Only one patient had an isolated 
reduction in LVEDV. However this patient had an increase in LVESV of 4.9ml, thereby almost but not 
quite meeting pre-defined threshold of 5ml for significant ESV increase. Physiologically, an isolated 
reduction in pre-load results in reduced stroke volume which is partially offset by an increase in HR (in 
this patient HR increased from 62 to 71 bpm), a decrease in afterload and, as a consequence a reduction in 
end-systolic volume.(247) Therefore the absence of a reduction in LVESV in this patient suggests 
possible concomitant reduction in myocardial contractility. Furthermore, when we examined GLS 
changes in patients with any reduction in LVEF >5% (sensitivity analysis), that fact that only patients 
with increase in LVESV had a statistically significant reduction in GLS also supports its association with 




a reduction in myocardial contractility. However, our work also suggests that if lower threshold changes 
in GLS (>11%) is used to define CTRCD approximately 1 in 8 patients may meet this threshold due to a 
reduction in preload. This finding of association with pre-load and small changes in GLS is consistent 
with a recent study of healthy patients with dehydration.(247)  
 
Comparison to prior work 
Our findings are different from two recent studies where CTRCD was driven by an isolated reduction in 
LVEDV in 19-26% of patients(241,242).  In addition, a reduction in CMR-measured circumferential 
strain and GLS were associated with a reduction in LVEDV.(241) In light of this, it has been proposed 
that the diagnosis of CTRCD should be considered in the context of changes in LV volumes. These data 
raised the possibility that a subset of patients diagnosed with CTRCD have normal myocardial 
contractility and hence should not be subject to the usual management of cancer therapy adjustment 
and/or addition of cardiac medications. These findings have important clinical consequences as one would 
need a robust method to measure concomitant changes in LVEF and LVEDV during cancer therapy. The 
most commonly clinically available 2D and 3D echocardiography techniques have a test-re-test variability 
for LVEDV measurement between 21-38ml (150) making it challenging to identify a 10ml reduction in 
LVEDV. The use of CMR in routine clinical practice would be challenging due to availability and cost.  
Our findings differ from previous work(241,242) and may be due to the following reasons. There 
were differences in the types of cancers included (100% breast cancer in our study versus <50% in prior 
studies) which are associated with different treatment regimens. The inclusion of hematological 
malignancies in the prior studies would have resulted in a subcohort of patients receiving higher 
anthracycline than in our study. Also the use of trastuzumab and taxanes was universal in our study and 
the latter has been associated with fluid retention.(248) Our study included 3 and 6 month follow-up 
while the prior study only included 3 month follow-up. Although the presence of emesis, nausea, diarrhea 




and poor oral intake may have been present at the 3-month follow-up, it is less likely to be present during 
trastuzumab therapy; majority of our patients developed CTRCD at 6-month follow-up. The definition of 
CTRCD in the prior studies (>10% decrement in LVEF or any absolute LVEF value <50% between 
baseline to 3-month) differs from our definition.(245) The definition of LVEF reduction to less to <50% 
may include patients with a small change in LVEF (e.g. from 54% to 49%). Our data shows that such 
small changes in LVEF can in fact occur due to isolated reduction in pre-load as shown in the prior 
studies. Finally Jordan et al(241) primarily demonstrated an association between CMR-measured 
circumferential strain using tagging and decreased preload whilst we used echocardiography measured 
GLS, as this is the most readily available and validated modality to assess strain in patients receiving 
cancer therapy(137).  
Strengths and Limitations 
Strengths of our study include the use of CMR to measure cardiac volumes, the focus on a uniform 
population of patients with uniform treatment, consecutive recruitment, prospective follow-up, and the 
use of contemporary definitions of CTRCD.  Limitations include a relatively small number of outcomes. 
However, our sample size and event rate is consistent with contemporary studies in cardio-
oncology.(241,242) Furthermore, each patient had repeated cardiac imaging at three separate time points 
with the acquisition of echocardiography imaging and CMR within 2 hours in large subset of our patients. 
We also utilized cardiac imaging findings as surrogate markers for potential future heart failure events, 
however, this is commonly done in the cardio-oncology literature. Since our cohort was limited to a 
specific group of HER2+ breast cancer patients, the results may not be extrapolated to non-breast cancer 
populations treated with other regimens. We made the assumption that a reduction in LVEDV represents 
reduced preload, however other causes (e.g. diastolic dysfunction secondary to cardiotoxicity) have not 
been excluded. Unfortunately, a reference standard for assessment of preload does not exist. Similarly, we 
assumed that an increase in LVESV is a reflection of reduction in contractility. However, there are no 
non-invasive ways to measure contractility in a reliable manner. A small subset of our patients had 




LVEF<55% at baseline, which may have impacted CTRCD incidence. However, only one of these 
patients developed CTRCD-LVEF. Inclusion of these patients was based on the fact that baseline 
screening was performed by echocardiography as per clinical practice.(249)   
 
Conclusion 
In a cohort of women with HER2+ breast cancer receiving anthracyclines, taxanes, and trastuzumab, our 
results support the fact that with current CTRCD definitions(239,245), changes in LVEF or GLS are 
associated with an increase in LVESV (reflective of reduction in myocardial contractility) and not due to 
a reduction in pre-load. However, if lower threshold changes in LVEF or GLS are used to define CTRCD, 
approximately 1 in 8 patients will meet this threshold due to isolated reduction in preload. Therefore 
using current definitions of CTRCD does allow identification of patients who would benefit from 




This chapter confirms that when LV volume measurements are made using techniques with greatest 
degree of accuracy, that CTRCD remains relatively common with an incidence of approximately 13%, a 
result which has been also seen in many other observational studies. This finding accurately represents 
cases of reduced myocardial contractility in the context of myocardial dysfunction, and therefore supports 
continuing use of current CTRCD criteria, which is defined by significant LVEF decrement either with or 
without accompanying symptoms as measured by contemporary cardiac imaging. 
This chapter however only limits itself to identification of myocardial contractility abnormalities 
secondary to chemotherapy and is based upon a CTRCD definition that was laid down 16 years ago. 
Since that time our understanding of cardiac function as evolved, and healthy function is now understood 




as successful integration in terms of both timing and function of simultaneous processes including 
cellular, conduction, valvular, mechanical, perfusion, systolic and diastolic dimensions that result in 
adequate and regular stroke volume ejection without requiring excessive venous pressures to achieve. The 
next chapter of this thesis will examine whether cardiac functional abnormalities other than LVEF 
changes are common in CTRCD, and the role of CMR in distinguishing between the predominant 
abnormality affecting cardiac function.     

















Phenotypes of Cardiac Injury After Cancer 
Treatment 
 
Part of the research presented in this chapter has been submitted as: 
 Nolan MT, Altaha MA, Amir E, Koch A, Yip P, Michalowska M, Wintersperger B, 
Thavendiranathan P. Cardiotoxicity Phenotypes in Women with Early Stage Breast Cancer 
Receiving Cancer Therapy. In process of submission 
  





The previous seven thesis chapters have uncritically adopted the LVEF-based definition of CTRCD, by 
which patients are separated in a binary fashion depending on their volumetric change from baseline. The 
rationale for this approach is based on a solid evidence-base describing a direct association between 
LVEF and mortality, but also risks missing significant and potentially treatable cardiac sources of 
morbidity and mortality.  
Readers might consider the trajectory of heart failure diagnostic criteria as an educational example. It was 
in 1955(250) that heart failure was recognised as a pathological state of reduced myocardial contractility, 
and it was over 50 years later until the syndrome of heart failure with preserved fraction (HFpEF) was 
comprehensively described. Currently the pharmacological and cardiac-device treatment armamentarium 
for heart failure with reduced ejection fraction with much larger and of greater demonstrated efficacy than 
that for HFpEF. It could be argued that the delay of several decades before rigorous diagnostic criteria for 
HFpEF were developed may have delayed research and have indirectly led to potentially avoidable 
morbidity and mortality. It is also possible that the current focus on reduction in LVEF in CTRCD may 
cause under-appreciation of other dimensions of cardiac dysfunction. 
The next thesis chapter will prospectively investigate the incidence of systolic diastolic dysfunction in a 
cancer cohort. The aim of this chapter will be to determine the prevalence of both overt and subclinical 
manifestations of cardiac dysfunction with comparison of frequency of CTRCD as defined by traditional 
LVEF criteria. The identification of various cardiotoxic phenotypes may allow cardiac imaging findings 
of cancer patients to be individualized rather than fitted into a binary disease-or-healthy approach and 
hence permit a more individualized approach to treatment and risk factor modification.       
 






Background: There is currently limited data on the effects of early breast cancer (EBC) treatment on 
different dimensions of cardiac function.  
Objectives:  To use CMR to identify different phenotypes of cardiac dysfunction in the EBC population. 
Methods: 66 consecutive women (50.3 ± 9.4 years) with early stage HER2+ breast cancer, receiving 
sequential anthracycline and trastuzumab, were recruited prospectively. All had CMR, including both 
systolic and diastolic assessment at 5 time-points over 14 months.  Diastolic dysfunction (DD) phenotype 
was diagnosed using society guidelines, with abnormal values defined as >2SD from reference ranges 
calculated from 29 healthy volunteers. SD was diagnosed using CREC criteria. No-diastolic-No-systolic 
dysfunction (NDNS) phenotype comprised the remainder. 
 Results: 13 (19.7%) patients developed SD, with median onset at 5 months with 84.6% demonstrating 
recovery by 14 months. SD patients were older with no other significant baseline differences from NDNS 
group, had -9.7% decline in LVEF and subclinical diastolic dysfunction (PDSR reduction p<0.001). DD 
phenotype was diagnosed in 13 patients (19.7%), 4 of which also had SD, with median onset 8 months 
with 38.5% demonstrating recovery by 14 months. DD patients were older, received higher chest-directed 
radiotherapy doses and more likely to have hypertension and diabetes. There was no significant LVEF 
change, but clinical systolic dysfunction was present (GLS reduction p=0.001). NDNS patients had 
significant small reductions in LVEF(p<0.0001) and GLS(p<0.0001), with no significant change in 
diastolic parameters  
Conclusions: Cardiac dysfunction is common after EBC therapy and can be described by three 
phenotypes which are characterized by different baseline characteristics, non-invasive imaging findings 
and different degrees of recovery of cardiac function. Long-term studies are indicated to determine the 
prognostic significance of each phenotype. 





Women treated for early stage breast cancer (EBC) are at a 2 to 3 fold higher risk of clinical heart failure 
(HF) compared to age matched controls(251,252). Despite HF with preserved ejection fraction (HFpEF) 
being common in the community, much of the focus in cancer survivors has however been on heart 
failure with reduced ejection fraction (HFrEF). Recent data in older women with breast cancer receiving 
radiation therapy demonstrated that HFpEF was more common than HFrEF(253). Furthermore dyspnea is 
a common complaint in breast cancer survivors(254) with prevalence at three year following being two-
fold greater than in the general population with rates exceeding that of systolic dysfunction(255).  
Although changes in diastolic parameters have been demonstrated in anthracycline-treated patients, these 
were generally short-term studies with small patient numbers(256,257). Also given the challenges in 
measurement of LVEF with echocardiography, determining whether diastolic functional abnormalities 
occur independently of systolic function changes has not been reliably assessed. Therefore, there is a 
paucity of data describing the different cardiotoxicity phenotypes in women with EBC receiving cancer 
therapy and their temporal relationships during treatment. This knowledge is essential for providing 
recommendations on strategies to evaluate patients during cancer therapy and to help better appreciate the 
relationship between cardiac dysfunction and symptoms.  
We hypothesized that women with EBC may develop diastolic dysfunction (DD) together or 
independently from systolic dysfunction, and that DD may contribute to the symptomatic burden in the 
short-to-intermediate term. To address this hypothesis, we used cardiac magnetic resonance (CMR) to 
identify the different phenotypes of cardiotoxicity (e.g. systolic versus diastolic) in a cohort of women 
with Human Epidermal Growth Factor Receptor Positive (HER+) EBC, and examined the association 








We prospectively recruited women with HER 2+ EBC (Stages I-III) from the Princess Margaret Cancer 
Center and St. Michael’s Hospital in Toronto, Canada between January 2014 and April 2017. We 
included women aged ≥18 years of age scheduled to undergo treatment with an anthracycline (Epirubicin 
or Doxorubicin) followed by trastuzumab and taxanes (Paclitaxel or Docetaxel). Exclusion criteria were 
(1) previous anthracycline therapy; (2) current or prior cardiovascular disease; and (3) general 
contraindications to MRI. Patient characteristics, cardiac risk factors, and cancer and treatment history 
were collected. In addition we recruited 29 healthy volunteers with the same age range as the EBC 
population to define 95% confidence interval thresholds for normal values, to assist in identifying 
diastolic dysfunction in our EBC cohort. Healthy volunteers had no cardiovascular disease, symptoms, or 
risk factors, were not on any medications, and had no systemic diseases. The study was approved by the 
local Research and Ethics Board, and all patients provided written informed consent. 
 
Cardiac Magnetic Resonance Imaging 
Cardiac MRI (CMR) studies were performed at 5 time-points (Figure 1); prior to initiation of cancer 
therapy, after completion of anthracycline but before initiation of trastuzumab / taxane (~2 months), at 3 
and 6 months after trastuzumab initiation, and within 1 month of trastuzumab completion (~12 months 
after trastuzumab initiation).  CMR scans were performed on 1.5T imager (Magnetom Avanto Fit; 
Siemens Healthcare, Erlangen, Germany), using dedicated array coil systems for optimized signal 
reception and retrospective electrocardiographic gating. After acquisition of multi-planar localizers (2,3 
and 4 chamber views), a short-axis stack of cine steady free-state free precession (SSFP) slices were 
obtained for ventricular function analysis in consecutive end-expiratory breath-holds. Typical parameters 
for SSFP sequence were: TR 2.8 msec, TE 1.2 msec, slice thickness 8 mm, in-plane resolution 1.6-1.8 x 
1.6-1.8 mm, temporal resolution of 35-40 msec.  
  

















Figure 8-1: Timeline of course of treatment for EBC and associated CMR examinations. 
  




Trans-mitral and myocardial velocity imaging were performed using retrospectively-gated 
electrocardiographically triggered phase-contrast MR technique, with velocity sensitivity of 150 cm/sec 
for trans-mitral velocities and 30 cm/sec for myocardial velocities(258). Both imaging techniques used a 
short-axis view at the level of mitral leaflet tips in diastole with slice thickness 10 mm, in-plane resolution 
1.5 x 0.8 mm and temporal resolution 35-40 msec. The following parameters were used for trans-mitral 
phase-contrast imaging; TR 37.0 msec, TE 3.7 msec, slice thickness 10 mm, in-plane resolution 1.5 x 0.8 
mm, temporal resolution 35-40 msec. Parameters for myocardial velocity imaging were: TR 39.5 msec, 
TE 4.2 msec, slice thickness 10 mm, in-plane resolution 1.5 x 0.8 mm, temporal resolution 35-40 msec.  
Myocardial T1 mapping was performed in 3 short-axis slices (basal, mid, and apex) using a modified-
look-locker inversion recovery (MOLLI) sequence before and 12-15 minutes after IV contrast 
administration (0.2mmol/kg, Gadovist; Bayer Healthcare, Berlin, Germany). The following recommended 




CMR analysis was performed by two experienced readers (M.N. and M.A, 2-5 years’ experience) using 
commercially available software (CVi42, Circle CVI, Calgary, Alberta, Canada). All CMR studies were 
de-identified and randomized to ensure that the analyst was blinded to all clinical data, patient 
identification, and imaging time points. Following predefined standard operating procedures, LV function 
was quantified by semi-automatic tracing of endo- and epicardial contours with assignment of 
trabeculations and papillary muscles to the LV blood pool. In addition, using 4 and 2 chamber SSFP cine 
images, left atrial volume was calculated using biplane area-length method and indexed to body surface 
area. 
Transmitral and myocardial velocities were measured using phase contrast images.  For mitral inflow 
velocities a region of interest (ROI) was generated by tracing around the mitral leaflet borders in diastole 
on the magnitude images and automatically transferred to the phase images. 10% color scale threshold 




was used on all magnitude images to assist in identifying anatomical region of flow and exclude pixels 
that did not represent transmitral or myocardial tissue velocities of interest. The ROI was propagated and 
examined in each frame with adjustments made to ensure that the appropriate location of the contours.   
 
 For myocardial velocity measurements, a circular ROI 20-40mm2 was placed within the inferior septal 
and anterior lateral segments on the magnitude image and automatically transferred to the phase image 
(Figure 8-2). Cine SSFP and color-overlay images were assessed to ensure that the region-of-interest did 
not capture blood pool or epicardial adipose tissue. Minor adjustments to the region-of-interest were made 
to ensure that the velocities were being measured from the myocardium and that the highest velocities 
were recorded(258). Velocity-versus-time curves were assessed to ensure robustness of the measurements 
and to exclude erroneous measurements. Background velocity correction was performed with contour 
applied to latissimus dorsi muscle. Measurements recorded include: early (E) and late (A) mitral inflow 
flow velocities, and medial and lateral annular (myocardial) velocities (e’).  
Myocardial systolic and diastolic strain analysis was performed offline using tissue tracking module of 
cvi42 (Circle Cardiovascular Imaging, Calgary, Canada). On SSFP cine images end-diastolic endocardial 
and epicardial contours were manually traced on 4-chamber, 3-chamber and 2-chamber views. The 
contours were then automatically propagated through all phases with subsequent generation of a 3D 
deformable myocardial strain model. Strain values were automatically calculated by software using 






















Figure 8-2: Example of measurement of diastolic function by CMR. (A) Phase-contrast through-plane cine 
images, including both magnitude and phase series, were used to measure mitral flow and tissue velocities. (B) 
An ROI was traced around trans-mitral flow in all images, with background correction applied. (C) For tissue 
velocity measurements, a smaller ROI was placed within myocardium in all images. (D) Flow overlay was 
applied to ensure that ROI corresponded to region of greatest myocardial velocity. (E) Velocities were 
displayed over time, with greatest velocity selected. (F) Feature-tracking PDSR measurements were obtained 
by creating end-diastolic contours in 4-chamber, 3-chamber and 2-chamber planes, and semi-automated 
measurements were extrapolated from all images.   




After inline, non-rigid motion correction of individual pre and post contrast MOLLI images, a T1 map 
was generated using standard three-parameter fitting. T1 measurements were performed using CVI 42 
using regions of interest carefully drawn along the endocardial and epicardial borders to avoid blood pool 
and epicardial fat. A second region of interest was drawn in the LV blood pool carefully avoiding the 
myocardium and papillary muscles. Myocardial ECV was calculated using pre- and post-contrast T1 
values and hematocrit values measured immediately prior to the CMR study as proposed by societal 
recommendations(260).  
For all patients, as a marker of afterload, arterial elastance (EaI) was calculated as end-systolic pressure 
(0.9xbrachial systolic pressure)/LV stroke volume indexed to BSA. Systolic blood pressure (SBP) was 
measured just prior to each the CMR study.  
 
Diastolic and Systolic Cardiac Dysfunction Definitions 
Normal reference ranges for diastolic parameters were calculated based on 29 healthy volunteers recruited 
from the community with age range identical to the patients. Values greater than 2 standard deviations 
beyond mean values of volunteers (Table 7-2) were considered abnormal. Presence or absence of diastolic 
dysfunction was determined by presence of ≥ 2 of 3 diagnostic criteria; 1) abnormal annular velocity 
(defined as medial e’ or lateral e’ < 2 standard deviations (SD) below normal), 2) abnormal E/e’ (defined 
as E/e’ > 2 SD above normal), or 3) abnormal left atrial volume index (LAVI) (defined as > 2 SD above 
normal). If diastolic dysfunction was diagnosed, then the diastolic grade was determined as following; 1) 
grade 1 diastolic dysfunction if E/A < 2 SD below normal and E velocity < 2 SD below normal, 2) grade 
3 if E/A ratio was >2.0 SD above normal, and 3) remaining cases was diagnosed as grade 1 if 1 of 
abnormal E/e’, abnormal annular e’ velocity or abnormal LAVI was present, and grade 2 if ≥2 were 
present. Systolic dysfunction secondary to chemotherapy (SD) was defined using the CREC criteria as a 
reduction in LVEF by >10% and to <55% without HF symptoms or a reduction by >5% and to <55% 
with HF symptoms determined by a cardiologist within the Cardio-oncology clinic(245).  






Continuous data are summarized as mean ± SD, and categorical data as percentages. All data were first 
assessed for normality by Kolmogorov-Smirnov test and no transformations were necessary. 
Comparisons of means was performed using paired or unpaired t-student’s test as appropriate, and one-
way ANOVA was used to compare means of >2 groups. If assumption of normality was not held, then 
Wilcoxon’s paired or unpaired test was used for 2 groups and Kruskal-Wallis if >2 groups were present. 
Longitudinal data analysis was performed using generalized linear mixed models with individual patients 
used as random-effect and timepoint used as fixed-effect and singular covariance matrix with Cholesky 
parameterization. For mixed linear models, p value was calculated using F test with Satterthwaite 
approximation.  Statistical analysis was performed using R statistical software (Vienna, Austria) and the 
lme4 package(152). P values ≤ 0.05 were considered significant. 
 
   
Table 8-1: 95% confidence intervals for diastolic parameters calculated with 29 age-matched volunteers 
 LL UL 
E velocity (cm/sec) 41.1 90.2 
A velocity (cm/sec) 13.8 70.1 
Inferoseptal e’ (cm/sec) 4.2 15.2 
Anterolateral e’ (cm/sec) 5.02 14.7 
Mean e’  5.0 14.7 
E/A ratio 0.31 3.2 
E/e’ ratio 3.5 10.3 
LAVI (mL/m2) 45.6 57.5 






Twenty-nine healthy volunteers were recruited to define thresholds for normal abnormal diastolic 
function (Table 8-1). A total of 66 women with HER2+ EBC were recruited with mean age 50.3±9.4 
years. Patients were treated with doxorubicin-equivalent doses of 202.6±8.2 mg/m2 (Table 8-2). Twenty-
four patients (36.4%) had ≥1 cardiovascular risk factor.  Sixty women (90.9%) received chest-directed 
radiotherapy. Heart rate significantly increased to peak values immediately post anthracyclines and 
returned to baseline by study end(p<0.001). There were no significant changes in systolic or diastolic 
blood pressure over the study period. There was an increase in BNP immediately post anthracyclines 
which then returned to baseline by end of study (p=0.002), there was also a nonsignificant trend towards 
increase in NYHA class during the study (p=0.08). 
Temporal Changes in Systolic and Diastolic Parameters 
Over the treatment period (mean 14.6±1.1 months), systolic function for the entire cohort was 
characterised by significant declines in both LVEF and GLS (Supplementary Figure 2).  LVEF 
significantly declined from baseline to a nadir (fall of -3.9%) at 4 months (i.e. 2 months into trastuzumab 
therapy), then displayed incomplete recovery after trastuzumab completion. GLS gradually declined 
throughout treatment with the largest fall at 4 months, with no recovery after trastuzumab completion 
(p<0.0001). There was no significant change in EaI over time suggesting reduction in systolic function 
was not secondary to changes in afterload. 
  



















































































Figure 8-3: Timeline of development of SD and DD per timepoint. A) Proportion of patients 
with either SD (brown) or DD (blue) that have a study meets criteria for dysfunction at that 
timepoint. For example, at 5 months, 69.2% of cohort of 13 SD patients have a study that meets 
SD criteria, and 30.8% of DD patients have a CMR study that meets DD criteria.  By 8 months, 
the proportion of SD patients with CMR study meeting SD criteria has reduced to 23.1%, 
demonstrating that some patients have normalized their systolic function  
Note that the total for SD and DD sums to greater than 100% because patients may have more 
than 1 study demonstrating cardiac dysfunction. DD studies are broken into diastolic Grade 1 
(light blue) or Grade 2 (dark blue), with no cases of Diastolic grade 3 dysfunction occurring 
during study 




Abbreviations; BB  - Beta-blocker; ACEI – Angiotensin Converting Enzyme Inhibitor; ARB – Angiotensin Receptor Blocker; BMI – Body Mass Index; DD – Diastolic Dysfunction; DBP – Diastolic 
Blood Pressure; HR – Heart Rate; NDNS – No-Diastolic-No-Systolic Dysfunction; SBP - Systolic Blood Pressure; SYSD – Systolic Dysfunction.    
 
Table 8-2: Baseline Demographics of Early Breast Cancer Cohort  
 Total (N = 66) DD (N=13) SYSD 
(N = 13) 
NDNS  
(N = 43) 
p-value for difference 
DD vs. NDNS SYSD vs. NDNS 
       
Demographics 
 
      
Age (years) 50.3 ± 9.4 56.7 ± 9.1 54.4 ± 8.0 48.2 ± 9.2 0.005 0.033 
 
BMI (kg/m2) 26.5 ± 5.0 25.1 ± 3.7 25.9 ± 4.2 26.3 ± 5.4 0.45 0.83 
 
Weight (kg) 66.7 ± 13.1 62.4 ± 9.9 67.7 ± 11.2 67.7 ± 14.0 0.21 0.99 
 
       
HR (bpm) 70.0 ± 11.1 69.2 ± 10.5 70.6 ± .6.9 70.2 ± 12.1 0.78 0.90 
 
SBP (mm Hg) 131.7 ± 20.3 141.2 ± 18.7 133.5 ± 21.3 128.0 ± 19.0 0.03 0.38 
 
DBP (mm Hg) 77.6 ± 17.0 83.2 ± 19.0 75.7 ± 19.0 75.2 ± 15.5 0.13 0.92 
 
LVEF (%) 55.5 ± 4.3% 59.8 ± 4.5 62.3 ± 3.5 58.9 ± 4.4 0.52 0.008 
 
LVEDVi (mL/m2) 75.7 ± 10.4   69.7 ± 12.8   78.9 ± 14.6 76.6 ± 8.4 0.09 0.61 
 
LVESVi (mL/m2)  30.8 ± 5.7  28.2 ± 6.7  29.9 ± 7.4  31.7 ± 5.2  0.11 0.42 
 
       
Co-morbidities       
Diabetes 2 (3.0%) 2 (15.4%) 1 (7.7%) 0 0.07 0.51 
 
Hypertension 12 (18.2%) 6 (46.2%) 3 (23.1%) 4 (9.1%) 0.008 0.38 
 
Hyperlipidemia 7 (10.6%) 4 (30.8%) 3 (23.1%) 2 (4.5%) 0.028 0.13 
 






16 (20.4%)  
 
0.69  
        
Medications       
ACEI/ARB 10 (15.2%) 5 (38.4%) 3 (23.1%) 3 (6.8%) 0.015 0.24 
 
BB 4 (6.1%) 2 (15.4%) 1 (7.7%) 1 (2.3%) 0.25 0.94 
Statin 6 (9.1%) 3 (23.1%) 3 (23.1%) 2 (4.5%) 0.13 1.0 
 
 






Figure 8-4: Change over time (mean ± SD) for hemodynamic parameters. A) Heart Rate (HR), B) Systolic Blood 
Pressure (SBP), C) Diastolic Blood Pressure (DBP), D) indexed Left Ventricular Stroke volume (LVSi), E) New 
York Heart Association (NYHA) dyspnoea class and F) Brain Natriuretic Peptide (BNP). Colour coding: Red for 
Diastolic dysfunction (DD); Black for systolic Dysfunction (SD); Green for No-diastolic-No-Systolic Dysfunction 
(NDNS). 
 
Figure 8-5: Change over time (mean ± SD) for systolic parameters. A) Left Ventricular Ejection Fraction 
(LVEF), B) Global Longitudinal Strain (GLS) and C) arterial impedance (EaI), an indirect measure if cardiac 
afterload. Note that GLS has been converted to absolute numbers to facilitate interpretation. Colour coding: Red 
for Diastolic dysfunction DD; Black for SD; Green for NDNS. 
 




For the entire cohort there was progressive increase in E/A ratio from a baseline value of 1.45±0.48 to 
1.62±0.58 at end of treatment (p=0.03) driven primarily by a reduction in A velocity (p=0.01) with no 
significant change in E velocity(p=0.85)(Figure 8-6). There was also an increase in mean E/e’ ratio over 
study course, from lowest value at baseline of 7.1 ± 1.4 cm/sec to highest value of 7.8 ± 2.4 cm/sec at 
study end (p=0.003) driven by a progressive decline in both septal and lateral e’ velocities. There was no 
significant change in LAVI. There was however a progressive decline in PDSR (p=0.01) during 
treatment.  
 
Timeline and Phenotypes of Cardiac Dysfunction 
During the study course we identified 3 different cardiac phenotypes in our patient cohort: (1) patients 
with systolic dysfunction (SD), (2) diastolic dysfunction (DD), and (3) those with no systolic or diastolic 
dysfunction (NSND). Baseline characteristics and intra-group comparisons are provided in Table 8-2.  
 
Systolic Dysfunction Phenotype 
Thirteen patients (19.7%) met criteria for SD; 6 had symptomatic >5% reduction in LVEF to <55% with 
CHF symptoms and 7 had >10% asymptomatic LVEF reduction to <55%. Median time to diagnosis was 
5months (range 2-14 months)(Figure 8-3). By 14 months, 11 patients (84.6%) had incomplete recovery of 
LVEF values and remaining 2 patients had newly diagnosed SD. At the diagnosis of SD, five patients 
(38.5%) received heart failure therapy or up-titration of their pre-existing anti-hypertensive therapy, and 2 
patients had their trastuzumab held. In the other patients since LVEF was still >50%, Herceptin therapy 
was continued at the discretion of the oncologist.  
 
At baseline, patients with SD were older and had higher baseline LVEF, but no other significant 
differences were seen compared to the NDNS subgroup (Table 8-2). There was a significant rise and 
recovery of HR, but no significant change in SBP, DBP, NYHA class or BNP over time (Figure 8-4). A 
significant fall in LVEF occurred (p=0.001) with the nadir at 5 months (fall by -9.7 ± 4.7%) followed by 




partial recovery by 14 months (Figure 8-5). There was also significant worsening of GLS (change of +3.2 
± 3.0%) with nadir at 5 months with no recovery at 14 months (Figure 8-5).  
The SD phenotype displayed a late increase in E/A ratio(p=0.047), primarily driven by a reduction in A 
velocity, and a gradual, progressive increase in mean E/e’ over time(p=0.023) due to reduction in both 
septal and lateral e’ velocities (Figure 8-6). PDSR significantly declined during study duration, with no 
recovery with completion of trastuzumab (Figure 8-7). There was no significant difference in the change 
in ECV between baseline and end of treatment between the SD and NDNS phenotype. Comparison of 
ECV between baseline and 14 months showed a non-significant reduction compared to NDNS and 
(ΔECV for SD: -1.3±2.9% vs. NDNS: -0.3±2.8%. p = 0.32).   
 
Diastolic Dysfunction Phenotype 
Thirteen patients met criteria for DD during treatment, of whom 4 had grade 1 DD and 9 had grade 2 DD 
with no patients having grade 3 DD (Figure 3). Median time to DD diagnosis was 8 months (range 2-14 
months). By 14 months, only 5 patients (38.5%) had incomplete recovery of diastolic function.  Eight 
patients (61.5%) were treated with heart failure or up-titration of anti-hypertensive medications during 
cancer therapy, at median 9.3 months (range 6.1-21.7 months). Four patients developed concurrent SD, of 
which 1 patient developed SD 9 months prior to DD, 1 patient developed DD 7 months prior to SD and 2 
patients developed SD and DD at same time-point. 
 
Patients with DD phenotype were older than NDNS and SD groups and had higher baseline SBP, were 
more likely to have a history of hypertension, diabetes or be on ACEI/ARB therapy at baseline (Table 8-
2). They also received higher cardiac radiation dose compared to NDNS group. There was no statistically 
significant change in SBP, but a trend towards increase in HR (p=0.08) and NYHA class over 
time(p=0.07). Unlike the NDNS phenotype, there was no significant reduction in BNP over time for DD 
phenotype(p=0.57). 
 




Patients with the DD phenotype had no statistically significant change in LVEF over time (p=0.11) 
(Figure 8-5). There was, however, a significant worsening of GLS (p=0.001), with nadir at 5 months 
(change of 2.2±1.7%) with no recovery by 14 months. There was a trend towards reduced EaI 
(p=0.06)(Figure 4). Patients with DD phenotype demonstrated gradual increase in E/A ratio over time 
(p=0.035) with peak at 6 months, and gradual rise in E/e’ ratio over time (p=0.007) (Figure 8-6). PDSR 
significantly and progressively declined during study duration, with no recovery at 15 months (p=0.0001). 
There was no significant change in LAVI over time (p=0.27) (Figure 7). Although the DD group was the 
only one with an increase in ECV between baseline and 14 months this was not significant compared to 
NDNS phenotype (ΔECV for DD +1.0±1.7% vs. NDNS, p = 0.29). 
  





Figure 8-6: Change over time (mean ± SD) for diastolic parameter as measured by phase-contrast CMR. 
A) E/A ratio, B) E wave peak velocity, C) A wave peak velocity, D) E/e’ ratio, E) septal e’ velocity and 
F) lateral e’ velocity. Colour coding: Red for Diastolic dysfunction (DD); Black for Systolic Dysfunction 






Figure 8-7: Change over time (mean ± SD) for diastolic anatomical parameters. A) Indexed Left Atrial 
volume (LAVi) and B) Peak Diastolic Strain rate (PDSR). Colour coding: Red for DD; Black for SD; 
Green for NDNS. 
 
 




No Systolic or Diastolic Dysfunction Phenotype 
There were 44 patients (66.7%) classified into the NSND phenotype. There was a significant rise in HR at 
8 months with recovery by the end of treatment (p=0.001), but no significant change in SBP or EaI 
(Figure 8-4).  There was no significant change in NYHA class. There was a significant reduction in BNP 
from baseline during study duration(p=0.001) (Figure 6).  
Even in this group, there was a small but statistically significant fall in LVEF (p<0.0001) with nadir at 8 
months ((-3.0 ± 3.6%) with partial recovery at 14 months (Figure 5). There was also a small but 
statistically significant fall in GLS (p<0.0001), with nadir at 8 months (change of +1.4 ± 1.9%) and no 
recovery by end of treatment. There was no significant change in E/A ratio, E/e’ ratio, septal and lateral e’ 
velocities (Figure 3), LAVI (Figure 6), PDSR (Figure 6), over time. 
 
Discussion 
Our results demonstrate that cardiac dysfunction secondary to cancer treatment is a complex phenomenon 
affecting multiple dimensions of cardiac function, and that using LVEF as the sole measure may cause 
underestimation of incidence and degree of cardiac injury. Our main findings are that: 1) cardiac 
dysfunction may be classified as predominantly systolic or diastolic; 2) different baseline characteristics 
and co-morbidities as well as radiotherapy to the chest has an impact on the phenotype experienced by the 
patient; 3) the phenotypes exhibit different trajectories, with SD exhibiting earlier onset and greater 
degree of recovery; ; 4) finally patients who do not meet criteria for SD or DD also have small but 
statistically significant reduction in LVEF and GLS that remains reduced even at the completion of 
trastuzumab therapy. 
We identified 3 different cardiac function phenotypes can occur with contemporary therapy for breast 
cancer.  Although there are currently no guidelines for monitoring or treating diastolic dysfunction in 
context of cancer treatment, our results suggest that DD phenotype may have comparable clinical 
significance to SD, as DD had equal incidence to SD, displayed non-significant trend to increased 
symptom burden and had cardiac biomarker elevation in comparison to the NDNS phenotype. Both SD 




and DD exhibited subclinical systolic and diastolic dysfunction (as evidenced by changes in both systolic 
and diastolic GLS and PDSR in both phenotypes) that did not show evidence of recovery, suggesting both 
phenotypes may result in reduced cardiac reserve to future cardiovascular risk factors. However, there 
were also indications that SD and DD have differences in pathophysiology, as SD exhibited dysfunction 
primarily secondary to ventricular and atrial cardiomyopathy and DD exhibited milder cardiomyopathy 
(evidenced by preserved LVEF and lateral e’ velocity) with higher baseline left atrial pressures. Given 
that DD was persistent in a significant proportion of patients at the end of trastuzumab therapy, it is 
possible that DD phenotype contributes to the long-term heart failure burden in cancer survivors. 
Additionally, progression of markers of systolic and diastolic dysfunction (e.g. GLS, E/’e) without 
recovery at study end imply that using LVEF as sole cardiac dysfunction marker may give a false 
impression of cardiac recovery, and under-appreciation of reduced cardiac reserve. Even the NDNS 
phenotype had significant reduction in systolic function (evidenced by change in LVEF and GLS) with 
incomplete recovery at 14 months. This finding suggests that cardiac dysfunction may be a more uniform 
outcome of EBC therapy than previously appreciated, and current guidelines that diagnose dysfunction in 
a binary fashion from echo-derived LVEF may inaccurately identify patients at risk of incident HF and 
lead to missed opportunities for risk factor modification. Long-term studies are warranted to determine 
the long-term clinical implications of our findings.   
Chemotherapeutics can cause cardiomyocyte damage through multiple different pathways and it is 
plausible that the predominance of certain pathways in susceptible individuals could lead to different 
clinical phenotypes. Anthracyclines may plausibly cause systolic dysfunction via topoisomerase-2β 
inhibition and adversely affecting the mitochondrial electron transport chain(261), which may both 
increase reactive oxygen radical complex (ROC) concentrations. Anthracyclines have also been 
demonstrated to decouple endothelial nitric oxide synthase from nitric oxide production(262) and inhibit 
sarcolemmal sodium-calcium exchanger(263), both processes associated with diastolic dysfunction. 
Additionally, cancer treatment may increase myocardial interstitial fibrosis. Studies of animals treated 
with anthracyclines have demonstrated 64% increase in extracellular fibrosis by 20 weeks(264), and 




increase in ECV has been documented in patients treated for cancer(265). Increased fibrosis may explain 
the numerically higher ECV values observed in the DD cohort compared to NDNC and SD subgroups, 
with lack of statistical significance possibly related to the smaller sample size.  Prior studies have 
demonstrated increased incidence of diastolic dysfunction associated with cancer treatment, although 
these studies are generally published several decades ago, with small groups of subjects and using 
echocardiography or nuclear imaging. Diastolic dysfunction occurred more commonly by 12 months in 
older breast cancer patients with more cardiovascular risk factors(266). One study of 125 children treated 
with anthracyclines found that 20% developed diastolic dysfunction by echocardiography at treatment 
end,(267) which is an incidence rate similar to our results. Additionally, a cross-sectional study of 1,820 
adult survivors of childhood anthracycline or radiotherapy treatment found 8.7% prevalence of diastolic 
dysfunction at 23 years from diagnosis, which was greater than the prevalence of abnormal LVEF 
measurements(118), and a population-based case control study of 229 EBC patients demonstrated OR 9.1 
(95%CI 3.4-24.4) for incident HF per log mean cardiac radiotherapy dose(253).These findings 
collectively demonstrate that diastolic dysfunction is a frequent complication of cancer treatment, and 
support the concept that it may occur in isolation from systolic dysfunction. .  
Strengths of our study include prospective recruitment, assessment over multiple timepoints and use of 
advanced cardiac imaging and biomarkers, however it does also have several limitations. Firstly, current 
diastolic grading criteria were formulated using data from large echocardiographic registries(125), and the 
utility of CMR for assessing diastolic function is not as well validated. There are several potential benefits 
for using CMR to address our primary goal which was to define the cardiac phenotypes in patients 
receiving cancer therapy. CMR is the gold standard for measuring LVEF(268) which is necessary to 
differentiate systolic from diastolic dysfunction as well as to understand subtle myocardial abnormalities 
that may occur in a larger subgroup of patients. Indeed the predominant method of cardiac analysis, 2D-
echocardiography, has a 10% temporal variability(150), which means that LVEF decrements of sufficient 
magnitude for SD diagnosis by 2D-echocardiography may simply reflect measurement error. Although it 
is possible to perform concomitant CMR and echocardiography, this would be an expensive and labor-




intensive approach. With experienced operators, use of phase-contrast imaging to measure flow and tissue 
velocity is comparable to that of echocardiography for conventional parameters(258,269,270), and may 
offer benefits of measuring additional diastolic parameters (e.g. ECV)(271). Additionally, 
echocardiographic windows can be particularly challenging in breast cancer patients due to surgery and 
radiotherapy causing soft-tissue fibrosis, and the frequent use of implants(239). For these reasons, the 
choice of CMR to address our primary question was felt to be ideal.  Secondly, published literature on 
validated normal CMR reference ranges for diastolic dysfunction is lacking, which may reduce 
confidence in our findings. We agree that further population-based data is needed. However even for 
echocardiography, reference ranges for diastolic function of cancer patients is lacking, and there are 
physiological reasons to believe that cut-offs based predominantly on data from populations of older 
hypertensive patients may not be transferable to our cohort. We therefore felt that creating reference 
ranges using a cohort of healthy volunteers was reasonable. Thirdly we acknowledge that the assessment 
of dyspnea aetiology in cancer patients is challenging(272), and cannot exclude the possibility of 
noncardiac dyspnea being incorrectly attributed to cardiac causes. However, all patients were reviewed at 
each timepoint by an experienced clinician within a dedicated cardio-oncology program, and our practice 
for diagnosing cancer-related cardiac dysfunction reflects current guidelines. 
 





Figure 8-8: Case example of a patient experiencing isolated, progressive diastolic dysfunction during 
course of breast cancer treatment. Patient was a 57 year-old woman with no cardiovascular risk 
factors. She received 226 cGy of cardiac radiation. She developed NYHA II dyspnea between 3 and 6 
months from baseline. A) At baseline her LV volumes were normal, which did not significantly 
change at end of anthracycline treatment (B) or end of trastuzumab therapy (C). Her E/A ratio 
increased from 1.24 at baseline (D) to 1.75 (E) and finally to 2.2 at final measurement (F). This was 
associated with decline in her medial e’ velocity (G-I), with E/’e increasing from 7.4 at baseline, to 
10.9 at 3 months and to 13.9 at 14 months. Her LAVI increased from upper range of normal (J) to 
mildly dilated (K-L). These changes correspond to clinical progression from normal diastolic 
function to grade 2 diastolic dysfunction, and finally grade  




We believe that our study is the first to use CMR to prospectively identify different phenotypes of cancer-
therapy-induced cardiac dysfunction. The long-term significance of these findings is undetermined, and 
further studies to determine the clinical course of this subgroup are warranted. 
 
Conclusion 
Cardiac dysfunction is common after EBC therapy and can be described by three phenotypes which are 
characterized by different baseline characteristics, non-invasive imaging findings and different degrees of 




This chapter thesis has demonstrated that cardiac damage from cancer treatments does not fit neatly into a 
binary categorization based on a single cardiac imaging metric, but rather manifests as disturbance along 
multiple axes of heart function with individual variations in degree of derangement across each axis. This 
finding is likely to have future clinical relevance, as clinical trials for potential HFpEF treatments near 
completion. It also demonstrated that even patients who did not meet current guideline criteria for either 
systolic or diastolic dysfunction had subclinical dysfunction and lends to support to recommendations for 
long-term monitoring in this at-risk population.  
The end of this thesis section concludes the clinical studies that are designed to provide guidance for 
practicing healthcare professionals. To date, this thesis has 1) identified potential harms of anti-cancer 
treatments and confirmed the clinical importance of these conditions, 2) confirmed that these harms can 
be either short-term or long-term and can occur in survivors of either adult or childhood cancer, 3) 
demonstrated that contemporary practice for monitoring for these harms are likely suboptimal in 
Australian hospitals, 4) shown that echocardiography-guided approach  is likely superior to MUGA-
guided approach for monitoring cancer patients, 5) provided evidence that automation is a viable strategy 




for improving utility of echocardiography in the cancer population, 6) demonstrated that in the majority of 
cases reduced LVEF measurements in cancer patients are truly secondary to decreased contractility in the 
context of cardiomyocyte damage and 7) demonstrated that cardiac dysfunction manifests as variable 
phenotypes which are under-appreciated in current guidelines.   
The rationale for this thesis was to provide a guide for use of cardiac imaging in Australia to reduce the 
burden of CTRCD. Current guidelines(104) have been equivocal regarding the optimal imaging modality, 
do not make specific suggestions to improve accuracy of the most commonly used modalities and do not 
make recommendations for cardiac measurements beyond LVEF. Partially as a result, the potential of 
collaboration between cardiologists and oncologists has not to date been made a reality. Therefore we 
hope this thesis makes a significant contribution that may translate to improved cardiovascular outcomes 
for cancer survivors. 
The challenge of utilizing beneficial cardiac imaging strategies is not solely due to physician preference. 
Widespread changes in the practice of imaging cancer patients would require significant diversion of 
resources. These changes would not occur in a vacuum, as there is competition for finite resources within 
the Australian healthcare system, and the gatekeepers for funding are usually elected public officials. The 
final chapter of this thesis will examine the issue of whether resource investment for cardiac imaging of 
cancer patients is likely to provide benefits on a societal level











Cost-Effectiveness of Strain-Guided 
Echocardiographic Strategy 
 
Part of the research in this chapter has been published(273) as:  
 Nolan MT, Plana JC, Thavendiranathan P, Shaw L, Si L, Marwick TH. Cost-Effectiveness of 
Strain-Guided Cardioprotection For Prevention of Chemotherapy-Induced Cardiotoxicity. Int J 









 It has been the aim of this thesis to provide a vision for and proposed template for utilizing the most 
effective cardiac imaging strategy to decrease the burden of heart failure in the Australian cancer survivor 
population. To achieve this, each of the sections to date has focused on one dimension of the heart 
damage secondary to cancer treatment; the first section demonstrated the scope of the issue and the 
brought attention to the unmet clinical need for improved services to reduce cardiotoxicity; the second 
section assessed first-line imaging modalities to determine the most appropriate technique and the third 
section assessed advanced second line techniques to provide greater understanding of pathophysiology 
underlying cardiotoxicity and to guide treatment in complex cases. Together these sections provide 
guidance at the physician level for preventing cardiotoxicity. But imaging decisions are not made by 
physicians in a vacuum, as there are issues of access, cost subsidization and insurance coverage that 
require policy changes at the higher levels of political and corporate leadership. The healthcare 
professionals in these fields have a duty of care to a population as a whole rather than to individual 
patients and a responsibility to manage finite societal resources, and therefore they require an evidence 
base that simultaneously measures the potential improvement in quality and quantity of life and resource 
cost of their decisions.   The final section of this thesis will examine whether there is evidence that using 
the imaging strategy described will lead to significant cost and health savings at a societal level. 
 
  








Background: Cancer chemotherapy increases the risk of heart failure. This cost-effectiveness model 
compared strain-guided cardioprotection with other protective strategies using a health care payer 
perspective and five-year time horizon.  
Methods: Three cardioprotection strategies were assessed: 1) Usual care (EF-guided cardioprotection, 
EFGCP) with cardioprotection initiated on diagnosis of LVEF-defined cardiotoxicity (EF-CTX), 2) 
Universal cardioprotection (UCP) for all such patients, 3) strain-guided cardioprotection (SGCP - treatment 
of patients with subclinical cardiotoxicity [S-CTX]). A Markov model, informed by the published literature 
on transitional probabilities, costs and quality-adjusted life years (QALYs) was developed to assess the 
incremental cost-effectiveness ratio (ICER). Costs, effects and ICER of each specified cardioprotective 
strategy were assessed over a 5-year range, with sensitivity analyses for significant variables. 
Results: In the reference case of a 49 year-old woman with stage IIb breast cancer treated with sequential 
anthracyclines and trastuzumab, strain-guided cardioprotection (3.79 QALYS and $4159 cost over 5 years) 
dominated both UCP (3.64 QALYs and $5967 cost over 5 years) and EFGCP (3.53 QALYs and $7033 
cost over five year). Model results were dependent on the probabilities of patients developing subclinical 
LV dysfunction, with UCP dominating alternative strategies at probabilities ≥51%. Variations in the cost 
of cardioprotective medications and probabilities of cardioprotection side-effects had no effect on model 
conclusions.  
Conclusions:  In patients at risk of chemotherapy-related cardiotoxicity, strain-guided cardioprotection 
provides more QALYs at lower cost than standard care or uniform cardioprotection. 





Advances in cancer management over recent decades have led to an increasing proportion of cancer 
survivors. Chemotherapy and radiotherapy (especially in combination) are associated with cardiac 
dysfunction in up to 26% of treated patients by six months(50) and symptomatic heart failure in up to 20% 
at 5 years(146) depending on the dose and type of chemotherapy. Heart failure in this setting has a two-
year mortality of up to 50%(7). The current standard of care involves regular monitoring of left ventricular 
ejection fraction (LVEF), with initiation of heart failure medications once LVEF drops to the point when 
cardiotoxicity (conventionally defined as an asymptomatic drop of LVEF by ≥10% to final value of <55% 
or a symptomatic drop of LVEF by ≥5% to final value of <55%) is diagnosed(245). This LVEF-guided 
definition of cardiotoxicity (EF-CTX) is a late stage of progressive myocardial functional impairment 
initiated at the time of cardiac insult(137). An alternative strategy, based on a small randomised controlled 
trial of pre-emptive treatment of all patients with maximum tolerated doses of enalapril and carvedilol at 
the time of chemotherapy, has been demonstrated to reduce the incidence of cardiotoxicity and symptomatic 
heart failure compared with a control group(52). The disadvantage of this approach is that most treated 
patients do not develop EF-CTX or symptomatic heart failure and would have unnecessarily been exposed 
to the potential side-effects and cost of medications.  
A third strategy would be to use a highly sensitive test to identify high-risk subgroups within the 
chemotherapy-treated population, and initiate cardioprotection only in these patients. This could provide 
the health benefits of cardioprotection while minimizing unnecessary medication costs and side-effects. 
Global longitudinal strain (GLS) derived from speckle-tracking echocardiography is a novel non-invasive 
imaging technique that quantitatively measures regional myocardial deformation, a sensitive marker of 
myocardial function.  Strain has been demonstrated to accurately predict development of 
cardiotoxicity(137,274)  and can identify early pathological changes in myocardial systolic function before 
any appreciable decline in LVEF becomes apparent. This stage of subclinical cardiotoxicity (S-CTX) 
identifies a population at high risk of EF-CTX and symptomatic heart failure and may represent an attractive 




opportunity for targeted cardioprotection (CP). No randomized trial has compared these options, so we 
developed a Markov model to incorporate probabilities and risks of three cardioprotection strategies to 
determine the costs and quality-adjusted life-years (QALYs) obtained by each strategy in patients treated 
with potentially cardiotoxic chemotherapy. 
 
Methods 
Model design. This decision-analytic model evaluated the morbidity, mortality, and costs inherent in three 
clinically-relevant strategies; 1) the current standard strategy of initiating cardioprotection medications after 
diagnosis of EF-CTX (diagnosed as an asymptomatic decline in LVEF by >10% to value of <55%) or 
symptomatic heart failure, 2) a strategy of uniform cardioprotection (UCP) for all patients at the time of 
chemotherapy, and a 3) a strategy of using S-CTX (defined as a decline in global longitudinal strain (GLS) 
of ≥11% from baseline by 3 months post chemotherapy-initiation) to commence cardioprotection treatment. 
Cardioprotection was defined as concurrent enalapril and carvedilol up-titrated to their maximum dose, as 
used in the active treatment arm of a large recent randomised controlled trial(52), and used throughout the 
5-years of modelling. Correction factors for time lapsing were used if cardioprotection was commenced 
after echocardiographic or clinical findings. This Markov model used Monte Carlo simulations (TreeAge 
Software Inc. Williamtown, MA), to assess the clinical and economic consequences of alternative strategies 
of using cardioprotective strategies in a hypothetical cohort of 10,000 patients in a micro-simulation model 
without tracker variables. Beta distributions were assigned to probabilities and utilities, and gamma 
distributions for costs based on standard errors derived from the associated literature. Means and 95% 
credible intervals (95% CI) were computed on the basis of 10,000 micro-simulations. Cost-effectiveness 
acceptability curves (CEACs, a method to quantify and graphically represent uncertainty in economic 
evaluation studies of health-care technologies) were used to report the probability that the ICER for an 
intervention was below the predefined willingness to pay threshold. This study was performed in 




accordance with the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) guidelines, 
as detailed by the   International Society for Pharmacoeconomics and Outcomes Research (ISPOR). 
We estimated costs and benefits of the interventions (deaths averted and quality-adjusted life-years 
[QALYs] gained) over a 5-year period of the cohort, because transition probabilities beyond this period are 
not currently well-described. We assumed that all interventions took place at the start of the time horizon, 
and discounted all future costs and benefits by 3% per annum. Cycle length is the time-frame of transition 
from one state to the next, during which period all information is held constant. For the purposes of this 
analysis, cycle length was assumed to be 1 year. 
Decision tree. The Markov model (Figure 1) accounted for the dynamics of cardiac screening and 
utilization of cardioprotective medications in a cohort of 10,000 patients scheduled to receive chemotherapy 
for cancer. The base case (a 49 year-old woman with stage II breast cancer receiving sequential 
anthracycline and trastuzumab therapy) was applied to all cohort patients. At commencement of the time 
horizon, this hypothetical individual was assigned to one of the three screening strategies. These patients 
progressed through the Markov model on the basis of transition probabilities.  
The model was intended to capture the high-level costs and effectiveness of screening and treating a large 
cohort. In sensitivity analysis, we considered a range of values reported in scientific literature for transition 
probabilities, costs and utilities. Where data were available, low and high values were chosen to reflect 
ranges in the literature.  The model structure was based in part on other models in the literature and was 
reviewed by clinicians involved in the care of cancer patients and chemotherapy-related cardiotoxicity.  


















Health states and transitions. Data on transitions between health states were obtained from the literature 
and expert sources (Table 9-1); 
The asymptomatic post-chemotherapy state described patients without any cardiac symptoms or apparent 
structural changes on cardiac imaging.  
Asymptomatic cardiotoxicity (referred to in this study as EF-CTX) was identified in patients with a ≥10% 
asymptomatic drop of LVEF. 
Subclinical LV dysfunction (referred to in this study as S-CTX) was diagnosed in patients without EF 
changes but with a ≥11% reduction of GLS.  
Other health states were heart failure and death. The background mortality rate was calculated from USA 
life tables specific to the base case of breast cancer or scenario analyses of other cancers 
(www.cdc.gov/nchs/products).  
Transition probabilities were separated into the categories of initial year of treatment, and for subsequent 
years. Further details regarding mortality in each health state is provided in the next section. 
Costs.  We conducted our economic analysis from the perspective of the healthcare payer and therefore 
used the amount reimbursed to the provider as the cost of care. Information regarding costs was obtained 
primarily from the literature, including diagnostic related groups (DRGs), Medicare payments for current 
procedural terminology (CPT) codes and discounted drug prices (Table 3). LVEF-guided 
echocardiographic screening costs were calculated by taking the CPT reimbursement cost and assuming a 
regimen of five echocardiographic studies (baseline and 3-monthly in the first year only). Strain-guided 
echocardiographic screening costs were calculated using the same CPT cost(275), but assuming the 
performance of monthly echocardiographic studies in the first year – which is the maximum that might be 
anticipated with trastuzumab therapy after anthracyclines. Medication costs were obtained from the 
Walmart Retail Prescription program drug list(276). Costs of routine biochemical or haematological 
screening for medication side-9-effects were not included as it was considered likely that patients receiving 




chemotherapy would receive regular investigations regardless of whether they received cardioprotective 
medications. Costs were expressed to 2015 US$ and a willingness to pay threshold of $53,000 per QALY 
was applied, as this represents the 2015 average annual gross domestic product (GDP) of the US and a 
national GDP value per capita has been suggested by the World Health Organization to represent how much 
a nation can reasonably be spend to save each QALY(277). The costs published in the literature more than 
two years earlier were corrected for intervening currency fluctuations using a commercial past currency 
converter (www.fxtop.com/en/currency-converter-past.php). 
Health outcomes. Information regarding health outcomes was obtained from searches linking health states 
with the words “utility” and “quality of life” (QOL). Table 9-1 lists the findings for utilities (values obtained 
from preferences associated with health-related quality of life where full health = 1.0 and dead = 0.0).  
Sensitivity analysis. Critical sources of variation in the input data were gathered by one-way sensitivity 
analyses, varying each input factor by its standard error. A threshold analysis was performed on the most 
influential factors to identify the point where the additional cost per QALY was <$53,000. The Net 
Monetary Benefit (NMB) was defined as the difference between the gain in QALYs and the ratio between 
the willingness to pay threshold and the difference in cost. Because of concerns regarding model sensitivity 
to synergistic influences of cardioprotective side-effects on costs and health-state utilities (as these represent 
the only trade-offs for uniform use), these transition probabilities were subject to two-way sensitivity 
analyses. 
Scenario analysis. To determine the applicability of cost-effectiveness of cardioprotective strategies for 
high-risk cancer patient subgroups other than breast cancer, two additional scenario analyses were run using 
the same Markov model. The first scenario utilized a reference case of a 50 year-old man with stage III 
non-Hodgkin’s lymphoma and a low-to-intermediate International Prognostic Index score.  The second 
scenario utilized a reference case of a 48 year-old man with acute myeloid leukaemia. Both cases involved 
treatment with anthracyclines. Transition probabilities and mortality rates were utilized from published 




literature and transition probabilities of significant GLS drop were utilized from subgroups of trials (see 
Online Appendix 1). 
Internal model validation: Markov model validation was performed as advised by ISPOR 
guidelines(278). In the base case analysis, distributions were sampled 100 times, and after each sample, 
1000 trials were run using values drawn from each sample in order to calculate the mean costs and 
effectiveness. For internal validity, we compared the life-expectancy generated by our Markov model with 
life-expectancy of non-metastatic breast cancer patients with clinical characteristics as our base case 
reported in the US Surveillance, Epidemiology and End Results (SEER) database of the National Cancer 
Institute. Goodness of fit was predicted by plotting model predictions versus SEER database observed data 
and fitting a linear curve through points with an intercept of zero. The squared linear correlation coefficient 
(R2), obtained using linear regression, was used as an index of association. External validation was not 
performed, due to insufficient studies which were not included in the Markov model construction. 
Results 
Health outcomes and costs. In the reference case (49 year old woman taking anthracycline and 
trastuzumab for breast cancer, annual cost of cardioprotective medication of $81 with 56% probability of 
medication side-effects, leading to 38% overall abandoning cardioprotection), the outcomes of SGCP 
(3.73±0.87 QALYs, $4161±$3997 over 5 years) were superior to those of UCP (3.64±0.75 QALYs, 
$5,753±$5840) and EFGCP (3.53±0.86 QALYs, $6820±$6450). Both UCP and EFGCP were dominated 
by SGCP strategy. 
Sensitivity analyses. One-way sensitivity analyses were performed over a clinically plausible range for all 
variables.  The impact of these variations on health outcomes is depicted in a tornado diagram (Figure 2). 
This sensitivity analysis revealed that the variables that had the largest impact on model outcomes were 
probability and utility of S-CTX, medication side-effects and cost of managing those side-effects.  
 















Figure 9-2: Tornado diagram demonstrating influence of cost, utilities and transition 
probabilities on expected value, assuming a willingness-to-pay value of US$53,000. EF-
CTX –cardiotoxicity with reduced ejection-fraction, HF – symptomatic heart failure, S-
CTX – subclinical cardiotoxicity, UCP – uniform cardioprotection  
 







Figure 9-3: One-way sensitivity analysis evaluating net monetary benefits (NMB) across a range of 
transition probabilities of patients having detectable subclinical cardiotoxicity when utilizing a strain-
guided strategy (SGCP). A willingness-to-pay threshold of $53,000 was assumed. At probability values 
higher than 34.1%, uniform cardioprotection (UCP) yielded higher NMB than SGCP. 
 
  




One-way sensitivity analysis of probability of a decrease in GLS revealed a strong impact on model’s 
conclusions (Figure 3). At S-CTX transition probabilities of <34%, SGCP dominated alternative strategies. 
Above these transition probabilities, UCP delivered higher net monetary benefits. EFGCP did not provide 
superior benefits at any level of transition probability.  
The impact of parameter uncertainty in the frequency of side-effects and the cost of side-effects was 
explored further in an additional sensitivity analysis across the plausible range of the frequency and cost of 
side-effect and showed that SGCP dominated both UCP and EFGCP throughout the plausible ranges of 
medication side-effects transition probabilities and costs. An additional sensitivity analysis revealed SGCP 
strategy remained below the willingness-to-pay threshold throughout a range of plausible EF-CTX 
transition probabilities.  
Monte Carlo simulation. The impact of parameter uncertainty in the frequency of transition probabilities, 
utilities and costs were examined using a Monte Carlo analysis with 10,000 simulations. This demonstrated 
that SGCP was the optimal strategy, with a mean survival of 4.66 years with SGCP, 4.56 years with UCP 
and 4.48 years with LVGCP. 
A cost-effectiveness acceptability curve (Figure 5) demonstrated that strain-guided strategy was 
consistently the most cost-effective strategy across a broad plausible range of willingness-to-pay thresholds 
(from $0 to $100,000 per annum). An incremental cost-effectiveness scatterplot of results of 1000 pairs of 
differences in costs and QALYs shows that both SGCP (Figure 6a) and UCP (Figure 6b) are more cost-
effective than the current standard of care (EFGCP). The comparison between SGCP and UCP (Figure 6c) 
does not show clear benefit for either approach, with SGCP being more cost-effective in 56% of instances.    
Scenario analysis: In a scenario analysis examining the cost-effectiveness of imaging-guided CP strategies 
in haematological malignancies, the index case consisted of a 50 year-old man with stage III non-Hodgkin’s 
lymphoma. Transition probabilities were altered to reflect the higher incidences of cardiovascular 
complications (Online Appendix 1) due to more aggressive chemotherapeutic regimens. The most 




significant change consisted of increase of cardiotoxicity in absence of CP from 20% to 36%. An 
incremental increase in costs and QALYs gained with SGCP (ICER $18,264 per QALY gained) with 
overall higher costs and lower QALY per strategy was seen than with breast cancer reference case (over a 
five-year period, SGCP 3.49±0.72 QALYs, $23,012±31,611; UCP 3.24±1.45 QALYs, $18,400±27,538; 
EFGCP 3.15±0.89 QALYs, $27,537±25,528). These findings are broadly similar to those of the base case 
of the main study with the ICER for SGCP falling below WTP threshold. The second index case, a 45 year-
old man with acute myeloid leukaemia, demonstrated extended dominance by UCP over both alternative 
strategies (over a five-year period, UCP 2.97±1.07 QALYs, $26,458±22,941; SGCP 2.87±1.29, 
$48,997±30,992; EFGCP 2.86±1.10 QALYs, $31,114±31,092). There was no clinically significant 
difference in QALYs gained between SGCP and EFGCP in this scenario. 
Model validation: The results generated by the model closely match the input data from which the input 
probabilities were derived: the linear regression slope was close to 1 (1.04, p<0.001), and the adjusted R2 
was 0.9993 (p<0.001), demonstrating that the model faithfully reproduced the published data. For the first 
scenario analysis, the linear regression slope was 2.71, and adjusted R2 was 0.9559 (p<0.001). For the 
second scenario analysis, linear regression slope was 1.41, and adjusted R2 was 0.9376. This suggests good 
model approximation to observed life expectancy in studies utilised for the model.    
 
Discussion 
In this analysis of the cost-effectiveness of three strategies for targeting cardioprotective medications for 
the prevention of chemotherapy-related cardiomyopathy, global longitudinal strain provided additional 
QALYs at lesser cost compared with UCP and LVGCP.  SGCP also produced the highest value of 5-year 
survival and was the optimal strategy in the majority of Monte Carlo simulations. The increased 5-year 
survival reflects the high mortality burden of heart failure, even small reductions in incidence of heart 
failure complicating chemotherapy can affect population survival rates. Sensitivity analyses demonstrated 




that cost-effectiveness was highly dependent on probability of reduced GLS. Scenario analyses revealed 
similar findings for an index case of non-Hodgkin’s lymphoma, but UCP was found to dominate both 
alternative strategies in the case of acute myeloid leukaemia. This is likely due to the higher incidence of 
reported cardiotoxicity and heart failure due to more aggressive chemotherapeutic regimens, which would 
lead to greater clinical benefit from a UCP approach. The conclusions of the model were robust when tested 
with sensitivity analyses, with a change in conclusions only if the cardiotoxicity incidence and cost of 
cardioprotective side-effects increased.  
Cardiotoxicity from cancer chemotherapy Both European and US cardiovascular society guidelines 
recognize the need to monitor and manage this patient subgroup(176) although they do not make specific 
recommendations regarding strategies for targeting therapy. The large population at risk of chemotherapy-
related cardiomyopathy, the time difference between chemotherapy and onset of cardiomyopathy 
symptoms and the high morbidity and mortality associated with the condition suggest that the financial and 
health burden that it places on society is likely underestimated, and a cost-effective method of decreasing 
its incidence could translate into tangible and wide-reaching benefits for healthcare systems as a whole.  
Specialized cardio-oncology clinics have been created in many countries in recognition of the special 
cardiovascular challenges of cancer survivors, and this analysis adds to the growing published literature, 
showing that promoting optimal cardio-oncology practice can provide both health and cost benefits. 
Strain-guided management. The adoption of strain guided therapy places little financial burden on the 
healthcare system, as it requires only an update in echocardiography software and a modest time investment 
in training for sonographers and cardiologists. This training would likely have additional benefits in a 
cardiology practice, as 2D strain echocardiography has shown clinical benefit in diagnosis and prognosis 
of many cardiac diseases. 
As the majority of costs in the models relate to managing chemotherapy-related cardiovascular 
complications arising either from HF, or alternatively managing predictable side-effects of medications, a 
method of minimizing HF by treating the smallest possible at-risk group could be expected to be optimal. 




Strain identifies a population with subclinical dysfunction who are at-risk of overt CTX, thereby targeting 
patients most likely to benefit from cardioprotection. The current strategy of EFGCP does not represent an 
effective use of healthcare resources, as therapy is targeted towards an advanced disease subgroup in which 
up to 58% of patients may not respond(22).  In contrast, sensitivity analysis showed that the cost-
effectiveness of SGCP remained below the conservative willingness-to-pay threshold of $53,000 even if 
the transition probability of cardiotoxicity was equal or higher than 45%.  
 
Figure 4:  One-way sensitivity analysis evaluating incremental cost-effectiveness across a broad range of 

















Figure 9-5: Cost-effectiveness acceptability curve representing the probability that each treatment strategy is 
cost-effective for a given maximum willingness-to-pay threshold per QALY gained. The graph is based on 
10,000 Monte Carlo simulations, drawing parameters for each input from probability distributions   
 





Figure 6: Incremental cost-effectiveness boot strap scatterplot. The y-axis represents the difference in 
mean costs (2015 US$) between strain-guided therapy and uniform therapy strategies, and the y-axis 
represents the difference in mean QALYs.  Quadrant 1 represents iterations for which new strategy is 
more expensive and less efficacious (i.e. inferior) than its comparator. Quadrant 2 represents iterations for 
which the new strategy provides additional QALYs at additional cost (cases below the willingness-to-pay 
(WTP) line represent iterations where this additional cost is deemed desirable. Quadrant 3 represents 
iterations where the new strategy is less expensive and less efficacious than the comparator. Quadrant 4 
represents iterations where new strategy was less expensive and more efficacious (i.e. superior). The 
ellipse represents the region containing 95% of iterations. 
A) Strain-guided cardioprotection strategy (SGCP) vs ejection-fraction guided cardioprotection strategy 
(EFGCP). 94.9% of iterations were either superior (15.1% of iterations) or provided additional 
QALYs at additional cost that was less than WTP (79.8%). 
B) Uniform cardioprotection (UCP) vs. ejection-fraction guided cardioprotection (EFGCP).  In 88.4% 
of iterations, UCP provided additional QALYs at additional cost but remained below the WTP 
threshold.  
C) SGCP vs UCP. In 55.9% of iterations, the SGCP strategy yielded either higher QALYs at lower cost 



























Scenario analysis: Scenario analyses were also conducted to investigate the cost-effectiveness of these 
cardioprotective strategies in haematological malignancies. These malignancies differ from breast cancer 
in having higher annual mortality rates, and also higher incidences of cardiotoxicity and cardiac failure due 
to more aggressive chemotherapeutic regimens. For non-Hodgkin’s lymphoma (NHL), the results were 
broadly similar to those of breast cancer, with SGCP offering incremental clinical benefit over UCP at 
higher costs. The ICER was higher for NHL ($15,251/QALY vs. $3,906/QALY), which was driven by a 
higher background mortality rate. For the scenario analysis of a man with AML, the high five-year mortality 
mitigated any clinical benefit from a cardiac imaging strategy, and UCP dominated both alternative 
strategies.  These results suggest that significant differences may exist in cost-effectiveness of strategies 
depending on malignancy involved. However only strain echocardiography findings in haematological 
malignancies are limited to small subgroups of trials that predominantly recruited breast cancer patients, so 
at present the findings of these scenario analyses should be considered hypothesis-generating. 
Assumptions. Strengths of this analysis include accounting for a spectrum of cardiotoxicity after 
chemotherapy, explicitly accounting for changes in costs and quality-of-life due to cardioprotective 
treatment and accounting for changes in incidence of conditions in first and then subsequent years. 
Nonetheless, the value ranges were drawn from retrospective data from different studies involving different 
populations and time-periods. Generally, when a range of transition probabilities and outcomes was 
considered, we used the most conservative assumptions. For example, we assumed cost for an annual 
cardiac screening regimen utilizing 2D-strain echocardiography to be five times higher than for a regimen 
using LVEF echocardiography, although the two techniques are approximately similar in terms of 
infrastructure and training. It is also entirely possible that 2D-strain echocardiography could reduce the 
need for further cardiac screening after three months due to its inherently higher sensitivity, which would 
significantly reduce costs and improve net monetary benefits associated with SGCP. However large 
clinical-outcome driven trials assessing shorter cardiac imaging protocols are yet to be conducted. Because 
some of these strategies are novel (e.g. strain echocardiography), clinical trials have been mostly small-




scale and single centre. However these trials have consistently reported similar findings, and sensitivity 
analyses of these variables did not substantially change the study’s conclusions.  
Publications detailing costs of adverse drug reactions are scarce in scientific literature, and most studies 
examined emergency or hospitalized patients. We recognise that this could potentially be a source of 
discrepancy between our model and current clinical practice. However, side-effects of ACE inhibitors and 
β-blockers encompass a spectrum that include life-threatening side-effects, and even milder side-effects 
may necessitate emergency room visits and expensive further investigations. 
Rare outcomes (e.g. death) were frequently not reported in these single-centre trials, and we needed to 
extrapolate from larger observational trials in which patient population characteristics differed in several 
regards. Additionally, costs of medical care and conditions differ in different countries and in different 
medical contexts (outpatient care, hospital inpatient care), which could affect modelling results.  
A health-payer perspective was taken, in order to make this study highly applicable for health-care 
managers and decision-makers. We recognise that a societal perspective may confer some advantages, such 
as detecting cost-shifting between sectors, but we think this is unlikely in this particular clinical setting. 
Changes in utility values for health states in sensitivity analyses had little effect on cost-effectiveness ratios 
and, in all cases the current strategy of LVEF-guided therapy was dominated with strain-guided therapy 
providing additional QALYs at modest additional cost. We also did not alter the baseline patient utilities to 
include reduced utilities of non-metastatic breast cancer diagnosis. The reason is that because the aim of 
the study was to assess three different strategies and applying breast cancer utilities would have added an 
unnecessary extraneous variable which would not alter the conclusion, as it would apply equally to all three 
strategies. Additionally utility values quoted in the literature for adjuvant chemotherapy for breast cancer 
are in the range of 0.94 – 0.99(279), so would not be expected to significantly change final derived utilities.  
Limitations. The specific clinical characteristics of the chosen index case and scenario analyses may limit 
the applicability of this study to a selection of cardio-oncology cases. This is unavoidable, as the wide 




spectrum of cancers treated with anthracyclines, the variability of chemotherapy regimens, the different 
cardiac screening modalities and regimens available, and different cardioprotection strategies available 
(including dexrazoxane) and the decision whether to continue chemotherapy would introduce so many 
variables that the model’s conclusions would lose applicability to specific patient subgroups. Nevertheless, 
we feel that our model encompasses the most common clinical scenarios.    
The use of troponin measurements for predicting cardiotoxicity represents an alternative strategy. However, 
studies of the utility of troponin for targeting cardioprotective medications have usually tested a population 
treated with relatively high doses of anthracyclines(280), with mean cumulative anthracycline doses of 
approximately 350 mg/m2. A subsequent study that investigated a strategy of concurrent strain 
echocardiography and ultrasensitive troponin I measurements for predicting cardiotoxicity in a population 
treated with low-to-moderate anthracycline doses found that in multivariate analysis, strain was an 
independent predictor of later cardiotoxicity, but troponin was not(44). For these reasons, we did not include 
troponin measurements into our model.  
Clinical relevance. The strategy of a screening process with strain imaging may be applicable to other 
situations where there is a risk of developing HF. Heart failure management costs the US economy $53 
billion/year(281), and treatments that reduce its incidence have the potential to be substantially cost-saving.  
Use of 2D strain echocardiography would represent an investment in potentially improving outcomes and 
reducing future healthcare costs of HF.   
 
Conclusions. A strain-guided strategy for targeting cardioprotective medications for patients at risk of 
chemotherapy-related cardiotoxicity provides more QALYs at lower cost than standard care and provides 
more QALYs at a reasonable additional cost compared with uniform CP strategy. 






Table 9-1. Values for model variables. 
Variable Base value Range Source 
Minimum  Maximum  
Annual Transition Probabilities 
Initial Year 
Probability of global 
longitudinal strain (GLS) drop 
after chemotherapy 
0.23 0.23 0.51 (157,274,282) 
 


















































































0.33 0.25 0.64  
Cardioprotective Medication 
discontinuation 
0.1 0.05 0.13  
Years 2-5 
Patients without GLS drop 
 
-Cardiotoxicity 0.005 0.001 0.009 * 
-Cardiac Failure 0.001 0.0005 0.0015 * 
-Cardiac Death 0.001 0.0005 0.0015 * 
Patients with GLS Drop (S-CTX) 
-Cardiotoxicity 0.008 0.005 0.015 * 
-Cardiac Failure 0.002 0.001 0.003 * 
-Cardiac Death 0.001 0.005 0.0015 * 
Clinically Well Patients 
-Cardiotoxicity 0.03 0.01 0.05 (19,52,280) 
-Cardiac Failure 0.01 0.005 0.015 (52,280,285) 
-Cardiac Death 0.005 0.001 0.009 (52,280,285) 
Cardioprotective Medication 
Side-Effects 
0.2 0.1 0.3 * 
Cardioprotective Medication 
Discontinuation 
0.05 0.02 0.08 * 
Cardiotoxicity Patients (EF-CTX) 




Congestive Cardiac failure 0.026 0.0 0.052 * 
Death 0.04 0.0 0.08 * 
Costs (annual, 2015 US$) 
Strain-Guided 
Echocardiographic Screening 
5127 2000 8000 8 
LVEF-Guided 
Echocardiographic Screening 
2564 1000 3000 8 
Cardiotoxicity 1800 1000 5000 24, 25, 26 
Cardiac Failure 7000 5000 20000 27, 28 
Cardioprotective Medications 81 81 800 9 
Cardioprotective medication 
side-effects 
750 50 5000 29, 30 
Utilities 
Cardiotoxicity 0.94 0.68 0.99 31, 32, 33 
Cardiac Failure 0.6 0.52 0.74 32, 34, 35 
Death 0 0 0 * 
Medication side-effects 
(medication continued) 
0.96 0.92 1.0 36 
Medication side-effects 
(medications ceased) 
0.99 0.95 1.0 37 
 *  represents expert opinion in the context of insufficient information in published literature due 
to low incidence (typically <1%) in small trials 
 EF-CTX refers to cardiotoxicity, as diagnosed by Seidman et al4, as either an asymptomatic 
decline in left ventricular ejection fraction of ≥10% or a symptomatic decline of ≥5%. 
 S-CTX refers to patients who develop as a decline in global longitudinal strain (GLS) of ≥11% 
from baseline by 3 months post chemotherapy-initiation 
 
  








Table 9-2: Scenario analysis of index case of a 50 year-old man with stage III Non-Hodgkin’s 
Lymphoma and low-to-intermediate IPI risk. 
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Table 9-3: Scenario analysis of an index case of a 45 year old man with acute myeloid leukemia. 
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The research in this thesis has endeavoured to illustrate the gap between the contemporary and projected 
burden of CTRCD and the current suboptimal clinical practices for preventing it and identifying strategies 
for reducing the morbidity and mortality associated with this condition. Earlier chapters confirmed that 
CTRCD affects 20% of cancer patients treated with potentially cardiotoxic regimens (35% if diastolic 
dysfunction is included as an adverse outcome), yet only 37% of such patients undergo sequential cardiac 
imaging as advised by contemporary guidelines. Subsequent chapters identified echocardiography as the 
optimal imaging technique with myocardial deformation imaging and automated measurements as 
feasible strategies for further improving the diagnostic and prognostic accuracy. Such imaging and 
management strategies were shown to be cost-effective with significant financial and quality-of-life 
savings on a societal scale. Cardiac MRI was demonstrated to provide yet further clinical information that 
may guide management on a per-patient basis, when echocardiography findings in isolation are 
ambiguous.  Together, these findings constitute a strong argument for improving Australian’s access to 
cardio-oncology services. 
There remain several further research pathways that this thesis could potentially have explored if further 
time and resources were available, and it can be hoped that future higher-degree candidates may use this 
thesis as a starting point to those pathways. One translational outlook is to explore the complementary 
role that cardiac biomarkers may play in identifying CTRCD. Blood-based biomarkers (e.g. NT-pro-BNP 
and troponin T) have the benefits of being inexpensive, not burdensome for the cancer patient and can be 
easily integrated into routine oncological care without delaying anti-cancer treatments(289). Future 
prospective studies assessing both cardiac imaging and biomarker approaches for diagnosing CTRCD 
could assist physicians and are highly desirable. Additionally, the optimal cardiac protection strategy 
remains to be determined. There remain ongoing debates regarding whether cardioprotection should be 
administered prospectively or after diagnosis of cardiac dysfunction (indeed one of the chapters of this 
thesis contains work published as a viewpoint arguing for prospective cardioprotection(290)).    




These conclusions of this thesis are broadly in agreement with a recent report by the European Cardio-
Oncology Council(291), that recommended that even district-level hospitals should have access to cardio-
oncology services, with larger hospitals having an in-house cardio-oncology team. The cardio-oncology 
team should ideally utilize a multidisciplinary approach in a specialized setting with access to advanced 
cardiac imaging, including CMR. However, the current status of cardio-oncology in Australia is in its 
infancy. To the best of my knowledge, the author of this thesis is the only cardiologist in Australia who 
has completed a dedicated cardio-oncology Fellowship. It is the author’s hope that this thesis may provide 
a road-map for creation of cardio-oncology units within Australia. 
 
This PhD thesis assists in identifying future paths for improving cardio-oncology care. Firstly, it is likely 
that part of the reason for poor utilization of cardiac imaging and referral rates to cardiologists for 
detected abnormalities relate to under-appreciation to the degree of cardiovascular burden shouldered by 
cancer survivors. It is a simple fact that medical specialities are to some degree fenced off from each 
other, with little opportunity for inter-disciplinary communication and team-building. It is therefore 
imperative that attempts are made to reach across this artificial rift and establish a model for 
collaboration. Because cardiologists are traditionally the gatekeepers to cardiac imaging and treatments 
and have primary responsibility for managing cardiac complications of cancer treatment, they should take 
the initiative of advocating for improved cardio-oncology services in Australia. One initial step would be 
to present research similar to that contained in this thesis at oncological meetings and conferences.  
Standardization of LVEF measurements in the cancer population would be ideal, as currently two 
competing modalities are used, and results are not interchangeable between modalities. This could be 
addressed by cardiologists altering the current “first-come-first-served” model for booking 
echocardiograms to a model triaged based on clinical characteristics, where the time-sensitive nature of 
cancer patient screening is appreciated. Efforts should be made to improve collaboration between 
Chapter 10- Summary and Conclusion 
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cardiologists and radiologists to improve CMR accessibility to cardio-oncology patients. Lastly further 
cost-effectiveness analyses should be performed regarding cardio-oncology intervention to assist in 
guiding policy makers. 
CTRCD has historically been an invisible burden shouldered largely by cancer survivors in Australia. 
This is now starting to slowly change as increased collaboration, both in the research and clinical 
domains, are leading to improved patient care. Hopefully this PhD thesis, which was created with the 
assistance of oncologists, hematologists, cardiologists, sonographers, statisticians and health economics 
experts, will constitute another step down this path. 
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